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Abstract
Inductively coupled plasma mass spectrometry (ICP-MS) has been widely used for 
environmental and trace analysis since its introduction in the early 1980s. This thesis 
describes an exploration of the potential of HPLC-ICP-MS within the pharmaceutical 
industry.
Determination of platinum in the anticancer drug ZD0473 was performed in comparison with 
conventional HPLC-MSMS, investigating limit of detection, linearity and reproducibility on 
spiked samples. Both methods were capable of providing accurate and precise results with 
samples from rats dosed intravenously 0.5 mg/kg and orally at 6 mg/kg, but the HPLC-ICP- 
MS Pt method had extended linear range and superior sensitivity, providing a limit of 
quantification of 0.1 ng/mL compared to 5 ng/mL by HPLC-MSMS. Impurity and metabolite 
profiles for ZD0473, using platinum as a marker with HPLC-ICP-MS, were compared to 
profiles from [14C] labelled compound with radioactivity detection, showing that the 
compound was converted to 2-picoline.
Since the number of compounds containing platinum found in the pharmaceutical industry is 
limited ICP-MS was then evaluated for other elements.
The detection of carbon was investigated, since this is present in all organic molecules, and a 
limit of detection of 0.47 pmol of carbon was achieved for sulphanilamide using superheated 
water as the mobile phase. Isotopically enriched solvents ([12C]-methanol 99.95 atom %) 
were used as organic modifier to aid chromatography. Detection limits of 86 pmol for 13C- 
triple-labelled caffeine and 79 pmol 13C-double-labelled phenacetin.
Halogen (Br, I and Cl) detection was investigated. Metabolite profiling and excretion balance 
studies were carried out using these elements after dosing suitable model compounds 
(substituted anilines and benzoic acids) to rats. Limits of detection for Br and I were measured 
down to 0.1 mM. Profiling for 2-, 3-, 4-bromobenzoic acids showed glycine and glucuronide 
metabolites, in different proportions dependant on the position of the Br. This was also seen 
for the 2-, 3-, 4-iodobenzoic acids.
Sulphur and phosphorous containing drugs were analysed using the reaction cell of the ICP- 
MS to chemically enhance the signal by reacting the element with oxygen (e.g. to give SO+), 
moving the detection away from a region of isobaric interference. Metabolite profiling of 
omeprazole was performed, with limits of detection of 800 pg of sulphur on column (an 
improvement of 100 fold in sensitivity from detection without oxygen). Similar studies with 
phosphorus containing drugs also showed a significant increase in sensitivity following 
reaction with oxygen compared to conventional analysis by ICP-MS.
The studies undertaken here demonstrate the significant potential of HPLC-ICP-MS as a 
contributor to the analysis of drugs and metabolites in the pharmaceutical industry.
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Chapter 1
An introduction to DMPK and inductively coupled plasma mass spectrometry 
1.0: Background
The pharmaceutical industry is required to conduct studies of the metabolic fate of potential 
drugs. The compound of interest is dosed into animals and subsequently blood, urine and bile 
samples are taken for analysis of parent and potential metabolites in order to establish the 
breakdown pathways and identify any toxic intermediates.
To do this, an easy traceable label must be attached to the parent drug so that its progress 
though the metabolic system can be determined. Traditionally, radiolabels (eg. 14C) have 
been used for this, but the use of radiolabels is costly, ethically problematic and slows time to 
market.
Great advantage would be gained if the atoms within the drug molecule could be uniquely 
detected, preferably without labelling, but at least without the use of radioactivity. High 
performance liquid chromatography (HPLC) is the method of choice for separating 
metabolites in biological samples, while inductively coupled plasma spectrometry (ICP-MS) 
offers the potential for compound independent quantification. This project was therefore 
established to investigate the usefulness of HPLC-ICP-MS in the study of drug metabolism. 
ICP-MS is an instrumental analytical technique based on the use of a high temperature 
ionisation source (ICP) coupled to a mass spectrometer. Papers on ICP-MS started to appear 
in the 1970’s; however commercial products did not appear until 1983 with the introduction
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of the Sciex ELAN 250 and the VG PlasmaQuad [1]. Since then many instruments have been 
developed and marketed by numerous manufacturers utilising different mass spectrometer 
(MS) types such as time of flight and quadrupole instruments. The technique has quickly 
developed in to the instrument of choice for routine ultra trace-element analysis, mainly due 
to the advantages of combining an ICP with a MS [2]. The ICP gives qualities such as multi- 
elemental capability, good precision, a wide linear dynamic range and is relatively free from 
chemical interference, which plagued techniques such as atomic absorption spectrometry [3]. 
The benefits of the MS as detector are simple spectra and low backgrounds, resulting in low 
detection limits. The ICP has one additional feature, which should ensure very simple spectra 
indeed: it firsts atomises and then ionises the sample. Ions extracted from the plasma into the 
MS are therefore expected to produce a spectrum, which is elemental, consisting of as many 
peaks as there are stable isotopes for each element present. This means that a sample 
containing all the elements from the periodic table would result in a total of a few hundred 
peaks, which is quite a contrast to a technique such as ICP-AES where a single element such 
as Fe and U can emit thousands of peaks.
The present project was designed to gauge how the ICP-MS could be utilised within a drug 
metabolism and pharmacokinetics department (DMPK). Commonly the mass spectrometers 
found within the laboratory of a DMPK department are quadrupole or time of flight 
instruments with electrospray ionisation (ESI) or atmospheric pressure ionisation (APCI) 
sources used for detection of molecular ions or large fragments. For quantitative analysis in 
pharmacokinetic studies within DMPK, triple quadrupole instruments have mostly been used. 
These instruments revolutionised the industry in the early 1990s, enabling analysts to obtain 
shorter run times, better selectivity and sensitivity than with more conventional methods of 
detection such as UV absorbance. The gains in sensitivity made the instruments the industry
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standard for quantitation. The quandrupole time of flight or triple quadrupole MS were the 
usual system of choice for qualitative metabolite identification studies within DMPK. The 
ability of the instrument to provide accurate mass information made it a useful tool in 
metabolite structure determination when used with identification software.
Figure 1.1 The structure of the platinum-containing anti cancer drug.
ICP-MS became an interest within the DMPK department when a problem in the analysis of 
an anti-cancer drug, similar to cis-platin, was encountered (Figure 1.1). The normal mode of 
detection, triple quadrupole mass spectrometry, in this case proved not to be the best mode of 
detection since the molecular ion of the compound could not be isolated [4]. With advances 
in the coupling of the ICP-MS to high performance liquid chromatography systems the 
instrument became capable of detecting low amounts of platinum eluting from a 
chromatographic system and therefore the combination became of interest within DMPK. 
Other characteristics of the instrument, such as its wide linear range made it a real alternative 
for the detection of platinum [5]. Because platinum anti-cancer drugs were relatively 
uncommon within the department, the instrument was also evaluated for the detection of 
elements more frequently found in drugs such as the halogens, sulphur, phosphorous and 
carbon [6-11].
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The unique capability of ICP-MS in giving an accurate quantitative value for a particular 
element when related to a standard independent of structure is of great interest for the 
detection and quantification of drug metabolites. Once the metabolites have been separated 
chromatographically then they can be quantified against an external standard, to gain a 
metabolite profile, due to the efficient atomisation and ionisation of the ICP source. Normally 
such work is carried out using a radio-labelled compound which has been produced and dosed 
to follow the compound though the animal model. The use of a stable isotope within the 
structure of the compound enables the type of work to be carried out earlier in the discovery 
process before the radio-labelled compound becomes available. Clinical studies, where the 
radiolabel would normally be dosed to human volunteers, also became easier because of the 
omission of radioactivity [12].
1.1: Why ICP-MS ?
ICP-MS is of interest as a mode of detection for the analysis of drugs and metabolites within 
DMPK departments predominately due to the instrument’s ability to give quantitative 
information based on an element contained within its structure, but independent of the 
structure. ICP-AES would also give this information, but was not considered because of the 
complicated spectrum gained, the generally lower sensitivity, and the inability to distinguish 
between isotopes. Given the complex mixtures in biological samples, the separation method 
is important. Gas chromatography (GC) can give high resolution separations, but most 
metabolites need derivatisation for GC because of their low volatility. The compounds under 
investigation are compatible with liquid chromatographic techniques without derivatisation.
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Liquid chromatographic separation processes are the preferred choice in metabolite profile 
studies as well as in quantitative analysis. The modes of detection associated with LC are 
numerous such as MS, UV, and fluorescence. However, the technique of ICP-MS can obtain 
quantitative data without identical standards being required. Radio-flow counters do show 
this quality, but the synthesis required is expensive. The advantage of not having to change 
the molecule and use an element within the structure is not only financial but also practical 
because of the regulatory constraints on radio-labelling and the safety and disposal problems 
associated with radioactive compounds.
1.2: The inductively coupled plasma as an ion source
The ICP torch was first developed in the early 1960s S. Greenfield and V. A. Fassel [13]. The 
flame like discharges, which can reach up to temperatures of 10,000 K, are formed in a stream 
of argon flowing though a strong radio frequency electromagnetic field [14].
The ICP gas flows though three concentric tubes, which are assembled together in what is 
commonly referred to as the plasma torch (Figure 1.2). The flowing gas in the outer tube 
(commonly in the range of 13-17 L/min) is referred to as the cooling gas, with its role to 
ensure that the high temperature of the plasma does not melt the torch. It also has a secondary 
role in that it gives the distinctive shape to the plasma. The gas flowing in the middle 
concentric tube (commonly in the range of 1 L/min) is known as the plasma gas. It is this 
flow of gas, which is ionised to form the plasma. The inner tube gas flow is known as the 
carrier gas and is used to punch the plasma whilst carrying an aerosol or particulate form of 
the sample to be analysed.
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atomisation and 
ionisation region
Carrier gas Non sample 
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Intermediate gas
Figure 1.2 Schematic drawing of the ICP torch. Diagram used with the permission of GV
Instruments [80].
A coil with a radio-frequency current flow encircles the torch to create an electromagnetic 
field in which the argon flows. A high voltage discharge spark is passed though the argon in 
the electromagnetic field to initiate the plasma. Electrons from the discharge gain energy 
which they transfer though collisions to argon atoms in the gas, thereby ionising them. This 
creates sets of ion-electron pairs that are in turn energised by the electromagnetic field and 
which take part in a cascading process of energy transfer from the coil to the gas. The result 
of this is a steady state plasma that is maintained as long as the radio-frequency current is 
maintained at a sufficient intensity and the gas flow is uninterrupted. The fire-ball like argon 
plasma is characterised by a bluish white discharge, which is a combination of emissions from 
the line spectrum of atomic argon and the continuous spectrum from ion-electron re­
combinations taking place within the plasma.
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When the plasma is formed the shape is that of a prolate spheroid, however the rapid 
expansion and acceleration of argon gas inside makes the introduction of sample difficult. 
This is achieved by punching a central channel inside the plasma thereby changing the shape 
of the plasma to the form of a doughnut with the outer plasma gas shielding the inner carrier 
gas so that virtually no mixing taking place between the two. As a result sample can be 
introduced in a gaseous or aerosol state along this central channel without disturbing the 
plasma or changing its composition. Whilst in the channel the sample will be desolvated, 
atomised, excited and ionised. Chemical species injected into the plasma will be broken 
down into their constituent elements, which are then ionised independently of their original 
form with efficiencies depending mainly on their ionisation energies. This can be predicted 
by the Saha equation [2].
Saha Equation
where:
[M*] = the population of positively charged ions of the element M
[M] = the population of atoms of the element M
ne = the electron number density in the plasma
me = the mass of the electron
h = Planck’s constant
Te = the free electron temperature
Q+ = the electronic partition function of the ion
Q° = the electronic partition function of the atom
IP = the ionisation potential of the element
Tion = the ionisation temperature
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Most o f the elements within the periodic table will be efficiently converted into singly 
charged ions. Figure 1.3 shows that the efficiency of ionisation decays as the ionisation 
energy of the element approaches that of argon (15.8 eV). This means that elements such as 
F, Ne and He are poorly ionised and the technique cannot be used for the analysis o f these 
elements.
120 .0%
100 .0%
80.0%
60.0%
40 .0%
20.0%
0 .0%
6.05.0 7.0 8.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0
IE (eV )
Figure 1.3 Efficiency o f ionisation of elements in an ICP torch, with the elements in the 
study marked as a function of their ionisation energy [2].
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1.3: Interfacing the Plasma Torch to the vacuum system
Interfacing the ICP torch to the MS requires transition from atmospheric pressure to a low 
operating pressure in order to avoid high voltage discharges and to ensure that the mean free 
path of ions is long enough to avoid collisions with the background atmosphere in the system 
[15]. The ICP-MS plasma is interfaced to the MS via a series of pumped chambers linked by 
extraction cones with small apertures. The design, shape and size of the apertures is 
important in the definition of the analytical performance for the instrument. Common to all 
ICP-MS systems is the presence of sampler and skimmer cones. The sampler is the interface 
between the plasma and the first vacuum chamber and therefore is subject to high 
temperatures since the plasma impinges directly on its surface. The sampler requires efficient 
cooling and therefore is made of material that has both good heat resistance and is an efficient 
thermal conductor. The most common material used is nickel, although depending on the 
application of interest Al, Cu and Pt have been used for this purpose. When the plasma makes 
contact with the surface of the sampler cone it cools down rapidly, forming a boundary layer. 
In this area ions recombine forming molecular species, such as ArCl+ and ArO+ that are not 
normally observed in bench chemistry. These types of molecular ions cause interferences and 
high backgrounds if they enter the mass analyser, so it is important that the opening aperture 
is designed to take ions from the central region only.
After entering the first vacuum chamber the sampled gas, which at this stage consists of ions, 
atoms and electrons, expands rapidly. The role of the skimmer cone is to ensure that a 
representative population of mixture is extracted into the next stage. To achieve this the 
skimmer cones are designed to have sharper edges and smaller apertures than the sampler 
cone (Figure 1.4).
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To p u m p
Figure 1.4 Schematic of an ICP-MS interface. The sampled region o f plasma expands 
behind the sampler whilst a representative portion flows through the skimmer 
into the ion optic region. Diagram used with the permission of GV 
Instruments [80].
Ion detector
MSinterlace
Mass separation device
ion optics
Turbo Turbomolecular molecularpump pump
ICP Torch A
iy
Spraychamber
Mechanicalpump
Nebulizer
RF power supply
Figure 1.5 The building blocks of the ICP-MS instrument. Diagram used with the 
permission of GV Instruments [80].
11
1.4: Sample introduction into ICP-MS
The first block of an integrated ICP-MS instrument is the sample introduction device. This is 
a well researched component and is often considered the problem area of the technique. It is 
crucial that the liquid delivery device delivers a representative portion of the sample. The 
common unit for this process consists of a pump, a nebuliser and a spray chamber. The pump 
ensures a consistent flow of the sample to the nebuliser, with another pump removing waste 
from the spray chamber. The nebuliser is used to convert the stream of liquid sample into a 
fine aerosol and the spray chamber acts as a trap that filters out the larger droplets. This 
process is not particularly efficient, with only about 2 % of the sample reaching the plasma 
due to the varied size of the droplets. This efficiency is dependent on the type of nebuliser, 
however, and much work in this area is on going [16-17]. If 100 % of the sample is required 
to reach the plasma then inlet sources such as ultrasonic transducers can be utilised [18]. 
However, if a large amount of solvent is introduced to the plasma, the plasma may quench or 
change characteristics. This problem has been overcome by introducing a desolvating stage 
prior to the aerosol reaching the plasma, or alternatively a low flow rate to deliver the sample. 
High efficiency low flow rate nebulisers have been used widely in the past few years. The 
efficiency of these nebulisers in producing an aerosol with small size droplets is extremely 
high, however, since the sample consumption rate is low, there is little overloading of the 
plasma or gain in sensitivity.
The stability of the sample introduction source is also an important consideration. To gain 
good quality data the instrument must be stable over the short term as well as the long term. 
Short term instability is usually caused by the pulsating nature of the nebuliser source. This 
gives the spray chamber a secondary role in smoothing this effect out. Long-term stability
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issues can be caused by partial blockages of the nebuliser and by physical parameters that 
affect the performance of the spray chamber such as temperature and surface wetting.
Making the right choice of nebuliser for the application can reduce blocking. When dealing 
with clean samples and solvents the standard concentric nebuliser would be the correct choice 
since it is possible to match these to the flow rate used. With samples, and solvents, 
containing high levels of salts cross flow nebulisers are recommended since they are more 
tolerant of these systems. For samples with suspended particulates a V-groove type of 
nebuliser is recommended, but when these are used a reduction in sensitivity is observed [2].
The use of thermally stable spray chambers is necessary to avoid long-term drift. A 
thermoelectric Peltier cooling device can be used, or a jacket around the spray chamber with a 
continuous flow of cooling fluid from a chiller unit. In addition, cooling units are used to 
minimise drift associated with selectively reduced plasma loading from volatile solvents such 
as alcohol by maintaining the spray chamber temperature between -5°C and -10°C to 
condense the solvent.
1.5: Passage of Ions though the ICP-MS
As described earlier, the aerosol passing though the spray chamber is ionised in the ICP and 
introduced into the vacuum through an interface. After the interface the ions are guided into 
the mass spectrometer by a series of focusing lenses. These are electrostatic lenses and are 
designed to steer the ions without changing the composition of the ion beam exiting the 
skimmer. This process is difficult since the beam is positively charged and therefore the ions 
have a tendency to repel each other, which is known as the coulombic effect. This process is 
combated by accelerating the ions or by making use of a number of focusing lenses.
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An additional use for the ion optics is to stop neutral species and protons reaching the 
detector, however, recently this has been prevented more efficiently by using reaction / 
collision cells.
The collision cell has an integral role in limiting spectral interferences. These interferences 
are predominantly ions generated from the argon gas, the solvent or the sample matrix.
Figure 1.6 shows examples of the ions produced, indicating that for the determination of 
elements such as Fe the spectral interference 40Ar16O would have an effect on the sensitivity. 
The cold / cool plasma approach, which uses lower temperatures to reduce the formation of 
the interference, is one way around the problem. The low power results in less interference 
products forming [2]. However, this approach is time consuming for optimisation and does 
not take into account many of the elements of interest. Collision / reaction cells were 
developed in the late 1990’s to deal with this problem [19]. Originally these were designed 
for mass spectrometers to generate product ion species to aid identification of precursor ions. 
When the technology was used in ICP-MS the collision cell was found to limit the formation 
of argon-based spectral interferences [20-22]. The ions enter the interface in the normal 
manner, from where they are extracted into an off-axis collision cell under vacuum. A gas 
such as hydrogen or helium is introduced into the collision cell, which is normally a hexapole 
or octapole, operated in rf-only mode. The rf-only mode acts as an ion focusing device, 
allowing collision and reaction with interferences, by a number of different mechanisms. 
These are predominantly ion-molecule reactions, with polyatomic interfering ions like 
40Ar16O+, and 38ArH+ converted to harmless non-interfering species. The analyte ions, free 
from interferences, then emerge from the collision cell into a quadrupole analyser for mass
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separation (Figure 1.7). This technique removes most of the polyatomic interferences found 
in the system and shows advantages over the cool flame technique [23-24].
Another device for removing interferences is the dynamic reaction cell (DRC) [25-26], which 
works in a similar manner to the collision cell. The main difference is that quadrupoles are 
used instead of hexapoles because of the greater stability gained, and reactive gases such as 
ammonia, methane or oxygen are bled in, with the cell acting as a catalyst for ion-molecule 
chemistry to take place. The mechanisms taking place are predominantly reaction based, 
rather than collisions, and the interfering molecules are converted into an ion dissimilar to the 
analyte mass, or to a harmless neutral species (Figure 1.8). An example of the reactions that 
can occur is NO+ + O2 N02+ + O. The analyte is then separated in a similar manner as 
before by an analyser quadrupole.
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o
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Figure 1.6 Mass spectrum from deionized water showing mass 40 to 85. The ions present 
represent interferences, which will reduce sensitivity of the species under 
investigation at the same mass. Taken from ref [20].
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Figure 1.7 Multipole collision / reaction cell as used in GV instrument technology. 
Diagram used with the permission of GV Instruments [80].
R eaction Cell Quadrupole
Gas Inlet
Reaction Gas
T J f l
IsobaricInterference
Analyte Ion
X
Analyzer Quadrupole #  j
A nalyte Ion
lon-Molecule Reactions
Figure 1.8 Principles of operation o f a dynamic reaction cell (DRC). Diagram used with 
the permission of Perkin Elmer [25].
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1.6: Coupling a HPLC system to an ICP-MS
The coupling of an HPLC system to the ICP-MS detector was an integral part of the project. 
The actual coupling of the HPLC system to the ICP-MS is not difficult, since the flow rates 
by the HPLC system (1 pL/min to 2-3 mL/min), are directly compatible with the sample 
introduction rates of the ICP infusion system. The first instance of this type of work was in 
the early 1980’s when HPLC-ICP-MS was to identify elemental species [27].
The process of coupling the HLPC to the ICP-MS may be easy in principle, but the reality is 
somewhat different. There are a number of published reviews considering the problem of 
coupling chromatography to ICP-MS [28-30]. The main problem with such a process is 
associated with the mobile phase. The high levels of salts used in most ion chromatography 
mobile phases cause blockages at the nebuliser tip, cone apertures and other nebuliser source 
such as the ultrasonic nebuliser. Mobile phases containing high levels of organic solvent 
(such as those used in reversed phase HPLC) cause rapid blockages of the cones due to the 
deposition of carbon. In order to address these issues various techniques have to be employed 
to overcome the problems. Salt problems can be overcome by making use of on line dilution 
step or an exchange membrane, whereby Na, K and Ca ions are exchanged with hydrogen 
ions. The main problem associated with this work, however, is how to handle the organic part 
of a reversed phase chromatographic system. Since most separations of metabolites are 
carried out with an organic modifier mixed with an aqueous component it is important to 
understand the problems. The organic part causes two problems. Carbon is produced in the 
plasma from the mobile phase due to its relatively high ionisation energy (11.3 eV) [31]. As a 
result, an lower ionisation energy compared to argon is found within the plasma flame, which 
results in large volume of carbon atoms in the plasma. These atoms tend to deposit on the
17
apertures of the sampler and skimmer cones, thereby causing blockages. The problem is 
overcome by the addition of oxygen, which is mixed with the argon carrier gas. The oxygen 
reacts with the carbon atoms to form volatile products. However, the addition of oxygen to 
the system has the effect of changing the electrical impedance of the ICP. Consequently this 
process can only be used if the instrument has computer controlled RF circuitry, which can 
adjust to the impedance shift. The second problem found was the cooling effect of the 
organic phase on the plasma. With high levels of organic solvent the electrical impedance can 
be affected and without the RF adjustment ICP operation is very difficult. To counter this 
problem the mobile phase flow rates have to be considered in the method development, and 
the amount of organic must be kept as low as possible, in order to achieve optimum 
conditions for the instrument. When operating with organic components the use of a sub-zero 
spray chamber (below -5°C) is necessary to desolvate the aerosol, thus limiting the amount of 
organic reaching the plasma. To aid desolvation, specialist nebulisers have been developed 
[32]. These nebulisers generate an aerosol which is then heated, passed though a chamber 
kept at sub zero temperatures, and finally passed past a desolvating semi-porous membrane 
with a counter flow of argon on the outside. Although these nebulisers provide an ideal way 
for linking HPLC to ICP-MS, volatile species can be lost through the membrane.
Although these difficulties exist in running the ICP-MS with a chromatographic system, 
advances in technology, as well as an understanding of ICP-MS processes have made this 
technique feasible. HPLC-ICP-MS was therefore looked at in detail to determine its 
usefulness to a DMPK department.
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Chapter 2
A comparison of quantitative methods for analysis of the platinum- containing 
anticancer drug (Cis-[amminedichloro(2-methylpyridine)] 
platinum(II)}(ZD0473) by HPLC coupled to either a triple quadrupole mass 
spectrometer or an inductively coupled plasma mass spectrometer.
2.1: Summary
The use of high performance liquid chromatography coupled with inductively coupled 
plasma mass spectrometry (HPLC-ICP-MS) as a means for the quantitative 
determination of ZD0473, a platinum anticancer drug, and its related biologically 
active “aqua” compounds in biofluid samples, is described. The performance of the 
resulting HPLC-ICP-MS method was compared with that of a conventional HPLC- 
triple quadrupole mass spectrometer based (HPLC-MSMS) system for properties such 
as limit of detection, linearity and reproducibility using spiked samples. The methods 
were then applied to the determination of plasma ultrafitrate concentrations of 
ZD0473 in dog plasma samples obtained following intravenous and oral 
administration at 0.5 mg/kg and 6 mg/kg, respectively. These experiments showed 
that both methods were capable of providing accurate and precise results but that the 
HPLC-ICP-MS method had advantages of extended linear range and superior 
sensitivity, providing a limit of quantification of 0.1 ng/mL for ZD0473 compared to 
5 ng/mL using the current HPLC-MSMS method. In addition, by using a single
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combined HPLC-ICP-MS/MSMS system it was possible to determine the relative 
MSMS response of the aqua compounds for the first time.
2.2: Introduction
ZD0473 {cis[amminedichloro(2-methylpyridine)]platinum (II)} is anew generation 
platinum compound designed to deliver an extended spectrum of antitumour activity 
and overcome platinum resistance [33-34]. The structures of ZD0473 and the related 
biologically active “aqua” compounds are shown in Figure 2.1. Traditionally the 
analysis of platinum drugs has relied upon atomic absorption spectrophotometry, ICP- 
MS or electrochemical detection [35-37]. However, in the absence of a separation 
these techniques do not provide an adequate process for a quantitative assay, due to 
the failure to distinguish between the compound, the active aqua species and inactive 
metabolites (including amino acid adducts) / degradation products. If such 
information is required then a chromatographic separation coupled to fraction 
collection and subsequent off-line determination of the platinum content can be 
performed, but this is labour intensive, time consuming and prone to error. Because 
of these practical difficulties the initial method developed for the determination of 
ZD0473 in biological samples was based on the HPLC-MSMS system developed by 
Oe et al [4], which enabled the compound to be quantified down to concentrations of 
10 ng/mL in biofluid samples such as plasma ultrafiltrate and urine. However, the 
advent of robust HPLC-ICP-MS systems offers great potential for the analysis of 
metal-containing compounds in biological matrices [38-41] as illustrated by a recent 
example for a platinum-containing compound in human plasma [5]. An HPLC-ICP- 
MS based method for the analysis of ZD0473 and related materials was therefore
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developed. This method has been compared to an in-house assay, based on the 
published HPLC-MSMS procedure [4], via the analysis of both spiked samples and 
samples derived from a dog study following the intravenous and oral administration 
of ZD0473 at 0.5 mg/kg and 6 mg/kg, respectively.
ZD0473
Nhk ,a
r ^ N 'R'a
CHj
Aqua Species
NH .a
'OH,
ca
NH3v 
/ ^ N " Pt' a
CHg
Figure 2.1 The structure of ZD0473 and the associated aqua species.
2.3: Experimental 
2.3.1: Reagents
t
Chromatographic solvents together with formic and hydrochloric acids were 
purchased from Fisher Scientific UK Ltd (Loughborough, UK) and were of analytical 
or HPLC grade. Ammonium acetate and sodium chloride were obtained from BDH 
Ltd (Poole, UK) and were of analytical grade. ZD0473 was formulated as a sterile 
solution in 0.9 % sterile sodium chloride for intravenous administration, and a 50:50 
w/w with lactose for oral administration, which was obtained from the Media 
Preparation Laboratory at AstraZenenca Pharmaceuticals (Alderley Park,
Macclesfield, UK). ZD0473 was supplied by AstraZeneca Pharmaceuticals (Alderley 
Park) and the deuterated internal standard, [2H?] ZD0473 (deuterated in the aromatic 
ring and methyl), was synthesised in the Isotope Chemistry Laboratory in the Dept, of 
Drug Metabolism and Pharmacokinetics at AstraZeneca Pharmaceuticals (Alderley 
Park).
2.3.2: Standard Solution Preparation
ZD0473 is light sensitive and care was taken when making up standard solutions for 
the two assays to avoid photo-degradation. Typically, 5 mg of ZD0473 was weighed 
out into an amber vial and 10 mL of 0.15 M sodium chloride was then added to 
achieve a concentration of 0.5 mg/mL. The presence of chloride ions stabilises 
ZD0473 by preventing the formation of the aqua species. Dissolution was obtained 
by stirring the sample for two hours at room temperature. The spiking standards were 
prepared by making the appropriate dilutions with sodium chloride (0.15 M) to 
provide standards of concentrations 500,10,1, 0.2 and 0.02 pg/mL. The initial 
solution was checked by UV spectroscopy at a concentration of 100 pg/mL and the 
data compared to previously generated data at this concentration to determine 
integrity of the preparation. The standard solution of the deuterated internal standard 
([2H7]-ZD0473) employed in the HPLC-MSMS assay was prepared in the same 
manner and diluted with sodium chloride to give a final concentration of 5 pg/mL.
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2.3.3: Intravenous and oral formulation of ZD0473 and sample collection
ZD0473 was formulated in physiological saline to a concentration of 0.5 mg/mL. 
ZD0473 was dissolved in 0.9% w/v sodium chloride by stirring overnight and then 
filtered through a 0.2 pm filter into a sterile vial. The formulation was then dosed 
intravenously as a bolus over 1 minute to a male beagle dog (12.8 kg) at a dose level 
of 0.5 mg/kg. Blood samples (4mL) were taken at 0.033, 0.083, 0.167, 0.25, 0.5,
0.75, 1, 2, 3, 6 and 12 hours post dose. The oral dose was formulated as a 50 % w/w 
solid mixture with lactose (90 mg) and dosed to a single male beagle dog (12.5 kg) at 
a level of 6 mg/kg. Blood samples were taken (4 mL) at 0.25, 0.5, 0.75,1, 2, 3, 6 and 
12 hours. On collection, blood samples were placed in lithium heparin tubes and 
centrifuged at 3000 rpm for 15 minutes to prepare plasma. Aliquots of these plasma 
samples were then taken (200 pL), placed into 6 Amicon Centrifree Filter devices 
(30,000 molecular weight cut-off, Millipore Corporation, Bedford, USA) and 
centrifuged at 3000 rpm for 30 minutes, at 4 °C to provide ultrafiltrates. The samples 
were then stored at -70 °C in glass vials wrapped in aluminium foil to protect the 
samples from photo-degradation until analysis (these conditions have been shown to 
provide stability for 5 months).
2.3.4: Preparation of standard curve and quality control samples.
The standards and quality control (QC) samples were prepared by spiking control dog 
plasma ultrafiltrate with standard solutions to produce the required concentrations. 
The standard curve prepared for the HPLC-MSMS assay contained samples spiked at 
5, 10, 50, 200, 600, 1000, 2500, 5000, 7500 and 10000 ng/mL, respectively, whilst
23
that for the HPLC-ICP-MS method had additional standards at 0.1, 0.5 and 1 ng/mL. 
The QC samples for the HPLC-MSMS and HPLC-ICP-MS assays were prepared at 5, 
100,1000 ng/mL and 0.1, 0.5, 5, 1000,10000 ng/mL, respectively and stored at 
-70°C in glass vials wrapped in aluminium foil until required.
2.3.5: Sample preparation.
Aliquots of the standards, QCs and samples (0.1 mL in each case) were placed into 
glass tubes (12 x 75mm). To these 25 pL of 0.15 M sodium chloride in 0.1 M 
hydrochloric acid was added, and the samples were then made up to 200 pL with 0.15 
M sodium chloride. For the HLPC-MSMS method 25 pL of the internal standard 
solution (5 pg/mL) was added before the sample was made up to 200 pL. The 
mixtures were vortex mixed for 20 seconds and then transferred to HPLC vials ready 
for injection. The addition of hydrochloric acid was designed to ensure that the 
equilibrium favoured ZD0473 rather than the aqua species in the presence of the 
ultrafiltrate. The samples were transferred to autosampler vials and then placed in the 
autosampler and kept in the dark prior to injection. Blanks were prepared as above to 
check there were no interfering peaks in the chromatograms.
2.3.6: Chromatography
An isocratic reversed-phase HPLC method was used for both ICP-MS and the MSMS 
assays based on a mobile phase of methanol / water (20:80 V/V) containing 0.1 % 
formic acid and 0.15mM ammonium acetate (pH 3). The column used was a 
Phenomenex Synergi polar RP 150 x 4.6 mm (Phenomenex, Macclesfield, UK)
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operated at ambient temperature with a flow rate of 1 mL/min, which give a run time 
of 7 minutes. An injection volume of 50 pL was used in the assays.
2.3.7: HPLC-ICP-MS
Chromatography for ICP-MS was performed using a Jasco PU-1580 HPLC system 
(Jasco Ltd, Great Dunmow, UK) with samples introduced via a PE 200 autosampler 
(PerkinElmer Ltd, Beaconsfield, UK). The injector was flushed using a methanol / 
water solution (1:1). ICP-MS was performed on a Platform ICP-MS, which uses a 
hexapole collision / reaction cell for simultaneous measurement of the platinum 
isotopes (Micromass, Wythenshawe, UK). The eluent from the column was 
introduced to the ICP-MS via either an ultrasonic nebuliser U-6000AT (Cetac 
Technologies, Omaha, Nebraska, USA) or a Meinhard concentric nebuliser coupled to 
a double pass spray chamber (Micromass, Wythenshawe, UK). MassLynx software 
(version 3.4) was used for instrument control, data acquisition and data handling. 
Table 2.1 shows operating and acquisition conditions of the ICP-MS including the 
flow of the nebuliser gases for sample introduction as well as an argon oxygen mix 
(95:5 V/V), which is used to reduce carbon build up from mobile phase combustion in 
the plasma.
Table 2.1 Instrument operating conditions for the Platform ICP-MS
Cooling gas 16.00 L/min Plasma Power 1350 w
Plasma gas 0.65 L/min Acquisition mode SIR
Nebuliser gas 0.75 L/min Dwell time 200 ms
Helium gas 5 mL/min Masses monitored 195
Hydrogen gas 5 mL/min Argon/Oxygen (95/5 %) 0.2 mL/min
Total analysis time 7 min
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2.3.8: HPLC-MSMS
Chromatography for HPLC-MSMS was performed using a PE 200 series pump 
(PerkinElmer Ltd, Beaconsfield, UK) with samples introduced via a CTC Analytics 
autosampler (Presearch, Hitchin, UK). The injector was flushed using a methanol / 
water solution (1:1). For quantification by MSMS an API-3000 mass spectrometer 
(Applied Biosystems, Warrington, UK) with a turbo ionspray inlet source was used 
for the multiple reaction monitoring of ZD0473 and its aqua species. Analyst 
software (version 1.2) was used for the instrument control, data acquisition and data 
handling. The operating conditions for the instrument are shown in Table 2.2.
Table 2.2 Instrument operating conditions for API-3000 MSMS
Ion Transformation
Component Ql Q3 Dwell time (mSec)
ZD0473 393.4 303.5 150
ZD0473D6 400.0 310.2 150
Aqua Species 358.0 303.5 150
2.3.9: HPLC-ICP-MS/MSMS
To evaluate the combination of HPLC-ICP-MS/MSMS, and enable the relative 
response for the aqua species by MSMS to be determined, the chromatographic
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system used for HPLC-ICP-MS described above was taken and the effluent from the 
column split using a splitter valve (600; Jasco Ltd , Great Dunmow, UK), positioned 
directly after the outlet of the column; this directed half of the flow (0.5 mL/min) to 
the HPLC-MSMS and the remainder (0.5 mL/min) to the HPLC-ICP-MS. PEEK 
tubing (0.005” bore) was used to connect the instruments and the lengths adjusted to 
give similar retention times for ZD0473 in both systems.
2.4: Results and Discussion, Assay Development and Validation 
2.4.1: Chromatography
ZD0473 is found in biological fluids together with a mixture of the pharmacologically 
active aqua species (structures in Figure 2.1). As the HPLC-ICP-MS method is based 
on the detection of platinum a chromatographic separation of ZD0473 from these 
aqua species was required to ensure specificity. Similarly, the use of MSMS for 
quantification necessitated the separation of the two aqua components as the same ion 
transformations are seen for both aqua species. The HPLC separation that was 
developed, based on reversed-phase chromatography with a methanol-ammonium 
acetate / formate (20:80) buffered eluent, provided this separation and was also 
compatible with both modes of MS detection [28,42]. The formic acid and 
ammonium acetate components of the mobile phase were primarily there for the 
benefit of the HPLC-MSMS system with formic acid added to aid the ionisation of the 
compounds in the turbo ion spray source, whilst the ammonium acetate was present in 
order to produce the ammonium adducts required for MSMS detection (Figure 2.2). 
For HPLC-ICP-MS methanol-water 20:80 alone would be suitable for
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chromatography, but a common mobile phase was used here to aid comparison of the 
two detection methods.
Q1 393.4 amu Q3 303.5 amu
NH - 90 amu
+
CH3 NH + CH3 NH 44
Figure 2.2 The multiple reaction monitoring transition for the HPLC-MSMS 
system with the mass 393.4 to 303.5 with a loss of 90 amu in the 
collision cell.
2.4.2: HPLC-ICP-MS
Having obtained a suitable chromatographic separation the development and 
validation of an HPLC-ICP-MS-based assay for ZD0473 was undertaken. For this, 
the various argon gas flows were optimised to produce the best sensitivity for 
platinum in the ICP-MS and the hydrogen and helium collision cell gases were set to 
produce the lowest background [20, 43] as detailed in Table 2.1. For successful 
HPLC-ICP-MS, efficient removal of the organic modifier prior to the introduction of 
the sample as an aerosol into the plasma is important. Various devices are available 
to achieve this [24] and in this study two types of nebuliser were investigated, namely
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an ultrasonic nebuliser and a concentric nebuliser with a double pass spray chamber. 
The latter was water-cooled to -4°C. The ultrasonic nebuliser is far more efficient 
than the concentric nebuliser in producing an ultra fine aerosol, which is desolvated 
prior to its introduction into the ICP plasma. This increased efficiency leads to an 
increased sensitivity (5 pg on column limit of detection) and low backgrounds, but at 
the expense of linear range due to losses of the analyte at high concentration in the 
desolvating step. However, in use it has proved to be more time consuming to set up 
and was found to be less reliable than the concentric nebuliser / double pass spray 
chamber combination. The latter provides an extended linear range (but with higher 
background levels) in comparison with the ultrasonic nebuliser, and has also proved 
to be more robust. The higher backgrounds observed with the concentric nebuliser 
result from its poorer efficiency, compared to the ultrasonic nebuliser, in removing the 
organic solvent from the mobile phase. However, this combination still offered a 
limit of quantification of 0.1 ng/mL (10 pg on column) at a signal to noise (S/N) of 
10, combined with a linear range extending over 8 orders of magnitude. Because of 
the extended linear range afforded by this method of sample introduction, further 
method development employed this nebuliser. If greater sensitivity was to be 
required and reduction in the calibration range was acceptable, then the increased set 
up time for the ultrasonic nebuliser would become worthwhile. Examples of the 
calibration curves for HPLC-ICP-MS using both nebuliser systems are given in 
Figure 2.3, with representative chromatograms obtained using the concentric 
nebuliser illustrated in Figure 2.4. The equation of the calibration line for the 
concentric nebuliser was y = 653.5x + 335.7 which was calculated by least squares 
linear regression for a range of 0.1 -  10000 ng/mL.
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Based on these conditions using the concentric nebuliser the method was validated for 
spiked plasma samples over the range 0.1 to 10000 ng/mL. The results, shown in 
Table 2.3, clearly indicate that the method is suitable for use over the concentration 
range examined. The excellent accuracy and precision data obtained, in the absence 
of an internal standard, are noteworthy. No reduction in response throughout the 
course of the analysis was noted, as shown by QC sample sets at the start and finish of 
the individual runs. The limit of quantification of the method using these conditions 
was 0.1 ng/mL (10 pg on column), using arguments based on either a S/N of 10:1 or 
the precision being better than 20%. A limit of detection based on a criterion of the 
signal to noise ratio being 3:1 would allow the detection of ZD0473 at 0.05 ng/mL.
Table 2.3 Accuracy and precision data for HPLC-ICP-MS on spiked ultrafiltrate 
samples over the range 0.1 to 10000 ng/mL (n=6). For experimental 
conditions see section 2.3.
Quality control samples mean (ng/mL) accuracy (%)
coefficient of 
variation (%)
LLQ (0.1 ng/mL) 0.101 101 19.9
LQC (0.5 ng/mL) 0.47 95 9.3
MQC (5 ng/mL) 4.6 92 1.8
HQC (1000 ng/mL) 913 91 2.5
UQC (10000 ng/mL) 9949 99 3.2
LLQ Lower Limit of quantification
LQC Lower Quality of Control
MQC Middle Quality of Control
HQC Higher Quality of Control
UQC Upper Quality of Control
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Figure 2.3 Examples of the calibration curves produced in the determination of 
platinum by ICP-MS using two types of nebulising sources a) 
Ultrasonic nebuliser showing saturation after 1000 ng/mL and b) 
Meinhard nebuliser with a double pass spray chamber showing 
extended linear range. For experimental conditions see section 2.3.
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Figure 2.4 Example chromatograms for HPLC-ICP-MS monitored separation of 
platinum at m/z 195. Chromatogram A) represents a blank ultrafiltrate 
sample, B) represents the Limit of detection at 10 pg on column of 
ZD0473 and C) a intravenous sample taken at 0.5 hour after a dose of
0.5 mg/kg to a male dog. For experimental conditions see section 2.3.
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2.4.3: HPLC-MSMS
ZD0473 is not a particularly good candidate for HPLC-MSMS because the compound 
could not be isolated in a Q1 scan due to decomposition in the source. The method 
developed by Oe et al [4] overcame this problem by making use of the presence of 
ammonium acetate in the mobile phase to produce an ammonium adduct, which was 
then fragmented to form product ions, one of which was then used in the multiple 
reaction monitoring transition (Figure 2.2).
For tuning purposes on the API-3000 mass spectrometer to achieve the required 
sensitivity, the resolution setting in the Q1 region was changed from unit resolution 
(peak width 0.7 ±0.1 amu) to low resolution (peak width 0.8 ±0.1 amu) with peak 
width determined at 50 % height of peak. This process allowed more ions through to 
the Q3 region, thereby increasing sensitivity, albeit at the expense of reducing the 
selectivity of the assay. The linear range of the assay was, however, limited to 5 -  
1000 ng/mL with the equation of the calibration line given by y = 0.00136x + 0.00101 
calculated by least squares linear regression. Above 1000 ng/mL the assay showed 
signs of saturation and the coefficients of variation were unacceptably large. Typical 
mass chromatograms are illustrated in Figure 2.5. These conditions were used to 
develop an HPLC-MSMS method for ZD0473 over the range 5 to 1000 ng/mL. The 
resulting data are summarised in Table 2.4. These results show the method to be 
suitable for the analysis of ZD0473 with a limit of quantification of 5 ng/mL, 
corresponding to an on column loading of 125 pg. This limit of quantification was 
calculated based on a signal to noise ratio of 10:1. Using a signal to noise ratio of 3:1 
would result in a limit of detection of ca. 2 ng/mL.
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The method, as developed, has proved to be robust in practice and has been used to 
examine numerous samples from animal studies.
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Figure 2.5 Example chromatograms obtained from the HPLC-MSMS assay of 
ZD0473 with MRM transition 393 to 303 amu. Chromatogram A) 
represents a blank ultrafiltrate sample, B) represents a 5 ng/mL 
standard of ZD0473 and C) a intravenous sample taken at 0.5 hour 
after a dose of 0.5 mg/kg to a male dog. For experimental conditions 
see section 2.3.
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As indicated above, the HPLC-ICP-MS method was able to provide accurate and 
precise results in the absence of an internal standard. For comparison, the data from 
the HPLC-MSMS method was evaluated without taking the internal standard into 
account to see if a similar approach could be adopted. However, this analysis showed 
that there was a gradual decrease in the response of the MSMS during the course of 
the run of 150 samples, with a difference of ca. 24% for QC samples analysed at the 
start compared to those at the end of the batch. A build up of deposits on the source 
probably caused this effect, so reducing the response of the HPLC-MSMS. The use 
of a suitable internal standard is, therefore, mandatory for the assay of ZD0473 by 
HPLC-MSMS.
Table 2.4 Accuracy and precision data for LC-MSMS (n=6)
Quality control samples mean (ng/mL) accuracy (%)
coefficient of 
variation (%)
LLQ (5 ng/mL) 5.2 104 12.3
MQC (100 ng/mL) 109 109 5.3
HQC (1000 ng/mL) 1076 107 5.4
Abbreviations as described on page 30
2.4.4: Application of HPLC-MSMS and HPLC-ICP-MS for the determination of 
ZD0473 in dog plasma.
In order to enable a comparison of the two methods to be performed on study-derived 
rather than spiked samples, both the HPLC-MSMS and the HPLC-ICP-MS methods 
were used to analyse plasma ultrafiltrate obtained following intravenous
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administration of ZD0473 at 0.5 mg/kg to a single dog. The data obtained using both 
methods are graphically represented in Figure 2.6 with the corresponding QC data in 
Table 2.5. Peak observed plasma concentrations were a little over 2000 ng/mL, 
falling rapidly to approximately 10 ng/mL by 3 hr post dose. Using HPLC-ICP-MS 
the concentrations of ZD0473 in the 6 and 12 hr post dose samples could be 
determined (2.0 and 1.4 ng/mL, respectively). HPLC-MSMS was, in contrast, unable 
to provide quantitative data for these samples. For those samples where both methods 
were able to provide results the correlation between the two sets of data was good, 
even though a small bias was observed. The HPLC-MSMS method generally shows a 
10-20 % higher value compared to the HPLC-ICP-MS method. However, when the 
data was put though statistical analysis (see below), where QC (validation study) and 
intravenous study sample data were included, the methods were shown to be 
equivalent as discussed in section 2.4.5.
Table 2.5 Quality control data for both HPLC-MSMS and HPLC-ICP-MS 
obtained during the analysis of plasma samples from a single dog 
dosed intravenously at 0.5 mg/kg with ZD0473.
QC Levels (ng/mL) 5 10 400 2500
HPLC-MSMS QC set 1 4.5 9.0 419 2670
HPLC-MSMS QC set 2 4.3 8.8 393 2490
mean 4.4 8.9 406 2580
accuracy (%) 88 89 101 103
HPLC-ICP-MS QC set 3 5.6 9.1 321 2700
HPLC-ICP-MS QC set 4 5.6 9.3 320 2568
mean 5.6 9.2 320 2634
accuracy (%) 112 92 80 105
NB The HPLC-MSMS and HPLC-ICP-MS were carried out on different days.
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The HPLC-ICP-MS and HPLC-MSMS-derived intravenous plasma profiles as 
illustrated in Figure 2.6 show the differences in the extent to which each technique 
can follow the plasma concentration of the drug leads to different plasma profiles 
being calculated. A two-compartment pharmacokinetic model consisting of a 
distribution phase and an elimination phase best fitted the HPLC-MSMS method, 
which followed the curve out to 3 hr when modelled. The ty2 for the terminal phase 
was 0.46 hr. When the HPLC-ICP-MS data were modelled the best fit was obtained 
using a three-compartment model. This consisted of a distribution phase followed by 
two apparent elimination phases. The first elimination phase gave a ty2 of 0.48 hr, 
which is comparable with the data obtained from the HPLC-MSMS system. The 
second apparent elimination phase gave a ty2 of 13.3 hr, however, more data points 
would be required to increase the degree of confidence in this value as it is based on 
data over a limited sampling period (12h). The AUC value for the HPLC-ICP-MS 
method was calculated to be 745 hr.ng/mL compared with 820 hr.ng/mL for the 
HPLC-MSMS method. The difference is primarily due to the slight bias observed in 
the methods with the HPLC-MSMS system having higher results; the longer terminal 
phase ti/2 value for the HPLC-ICP-MS method has a much smaller impact.
Overall, the pharmacokinetic data obtained for the two systems were shown to be 
comparable, with additional information gained from the HPLC-ICP-MS method as a 
result of the increased sensitivity of the instrument.
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Figure 2.6 Intravenous profiles gained from a male dog dose with ZD0473 at 0.5 
mg/kg. Two traces are represented with A) using plasma 
concentrations obtained from the more conventional technique of 
HPLC-MSMS. Trace B) shows plasma concentrations obtained using 
HPLC-ICP-MS demonstrating the extended range due to the lower 
detection ability.
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2.4.5: Statistical Comparison of Methods
In order to compare results statistically from two different instruments it is necessary 
to look at random error and systematic error. The statistical method used to 
investigate these parameters was based on the methodology of Gilbert et al [44], 
which requires at least 30 data points made up of QC and real samples. The data used 
for statistical comparison was therefore made up of the QC samples, obtained from 
the validation experiments, together with the samples obtained from a single dog 
dosed intravenously. A total of 35 data pairs were included in this comparison.
Random error was compared by examining the differences between the two sets of 
results, normalized to the reference concentration. The standard deviation was 
calculated and then the range of the mean ± 2*s.d. If this range then includes the 
value of zero then there is no significant random error between the two sets of results. 
The data from the two systems showed +2 s.d. of 272 and -2  s.d. -131, therefore 
showing that there was no random error associated with the data.
If the ratio between each paired result is calculated, the standard deviation is then 
calculated from these ratios and then the range of the mean ± 2* s.d. If this range 
includes the value of 1.0 then there is no significant systematic error between the two 
sets of results. The data from the two systems showed + 2 s.d. of 1.4 and -2  s.d. 0.8. 
This data therefore confirms that the error is within acceptable limits.
Even with the apparent bias observed between the two analytical techniques when the 
single dose intravenous data were subjected to statistical analysis the QC and real
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sample data sets were comparable within the limits of the test indicating that the 
methods are equivalent.
2.4.6: Aqua species comparison of HPLC-ICP-MS and HPLC-MSMS
Additional data were obtained from the HPLC-ICP-MS method, which enabled the 
determination of the aqua species in addition to ZD0473. Thus, the response for 
platinum remains constant no matter which compound contains the element and the 
concentrations of platinum-containing analytes such as the aqua species can be 
determined (Table 2.6), even in the absence of an authentic standard, in plasma 
samples. These data show that, even though acid was added to the samples to force 
the equilibrium in favour of ZD0473, the aqua species were still present to some 
extent (e.g. see Figure 2.4C). In the case of MSMS, where the relative ionisation 
efficiencies of the aqua species were not known, only qualitative data for these 
compounds could be obtained in the absence of response factor data. In order to 
determine the relative responses for these aqua compounds compared to ZD0473, a 
hyphenated HPLC-ICP-MS/MSMS system was constructed and samples from an oral 
dog study analysed. From the chromatograms illustrated for the combined system 
(Figure 2.7) it can be seen that the integration of the two spectrometers into a single 
system readily enables the determination of the MSMS responses for the aqua species 
by comparison with the values obtained simultaneously by ICP-MS. Thus, the 
relative responses for the aqua species, calculated by comparing the ratio of the 
responses for the ICP-MS based assay to the MSMS assay, were 1.1 ± 0.1 for the 
aqua species at Rt 2.3 min and 0.9 ± 0.2 for the aqua species at Rt 3.2 min (N = 4). In 
this instance therefore, the relative MSMS response for the aqua species was in fact
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essentially the same as that of ZD0473. The results for the aqua species present in the 
oral samples provided by both HPLC-ICP-MS and HPLC-MSMS (calculated using 
the above response factors) are given in Table 2.6.
Table 2.6 Plasma concentrations obtained from HPLC-ICP-MS and HPLC-
MSMS run in parallel after ultrafiltrate plasma samples were collected 
from a single male dog dosed orally at 6 mg/kg.
HPLC-ICP-MS
ZD0473 Aqua species at 2.3 min Aqua species at 3.2 min
sample (hour) (ng/mL) (ng/mL) (ng/mL)
0.25 200 14.1 9.4
0.5 326 25.9 21.8
0.75 230 17.9 12.0
1 196 20.8 14.2
HPLC-MSMS *
0.25 224 15.8 10.6
0.5 352 28.1 22.8
0.75 253 19.7 15.7
1 210 21.4 14.8
As shown elsewhere, such combined systems also provide a powerful technique in 
metabolite identification studies [40] where the ICP-MS data can be used to direct 
MSMS analysis to compound-related materials.
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Figure 2.7 Chromatograms obtained from the HPLC-ICP-MS and HPLC-MSMS 
assays run in parallel on a sample taken at 0.5 hours from a single dog 
dosed orally at 6 mg/kg. Chromatogram A) represents HPLC-ICP-MS 
trace monitored at m/z 195 for platinum and chromatogram B) 
representing an HPLC-MSMS trace monitoring the mass transitions as 
described in Table 2.2. Both traces show the two aqua species and the 
parent component ZD0473. For experimental conditions see section 
2.3.
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2.5: Conclusion
Both HPLC-ICP-MS and HPLC-MSMS enabled the detection and quantification of 
ZD0473 in plasma samples and provided the basis for robust bioanalytical methods. 
However, the HPLC-ICP-MS system was found to have greater sensitivity, with a 
limit of quantification for ZD0473 of 0.1 ng/mL (0.05ng/mL of platinum) compared 
to 5 ng/mL for the HPLC-MSMS method. Because it is based on the quantification of 
platinum, the HPLC-ICP-MS method also enables the facile quantification of the 
platinum-containing aqua species, even in the absence of standards. HPLC-ICP-MS 
provided an assay with a much greater linear range than HPLC-MSMS, being linear 
over 8 orders of magnitude, compared to just over 3 orders of magnitude for HPLC- 
MSMS. These studies show that HPLC-ICP-MS provides the basis for a routine 
method for the sensitive determination of ZD0473 and the related aqua species in 
biofluid samples.
The results presented in this chapter were published in Analytical Chemistry 75, 2003, 
1463-1469. (appendix A).
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Chapter 3
Analysis of a [14C]-labelled platinum anticancer compound in dosing 
formulations and urine using a combination of HPLC-ICP-MS and flow
scintillation counting.
3.1: Summary
HPLC-ICP-MS was used in combination with on-line radioactivity detection for the 
determination of [14C]-ZD0473, a platinum anticancer drug. Initially the system was 
set up to look at the purity of the formulations used in a dog study. This analysis 
showed that the oral formation had a purity of 93 %, with 91 % for the intravenous 
(i.v.) dose. The system was then adapted for use within the dog urine study following
i.v. administration to investigate the metabolism of ZD0473. The main purpose of the 
study was to investigate the difference between the values gained from the [14C]- 
labelled study compared to the data obtained from the total platinum results from an 
external laboratory. The results showed that the platinum levels were higher than that 
was seen for the [14C] data and it was postulated that the differences were due to the 
compound converting to the 2-picoline moiety, which retained the [14C]-label but lost 
the platinum element. The metabolism study in the dog showed 2-picoline to be 
present in urine samples. Samples from studies in rats were also successfully 
analysed.
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3.2: Introduction
As described in chapter 2, ZD0473 {cis-[amminedichloro(2-methylpyridine)] 
platinum(II)} is a new generation platinum compound designed to deliver an extended 
spectrum of antitumour activity and overcome platinum (Pt) resistance [45]. The 
structure of ZD0473 and related compounds, including the biologically active “aqua” 
compounds is shown in Figure 3.1. Having shown that HPLC-ICP-MS provided a 
suitable analysis for ZD0473 and related Pt-containing molecules in plasma, this 
methodology was used to provide a rapid, efficient and sensitive method of analysis 
for Pt in other samples containing ZD0473 and related materials. Here the use of 
HPLC-ICP-MS coupled with a radio flow scintillation counter and a UV detector is 
described to provide a method of analysis for [14C]-labelled ZD0473. The techniques 
were used in combination to determine whether the profile for [14C]-labelled 
compounds matched the profile obtained for Pt in chromatograms obtained for dose 
formulations and urine samples from a metabolism study.
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Figure 3.1 The structure of ZD0473 with the associated aqua species and position 
of radiolabels, and known impurities.
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3.3: Experimental
3.3.1: Reagents
Trifluoroacetic acid was purchased from Fisher (Fisher Scientific UK Ltd, 
Loughborough). Solvents for chromatography were of HPLC grade and were 
obtained from Fisher Scientific. The physiological saline used in the study for the 
dilution of samples and for the preparation of i.v. formulations, together with the 
hydroxypropylmethyl cellulose (HPMC) used in the preparation of the oral dose 
solution, was obtained from the Media Preparation Laboratory at AstraZeneca 
Pharmaceuticals. The scintillant used was Ultima-Flo M from Packard Ltd 
(Berkshire, UK).
ZD0473 was obtained from AstraZeneca Pharmaceuticals (Alderley Park, 
Macclesfield, UK) whilst [14C]-labelled ZD0473 was synthesised in the Isotope 
Chemistry Laboratory at AstraZeneca Pharmaceuticals at a specific activity of 55 
pCi/mg. The [14C]-labelled isotope was placed in the aromatic ring of ZD0473.
3.3.2: Reference compound
ZD0473 was dissolved at a concentration of 0.005 mg/ml in 0.5M sodium chloride.
In aqueous solution, ZD0473 forms equilibrium species (Figure 3.1). The 
concentrations of these species were dependent on the chloride ion. Radioactive label 
positions were shown in Figure 3.1.
48
3.4: Samples for Oral and tv. Dose Formulations
3.4.1: Oral and Lv. Dose Formulations of ZD0473
ZD0473 was formulated in physiological saline or 0.5 % HPMC for i.v. and oral 
administration respectively at a concentration of 0.5 mg/mL and a specific activity of 
55 pCi/mg. To ensure that ZD0473 was completely dissolved the formulations were 
made up and stirred for 3 hr prior to analysis.
3.4.2: Urine
Urine was collected for the period 6-12 hr following i.v. administration to a male 
beagle dog (Age 11 months, Weight 12.8 kg, Dose 0.5 mg/kg, 55 pCi/mg of [14C]- 
ZD0473). At the end of the sample period the weight was recorded and the urine split 
into two 20 mL portions and stored at -70°C in a freezer. Thawed samples were pre­
treated by centrifuging in an Eppendorf 5417C centrifuge (Eppendorf, Hamburg, D) 
for 5 minutes at 14000 rpm before injection (25 pL) onto the HLPC system.
3.4.3: Chromatography
Reversed-phase HPLC was performed using a Jasco gradient HPLC system PU-1580 
(Jasco Ltd, Great Dunmow, UK) with samples introduced via a PE 200 autosampler 
(PerkinElmer Ltd, Beaconsfield, UK). Chromatography was performed on an Inertsil 
ODS-3 150 mm x 4.6 mm 5 pm column (Hichrom Ltd, Reading, UK) at a flow rate of
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1.0 mL/min. The solvent system used for these separations was a gradient formed 
from 0.2% trifluoroacetic acid in water (solvent A) and methanol (solvent B). The 
gradient conditions are as shown in Table 3.1.
Table 3.1 Chromatographic gradient conditions
Time
minutes
Pump
programming
Mobile Phase 
A %
Mobile Phase 
B %
0 -4 Isocratic 98 2
4-11
Linear
gradient 98 to 80 2 to 20
11 -14 Isocratic 80 20
14-20
Linear
Gradient 80 to 98 20 to 2
3.4.4: UV and [14C]-Detection
The eluent from the column was directed via an splitter (LC Packings, Presearch, 
Hitchin, UK) to either a Micromass Platform ICP-MS (GV Instruments UK Ltd, 
Wythenshawe, UK) (250 pL/min) or to a Jasco UV-1575 intelligent vis / UV detector 
set at 265 nm (Jasco Ltd, Great Dunmow, UK) and a Flow One radio scintillation 
analyser (Packard, Berkshire, UK) (750 pL/min) connected in series. The Flow One 
detector was fitted with a low volume (50 pL) flow cell in order to preserve the 
resolution between peaks. For both UV and [14C]-detection Masslynx software 
version 3.4 (Micromass UK, Wythenshawe, UK) was used for data analysis.
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3.4.5: ICP-MS
The Platform ICP-MS instrument employed in these studies used a hexapole collision 
/ reaction cell based ICP mass spectrometer [42] for the simultaneous measurement of 
14C and 195Pt. The eluent from the column was introduced to the ICP-MS via a 
concentric nebuliser and a double pass spray chamber, which was cooled to -3 °C to 
allow an increase in the percentage of methanol used within the system. Masslynx 
software was used for the instrument control, data acquisition and data handling. The 
flow of the nebuliser gases and the operating and acquisition conditions of the ICP- 
MS are shown in Table 3.2.
The isotope envelope for Pt contains masses at 194,195,196 and 198 (at percentage 
abundance’s of 32.9, 33.8, 25.3, 8.0 %). Although it is possible to run the instrument 
in such a way as to sum these ions (which would theoretically give rise to an 
increased signal) in practice the increase in the background caused the process not to 
be beneficial in that the signal to noise ratio was not increased. Therefore the ion 195 
was monitored because it is the most abundant isotope of Pt.
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Table 3.2 Instrument operating conditions for the ICP-MS
Cooling gas 16.00 L/min Plasma Power 1350 w
Plasma gas 0.65 L/min Acquisition mode SIR
Nebuliser gas 0.75 L/min Dwell time 200 ms
Helium gas 1 mL/min Masses monitored 195,14
Hydrogen gas 4.0 mL/min Total analysis time 20 min
3.5: Results and Discussion 
3.5.1: Assay Development
The chromatographic system designed for this assay had to achieve the objectives of 
separation of the components in Figure 3.1, whilst under the constraints of solvent 
composition imposed by the ICP-MS [24,49]. This meant that the percentage of 
organic modifier had to be kept below approximately 40 % or the plasma would be 
compromised and / or extinguished. To overcome this limitation ion pair buffers (1- 
hexanesuluphonate, sodium salt) with a low percentage of methanol were investigated 
to obtain the required separation. This approach provided an adequate separation but 
was ultimately unsuccessful due to the buffer creating blockages within the ICP-MS 
system and poor chromatographic reproducibility between runs (Figure 3.2). The 
buffers were therefore, replaced with a water-methanol gradient system, which had a
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final methanol composition of 30 %. The instrument was able to run at this 
percentage of methanol due to the low flow rate (250 pL/min) and the spray chamber 
being cooled to -3 °C. The system was further optimised and the final 
chromatographic conditions were as described in Table 3.1. A standard 
chromatogram is shown in Figure 3.3. The change of HPLC system resulted in 
improved equipment reliability and more robust chromatographic separation.
3.5.2: Oral and IV Dose Formulation Purity Determination
The dose solutions prepared for the i.v. and oral formulations were analysed to see if 
they were of the required purity before dosing was carried out. Typical results for the 
UV, 195Pt, and [14C]-profiles generated for the oral and i.v. formulations are shown in 
Figures 3.4 and 3.5 respectively. The dose purity can be calculated by summing the 
ZD0473 peak area with those for the aqua species to give the total percentage of 
active drug. In this instance this was found to be 91 % for the oral dose solution and 
93% for the i.v. dose by ICP-MS. These results show that for the dose solutions there 
was a good degree of correspondence between the chromatograms obtained for the 3 
modes of detection.
The method demonstrated that the ratio of aqua species was different for each sample 
analysed. The reason for the increased levels and different ratio of aqua species in the 
oral sample was probably due to the formulation having a higher salt content and 
therefore driving the equilibrium in the direction of the aqua species.
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Figure 3.2 A typical example of a chromatogram obtained using an ion pair 
reagent with ICP-MS detection of Pt at m/z 195. A large peak for 
ZD0473 is shown at 10.0 min for a purity sample. However, the 
chromatography at the start of the run shows a loss in resolution due to 
poor chromatography caused by the sodium 1-hexanesulphonate ion 
pair reagent. The reagent also caused problems with blockages with 
the nebuliser making the system unreliable. For experimental 
conditions see section 3.3.
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Figure 3.3 A typical chromatogram obtained from of the methanol-water gradient 
elution developed for the separation of the aqua species and impurity 
components. A: TCAP B: Aqua species 1 C: 2-Picoline D: ZD0473 
E: Aqua species 2 F: TCPP.
a) UV absorbance trace at 267 nm, b) ICP-MS trace at m/z 195 forPt. 
For experimental conditions see section 3.3.
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Figure 3.4 Typical a) ICP-MS platinum, b) radioactivity and c) UV absorbance 
traces obtained for the oral dose solution at concentration of 0.5 
mg/mL. Peaks B, D and E represents aqua species 1, ZD0473 and 
aqua species 2 respectively. A purity value of 91 % was obtained when 
the peaks from the Pt trace were summed. For experimental conditions 
see section 3.3
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Figure 3.5 Typical a) ICP-MS platinum, b) radioactivity and c) UV absorbance
traces obtained for the IV dose solution at concentration of 0.5 mg/mL. 
Peaks B, D and E represents aqua species 1, ZD0473 and aqua species 
2 respectively. A purity value of 93 % was obtained when the peaks 
from the Pt trace were summed. For experimental conditions see 
section 3.3
57
3.5.3: Analysis of Urine samples obtained from i.v. dose.
The chromatographic system developed for the analysis of the formulation samples 
was also used for urines obtained from a radio-labelled excretion balance study 
carried out in the dog, following intravenous administration of [14C]-ZD 0473. The 
UV absorbance (254 nm), 14C radio detection and ICP-MS at m/z 195 traces obtained 
for a single dog (6-12hr post dose) are shown in Figure 3.6. From the 195Pt trace 
unchanged ZD0473 accounted for 6.95% of the total based on the retention time. The 
remainder consisted of 8 Pt-containing peaks, eluting between 2 and 14 minutes, but 
none of these peaks corresponded to any of the degradation products represented in 
Figure 3.1. Comparison of the 195Pt trace with the radioactivity profile revealed 
several noticeable differences. In particular a large radio-labelled peak was observed 
at 13.10 min, which was not present in the 195Pt trace. This discrepancy in the profiles 
obtained for the 195Pt and 14C traces indicates that at some stage in the metabolism of 
the compound by the dog, the 2-picoline moiety, which contains the radio-label, has 
been detached from the platinum. The use of both detectors, therefore, provides 
valuable and more robust metabolic information that would not have been obtained 
had only one been used. The identity of these metabolites is considered in the 
following sections in relating to [14C] and ICP-MS detection. No useful metabolic 
information could be gained from UV absorbance detection at 267 nm due to the 
interference from endogenous material.
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Figure 3.6 A typical set of traces for A) ICP-MS platinum, B) radioactivity and C) 
UV absorbance (267 nm) obtained for a dog urine sample. The ICP- 
MS trace shows that ZD0473 is present and can be quantified against 
an external standard. The [14C]-trace shows the presences of 
metabolite peaks, which have lost the Pt element. The UV trace is not 
selective enough to provide useful information. For experimental 
conditions see section 3.3
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3.6: Radioactivity and platinum profiling of urine samples from tissue
distribution and excretion studies in the rat.
The previously described analytical system was set up to investigate the metabolism 
of ZD0473 in samples from rodents. The purpose of this study was to compare the 
chromatographic profiles of platinum and 14C in urine, following single and multiple 
intravenous administration of [14C]-ZD0473 to male rats. A mass spectrometer was 
also run in parallel to gain molecular information.
3.7: Radioactive samples for dosing
Three sets of dosings were carried out in the study.
3.7.1: Single dose
Three male rats each received a single intravenous dose of [14C]-ZD0473 at 30 mg/kg 
with a target radioactive dose of 150 pCi/kg. Urine was collected at 0-6, 6-12,12-24 
hours and subsequently at daily intervals up to 7 days post dose. Pooled urine 
samples collected over the first 24 hours from one animal were analysed in this study. 
This represented more than 80% of the urinary excretion of total radioactivity from 
this animal.
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3.7.2: Low multiple dose
Three male rats each received an intravenous multiple dose of [14C]-ZD0473 at 5 
mg/kg/day for 5 days with a target radioactivity dose of 175 pCi/kg. Urine was 
collected at 0-6, 6-12 and 12-24 hours post dose on days 1 to 5 and at daily intervals 
up to 7 days post the fifth dose. Pooled urine samples from one animal were analysed 
in this study. This represented greater than 90% of the urinary excretion of total 
radioactivity from this animal.
3.7.3: High multiple dose
Three male rats each received an intravenous multiple dose of [14C]-ZD0473 at 7.5 
mg/kg/day for 5 days with a target radioactivity dose 260 pCi/kg. Urine was 
collected at 0-6, 6-12 and 12-24 hours post dose on days 1 to 5 and at daily intervals 
up to 7 days post the fifth dose. Pooled urine samples from one animal were analysed 
in this study. This represented greater than 95% of urinary excretion of total 
radioactivity from this animal.
3.8: Analytical design and sample preparation
For the single 30 mg/kg and the multiple 7.5 mg/kg/day doses, pooled urine samples 
were generated by taking 40-50% of the sample generated over the time periods, 0-6, 
6-12 and 12-24 post doses on days 1 and 5, respectively. Samples analysed were 
from one animal for each dosing regimen. For the 5 mg/kg/day dose, a single urine
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sample from one animal, generated over the first 24 hours following the fifth dose, 
was analysed.
The samples were injected onto the HPLC system either undiluted or following 
dilution with an equal volume of distilled water, with no pre-treatment.
3.9: Analytical procedures and equipment
Injections were made using a Perkin Elmer series 200 autoinjector on to a reversed 
phase HPLC column, (Inertsil ODS-3 5pm, 150 x 4.6 mm id) in a column oven set at 
35 °C.
The HPLC mobile phase was delivered using a Jasco PU-1580 pump delivering the 
gradient shown in Table 3.1 with mobile phase made up of 0.2% TFA in distilled 
water and methanol (eluents A and B, respectively). The HPLC flow was split twice, 
the initial split, using an accurate splitter, directing 250 pL/min to the radioactivity 
detector and 750 pL/min towards the mass spectrometer. The second split, of the 750 
pL/min flow, was achieved using a model 600 (Jasco) splitter valve directing 375 
pL/min to both the ICP-MS and the API 3000 mass spectrometer.
The UV detector was a model 1575 (Jasco) set at 267 nm. The radio-detector was a 
series 150TR instrument (Packard) fitted with a liquid flow cell.
A Sciex API 3000 triple quadrupole LC-MSMS mass spectrometer operated in 
positive mode, scanning between 50-150 and 300-500 amu, and a Micromass ICP-MS
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were operated in parallel to the UV and radioactivity detectors. Figure 3.7 shows the 
system used in the study.
Jasco gradient pump system Row one Scintillation counter
Row rate 1 ml/riin
Perkin Hrrer series 200 autosanpler Ultra violet detector
ICPMS
Cokumoven ►
Accurate splitter
Jasco splitter
API-3000 miss spectrometer
375 pl/rrin
Figure 3.7 Schematic diagram of the system used for the analysis of 
ZD0473 and its associated metabolites and impurities with 
simultaneous measurement of 14C, UV absorbance, organic 
mass spectra and Pt.
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3.10: Results and discussion (rat urine profiling experiment)
A typical Pt trace for a rat urine sample is shown in Figure 3.8, and a radio HPLC 
chromatogram in Figure 3.9. The relative proportions of radio-labelled components 
detected, as a percentage of the traces, are shown in Table 3.3, with retention times in 
Table 3.4. HPLC-MSMS traces and fragmentation patterns for ZD0473 and 2- 
picoline standards are shown in Figure 3.10. HPLC-MS traces and fragmentation 
patterns for two unknown components are shown in Figure 3.11. Comparison of the 
components seen by the three detection methods is given in Table 3.5.
The radio-chromatograms of urine showed three major components in all samples 
accounting for a total of approximately 50 to 70 % on the trace (Figure 3.9 and Table 
3.3). The remaining activity consisted of several components, which could not 
reliably be quantified above the background levels.
The proportion of ZD0473 in urine [14C]-traces was in the range 4.5 to 24 %. Levels 
of ZD0473 were at the lower range for samples taken from animals following 5 daily 
intravenous administrations of ZD0473 as compared to those collected following 
single administration (Table 3.3).
The aqua species were not detectable in the radio-labelled traces, but were seen with 
platinum detection at approximate relative retention times of 0.63 and 1.1, 
corresponding with those of the aqua standards (Figure 3.3 and Table 3.6). The 
identity of the component at relative retention time of 0.63 was confirmed as being
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one of the aqua species, due to the presence of the characteristic fragmentation pattern 
for ZD0473 shown in Figure 3.10.
The peak at relative retention time 0.72 in the [14C]-trace had no corresponding 
platinum peak (Table 3.6) suggesting this to be a product derived from cleavage of the 
platinum - 2-picoline ring bond as suggested, and furthermore the relative retention 
time was similar to the 2-picoline standard, suggesting this to be the identity of this 
component. The identity of 2-picoline was confirmed from the MS data, since the 
product ion was characteristic for 2-picoline at 94 amu (Figure 3.11).
In the radioactivity and ICP-MS platinum chromatograms for all samples, a 
component eluted later than ZD0473, with relative retention time of approximately 
1.4. The identity of this component could not be identified, but since it contains both 
platinum and [14C]-labels, this suggests that the platinum to 2-picoline bond was 
intact. There was platinum isotope pattern data at around 400 amu suggesting this 
component to have molecular weight greater than ZD0473. This suggests that the 
component may be a conjugate or adduct, e.g. with an endogenous amino acid, 
however there was insufficient data to make an identification.
There may be additional, but minor, components present, which may be adducts or 
conjugates with higher molecular weights than those discussed above. However, MS 
analysis was only performed for mass units of up to m/z 500 in this study due to 
limitation in the spectrometer, in order to maintain sensitivity.
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No data were obtained to aid the identification of the relatively minor components 
seen at a relative retention time of 0.34 to 0.38 in the platinum and [14C]-traces.
Table 3.3 Components detected in the radio-chromatogram from 0-24 hour
pooled urine samples following intraveneous doses of ZD0473 to male 
rats given either as single doses or as multiple once daily 
administration over 5 days.
Relative retention time to ZD0473 =1 (min)
Dose level Sample 0.34 0.5 0.72 ZD0473 1.45
Percentage amounts for peaks in the racio trace Total %
30 mg/kg M15 Day 1 1.43 - 12.7 23.8 34.2 72.1
5 mg/kg M10 Day 1 1.33 - 13.2 15.9 35 65.4
5 mg/kg M10 Day 5 12.9 - 15.6 4.49 22.3 55.3
7.5 mg/kg M19 Day 1 0.98 - 14.7 16.8 35.9 68.4
7.5 mg/kg M19 Day 5 7.7 6.5 16.6 7.6 30.5 68.9
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HPLC platinum trace of a 0-24 hour urine sample (animal 15M) 
following a single intravenous dose of [14C]-ZD0473 at 30 mg/kg. The 
peak at relative retention time 0.34 is an unknown. No Pt peak was 
seen at 0.72, which corresponds to 2-picoline retention time. The peak 
at 1.45 has been postulated as a conjugate or adduct. For experimental 
conditions see section 3.3
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Figure 3.9 HPLC radiochromatogram of a 0-24 hour urine sample (animal 15M) 
following a single intravenous dose of [UC]-ZD0473 at 30 mg/kg. The 
peak represented at relative retention time of 0.34 is an unknown. The 
peak at 0.72 having a [14C] response represents 2-picoline moiety. The 
peak at 1.45 represents a metabolite suggesting a conjugate or adduct. 
For experimental conditions see section 3.3.
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Table 3.4 Mean retention times relative to ZD0473 for HPLC-ICP-MS
components detected in all 0-24 urine samples obtained following 
intravenous doses of ZD0473 to male rats given as single doses or as 
multiple once daily administrations over 5 days.
Retention times (min) relative to ZD0473
mean 0.38 0.62* ZD0473 (1.00) 1.12 1.24** 1.39 1.52* 1.68*
Not present in all samples 
Present only in day 5 samples
Table 3.5 Mean retention times relative to ZD0473 for HPLC-MS components 
detected in all 0-24 urine samples obtained following intravenous 
doses of ZD0473 to male rats given as single doses or as multiple once 
daily administrations over 5 days.
Retention times relative to ZD0473
mean 0.41 0.63 0.74 ZD0473 (1.00) 1.38 1.71
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Table 3.6 Summary of the relative retention times (min) with all detection
methods for all 0-24 hr urine samples analysed following intravenous 
doses of ZD0473 to male rats given as single doses or a multiple once 
daily administrations over 5 days.
[14C] Platinum data MS data
Tentative component 
Identification
0.34 0.38 0.41 Unknown**
n.d. 0.62 0.63 Aqua
0.72 n.d. 0.74 2-picoline
ZD0473 ZD0473 ZD0473 ZD0473
n.d. 1.12 n.d. Aqua
1.45 1.39 1.38 (Pt isotope pattern at 400 amu) Unknown 1
n.d. 1.68 1.71 Unknown 2
** eluted at the solvent front and hence may be a mixture of components
n.d. Not detected
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Figure 3.10 HPLC-MS reference compound trace of ZD0473 at a concentration of 
1 pg/mL. A. Represents a Q1 scan of ZD00473 showing a high 
background due to the wide scan range. B. Mass spectrum showing 
the fragmentation product indicative of ZD0473. For experimental 
conditions see section 3.3.
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Figure 3.11 A. HPLC-MS TIC from a 0-24 hour pooled urine sample following a
single dose of [14C]-ZD0473 at 30 mg/kg to a male rat. B. Mass 
spectrum of 2-picoline. C. Mass spectrum of unknown showing Pt- 
isotope pattern near 400 amu. For experimental conditions see section 
3.3
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3.11: Study conclusions (rat urine profiling experiment)
The primary objective was to obtain HPLC profiles of platinum and radio-activity in 
rat urine samples taken from studies following administration of [14C]-ZD0473 as 
single doses at 30 mg/kg and multiple, once daily intravenous doses at 5 and 7.5 
mg/kg/day over 5 days. A second aim was to identify components where possible.
Samples were analysed by HPLC interfaced with radio-detection, ICP-MS for 
platinum detection and MS for tentative identification.
Following single and multiple dosing regimes, 3 major radio-labelled components and 
2 major and at least 2 minor platinum containing components were detected in rat 
urine, as summarised in Table 3.6.
ZD0473 was detected in both [14C] radio-activity and ICP-MS-Pt chromatograms.
One of the components in the [14C] trace was absent from the platinum trace and was 
identified by LC-MS as 2-picoline suggesting cleavage of the platinum to 2-picoline 
bond in the ZD0473 molecule.
Two components which eluted later than ZD0473 were detected. The first of these 
components contained both platinum and [14C] labels indicating the platinum to 2- 
picoline bond to be intact. HPLC-MS showed the molecular weight of this 
component to be greater than ZD0473 suggesting it to be a conjugate or adduct.
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Further work is required to establish the metabolism of ZD0473 in the rat.
3.12: Conclusion
HPLC-ICP-MS provided a sensitive and specific method for the detection of the 
anticancer drug ZD0473 and its Pt-containing impurities and metabolites in 
formulations and biological fluids. The use of ICP-MS and a radio activity detector in 
parallel enabled the simultaneous detection of radioactivity and Pt providing a more 
complete and robust profile of components in samples than would have been possible 
using either technique on its own. Addition of an HPLC-MS into the system to 
provide molecular mass information aided identification of the peaks observed with 
the other techniques. This combination showed clear benefits in that components 
were observed which contained only Pt or [14C] giving both quantification and 
identification.
Some of data presented within this chapter were published in Smith etal, 
Chromatographia 55, 2002,151-155. (appendix A).
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Chapter 4
HPLC-ICP-MS and HPLC-ICP-MS-MSMS for the detection of carbon- 
containing compounds. 
4.1: Summary
High performance liquid chromatography (HPLC) combined with inductively coupled 
plasma mass spectrometry (ICP-MS) has been studied as a means for the detection of 
carbon to provide a “universal” method for detecting organic compounds in 
chromatographic eluents. Initial interest was generated in the detection of carbon 
when analysis of a platinum anti cancer compound containing a [14C]-label was 
carried out. The ICP-MS was set up to look for the [14C]-element and a response was 
gained from a peak containing 25600 dpm from an initial loading of 1.37 x 106 dpm. 
An attempt was therefore made to try to detect the non-radioactive isotopes of carbon. 
Carbon is particularly difficult to ionise and the amount of carbon present in normal 
chromatographic systems leads to high backgrounds, making detection a challenge. 
Novel separation approaches were therefore employed, using either entirely aqueous 
eluents (at temperatures of 60 and 160°C, dependent on the column used) to eliminate 
the organic modifier completely, or isotopically enriched solvents. For the aqueous 
eluents, detection limits for sulphanilamide were found to be 1.13 pmol (0.47 pmol of 
carbon), injected on a conventional 4.6 mm i.d. column. The use of a narrow bore 
column with highly isotopically enriched [12C]-methanol (99.95 atom%) as organic 
modifier for the mobile phase enabled the detection of 86 pmol for [13C]-triple- 
labelled caffeine and 79 pmol for [13C]-double-labelled phenacetin. The sensitive
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19 1 “3detection of [ C]-compounds with [ C]-enriched methanol as organic modifier 
proved impractical due to a lower level of isotopic purity (99 % atom) of this solvent, 
with the residual [12C]-methanol resulting in significant interference.
4.2: Introduction
The combination of ICP-MS with liquid chromatography has resulted in renewed 
interest in element specific detection in HPLC. In addition to the detection of metals 
such as platinum [5, 54], the technique has been found to be suitable for the detection 
of elements such as bromine [6,41], chlorine [55], iodine [8, 56], phosphorus [16,42] 
and sulphur [9, 57, 58] for both quantitative and qualitative analysis.
As part of an investigation on the use of HPLC-ICP-MS for drug analysis the ability 
of HPLC-ICP-MS to detect a [14C]-labelled anti-cancer compound in a formulation 
[39], based on the presence of 14C+ was investigated. The specific detection of 14C+ by 
ICP-MS was possible because of the low natural abundance of this isotope. This 
meant that interference from endogenous carbon, for example from the HPLC mobile 
phase, was negligible. Despite the fact that the resolving power of quadrupole ICP- 
MS instruments is insufficient to separate the masses 14N+ (14.0031) and 14C+ 
(14.001), the addition of H2 to the collision cell to remove 14N+ allowed 14C+ to be 
detected with good specificity. These results led us to consider the possible use of 
ICP-MS to provide a “universal” method for the detection of organic compounds 
based on the detection of the more abundant isotopes of carbon (as has been 
investigated to some extent in HPLC-AES [59]). Such a technique would potentially 
be useful in that it would enable the amounts of individual components in a mixture
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(e.g. from combinatorial synthesis) to be determined in the absence of authentic 
standards or knowledge of e.g. molar UV extinction coefficients etc. Such 
information is currently sought using e.g. chemiluminescent nitrogen detectors 
(CLND) for N and S-containing compounds, or evaporative light scattering detectors 
(ELSD) [60], but similar results should be obtainable though HPLC-ICP-MS with 
carbon detection. Such information might be especially valuable when combined 
with some means of determining the molecular mass of analytes, such as mass 
spectrometry, to enable molar responses to be calculated. The problem with the 
detection of 12C+ and 13C+ is that they are omni-present, from the organic modifiers 
used for conventional chromatography. This leads to high background interferences, 
so that sensitive detection is not possible. However, analysis of the more common 
isotopes of carbon might be possible if such interferences could be removed from the 
system. One possible answer explored here is the use of entirely aqueous eluents, 
including superheated water [61], where the mobile phase consists entirely of water, 
with separation controlled by changing the column temperature. Other background 
interferences can be controlled by chemical reaction with collision gases in the 
quadrupole [23]. An alternative way of reducing background interferences to 
manageable levels, also investigated here, is the use of 12C or 13C enriched solvents 
for the detection of [13C]-enriched and normal [12C]-containing compounds 
respectively.
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4.3: Detection of [14C] by ICP-MS
In addition to the detection of 195Pt as described in chapter 3, we also undertook an 
investigation of the potential of HPLC-ICP-MS to detect the 14C+ isotope present in 
[14C]-ZD0473. Detection of 14C+is subject to two major difficulties namely; 1) high 
background at mass 14 from the presence of 14N+ ions, and 2) relatively low 
sensitivity due to the high ionisation energy of carbon.
The atomic mass of 14N+ is 14.00307 amu whereas the atomic mass of 14C+ is 
14.00324 amu. Therefore, the resolution required to separate these two ions by mass 
spectrometry is m/Am = 82371. Commercially available high-resolution ICP-MS 
systems do not offer much higher resolution than m/Am =10000. As such, it is 
impossible to separate 14N+ from 14C+ by high resolution ICP-MS. However, the ICP- 
MS instrument used in this study, albeit being a quadrupole based system with a 
nominal resolution of m/Am = 400, is equipped with a hexapole collision / reaction 
cell. It was therefore decided to investigate the potential of using this cell to 
chemically separate the 14C+ and 14N+ ions. Literature data on ion / molecule 
reactions clearly show that C+ ions do not react with H2 whilst the reaction of N+ and 
H2 (N+ + H2 NET + H+) is very efficient [52]. In agreement with these data, we 
observed that the addition of 4 mL/min of H2 in the cell resulted in a virtually 
complete conversion of the N+ ions into NH+ without significantly affecting the 
sensitivity for 14C+.
Because the first ionisation energy of C is high (11.3 eV) the population of C+ ions 
formed in the ICP is relatively low (c.a. 5%). Therefore, the sensitivity of ICP-MS
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for 14C+ is about 20 times lower than it is for elements with low ionisation energies 
(where the ionisation efficiency is nearly 100%). However, it is possible to optimise 
for maximum sensitivity for 14C+ by adjusting the plasma operating conditions 
(though changes in the argon gas flows) and the ion extraction conditions (via 
changes the cone voltages within the Masslynx software).
As a result of tuning the instrument and using H2 in the collision cell, it was possible 
to detect 14C+ in the samples under investigation. The chromatogram shown in Figure 
4.1 was obtained for radio-labelled ZD0473 in the IV formulation with initial loading 
of 1.36xl06 dpm. When this quantity was injected onto the column a measurement of 
25,600 dpm was found. It is apparent from this chromatogram that minor peaks were 
not observed and that in its current state of development ICP-MS detection could not 
be used alone for the determination of both 195Pt and 14C+, nevertheless the detection 
of the radiolabel 14C associated with the main peak of ZD0473 was promising.
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Figure 4.1 HPLC-ICP-MS chromatogram obtained for the monitoring of the radio 
label [14C] at m/z 14 after 100 pL injection of 0.5 mg/mL (1.37 x 106 
dpm) ZD0473 standard. 95 % of the molecule was labelled and a 
response of 25,600 dpm was achieved. For experimental conditions 
see section 3.3.
80
The work carried out on 14C+ showed it was possible to detect carbon using ICP-MS. 
This was the first time the ICP-MS had been used in this manner and the data were 
published in Chromatographia [39]. The full potential of the HPLC-ICP-MS for this 
type of work was further investigated, utilising new modes of operation to allow the 
detection of 12C+ and 13C+.
4.4: Experimental 
4.4.1: Reagents
Sulphanilamide, caffeine, antipyrine, and paracetamol (acetaminophen) used in this 
study were obtained from Sigma-Aldrich (Dorset, UK) at a purity of 99 %. The [13C]- 
enriched caffeine (13C-triple-labelled, 99 atom %), phenacetin (13C-double-labelled,
99 atom %) and the [12C]-enriched methanol (99.95 atom %) were also supplied by 
Sigma-Aldrich. The [13C]-enriched methanol (99 atom %) was obtained from 
Cambridge Isotope Laboratories (Andover, USA).
4.4.2: Standard Solution Preparation
Caffeine, antipyrine and paracetamol stock solutions were prepared in water at a 
concentration of 5 mg/mL in 10 mL volumetric flasks with gentle heating to aid 
dissolution. Further dilutions were prepared in water to the concentrations of 1 and 
0.1 mg/mL. [ CJ-enriched caffeine and phenacetin were dissolved in [ C]-enriched 
methanol / water (1:1) mixture to a concentration of 1 mg/mL.
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4.4.3: Preparation of standard curve and quality control samples.
A standard curve was constructed for caffeine with quality control data also obtained 
at each calibration point by injecting the sample six times. The caffeine standard 
curve was prepared at concentrations of 10, 5, 2,1, 0.75, 0.5, 0.25, 0.1 and 0.05 
mg/mL. A similar experiment was carried out for the [13C]-labelled caffeine with 
concentrations of 1, 0.5, 0.3, 0.15 and 0.075 mg/mL used to construct the standard 
curve.
4.3.4: HPLC-ICP-MS and HPLC-ICP-MS-MSMS
The HPLC-ICP-MS was set up in three different configurations as described below.
Chromatography for the ICP-MS with entirely aqueous solvent systems was 
performed using a Jasco PU-1580 HPLC pump (Jasco Ltd, Great Dunmow, UK) with 
samples introduced via a PE 200 autosampler (PerkinElmer Ltd, Beaconsfield, UK). 
Column heating was carried out using an Eppendorf TC-50 column heater (Presearch, 
Hitchin, UK). ICP-MS was performed on a Platform ICP-MS, which used a hexapole 
collision / reaction cell for simultaneous measurement of the carbon isotopes (GV 
Instruments, Wythenshawe, UK). MassLynx software was used for instrument 
control, data acquisition and data handling. Flow rates of the nebuliser gases and 
operating conditions of the ICP-MS are shown in Table 4.1.
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Table 4.1 Instrument operating conditions for the ICP-MS
Cooling gas 16.00 L/min Plasma Power 1350 w
Plasma gas 0.65 L/min Acquisition mode SIR
Nebuliser gas 0.75 L/min Dwell time 200 ms
Helium gas 1 mL/min Masses monitored 12, 13
Hydrogen gas 4.0 mL/min Total analysis time 7 min
For some experiments, see below, an API-365 MS (Applied Biosystems, Warrington 
UK) was connected in parallel via an in line splitter to a turbo ionspray inlet source, 
scanning over 100 to 400 m/z. Analyst software was used for the instrument control, 
data acquisition and data handling. The system was connected into the HPLC-ICP- 
MS system via PEEK tubing (0.13 mm) with the flow controlled by an accurate 
splitter (Presearch, Hitchin, UK).
4.4.4: Aqueous Separations at 60°C
The separation of caffeine, antipyrine and paracetamol with an aqueous mobile phase 
at 60°C was performed with 20 pL injection into a Discovery Zirconia-PDB 150 x 4.6 
mm, 5 pm column (Supelco, Bellefonte USA) at a flow rate of 1 mL/min. The mobile 
phase was heated to 60°C and for this experiment the flow was split using an accurate 
splitter with 700 pL/min to an API-365 mass spectrometer, and 300 pL/min to the 
ICP-MS using a concentric nebuliser with a double pass spray chamber (GV 
Instruments, Wythenshawe, UK), for sample introduction. The flow into the mass
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spectrometer was adjusted to allow 200 pL/min to enter the turbo ionspray source via 
a 1 to 5 splitter.
4.4.5: Aqueous Separations at 160°C
The separation of caffeine, paracetamol and phenacetin was also performed using 
superheated water at 160°C as the mobile phase on an XTerra C8 150 x 4.6 mm 5 pm 
column (Waters, Watford, UK) at a flow rate of 1 mL/min with an IS6000 ultrasonic 
nebuliser (Cetec Technologies, Omaha, Nebraska, USA) for sample introduction to 
the ICP-MS. The injector was flushed with 100 pL of water between samples with an 
injection volume of 20 pL.
4.4.6: Application to Caffeine Determination in Coffee
Instant coffee, 20 mg, (Carte Noire), purchased from a local supermarket, was 
dissolved in water, with gentle heating to aid dissolution. An aliquot (100 pL) of this 
sample was analysed by HPLC-ICP-MS using an XTerra column operated at 160°C 
and a flow rate of 1 mL/min as described above.
4.4.7: Separations with Isotopically Enriched Solvents
For both the [12C] and [13C]-istopically enriched mobile phases a microbore 
chromatographic system was used. Jasco PU-1580 pumps were used for solvent 
delivery at a flow rate of 0.1 mL/min. Separations were performed on a Polaris 50 x 1 
mm i.d., 3p column (Varian, Lake Forest, USA) with injection volumes of 10 pL
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from a PerkinElmer 200 series autosampler. Mobile phases were made up of the 
enriched [12C] or [13C] solvent with water (20/80 V/V).
Gradient elution was also employed for the chromatography of phenacetin (from 95 % 
water 5% enriched methanol to 50 % water 50 % enriched methanol linearly over 10 
minutes).
4.5: Results and Discussion
It was possible to detect 14C+ in the eluent from an HPLC column using ICP-MS [39] 
because of the absence of significant interference from background levels of 14C+ in 
the organic modifier used for the eluent. However, for sensitive detection of the 
naturally abundant isotopes of carbon, the ICP-MS clearly has to be operated in such 
away that as much of the external carbon interference as possible is eliminated to 
minimise background levels. One strategy to achieve this is the use of entirely 
aqueous eluents, as this removes organic modifier that would otherwise make carbon 
detection impractical. This is possible for a limited number of polar analytes and this 
range can be extended by performing chromatography at elevated temperatures (e.g. 
above 100°C with so-called superheated water [61]). Indeed, in many ways water 
provides the prefect chromatographic eluent to use with ICP-MS since there are no 
organic components present to quench the plasma.
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4.5.1: HPLC-ICP-MS with Entirely Aqueous Mobile Phases.
Initial experiments with sulphanilamide, using superheated water chromatography at 
160°C on the XTerra phase, confirmed the principle and indicated that a detection 
limit of ca 1.13 pmol of material could be achieved (470 nmol of carbon). Under 
these conditions sulphanilamide eluted rapidly from the column, with a retention time 
of just over 2 min. as shown in Figure 4.2a. These early investigations highlighted the 
importance of eliminating organic solvents from the system if possible. Thus, in one 
experiment, the compound was taken up in methanol: water (5:95 % V:V) and then 
diluted with water (1:10) for injection on to the system. As shown in Figure 4.2b, 
whilst the peak corresponding to analyte is still clearly visible it is superimposed on a 
much larger, and very broad, peak due to the residual methanol present in the 
injection solvent. It is noteworthy that the methanol peak required ca. 40 minutes of 
elution before it returned to baseline again (Figure 4.2 C). Thus the required solvent 
for both sample dissolution and chromatography is clearly water, though this does 
place constraints on the type of compounds for which this strategy would be suitable. 
We also noted that when the PEEK tubing was used at these high operating 
temperature it showed signs of degradation, which caused an elevated background 
level. Steel stainless tubing was therefore substituted to minimise this problem.
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Figure 4.2. (A) 12C HPLC-ICP-MS chromatography of 2.26 pg of sulphanilamide
(1.13 pmol, 470 nmol of carbon) on an Xterra column at 160°C and 1 
mL/min. (B) The same analysis for a sulphanilamide sample made up 
in 0.5 % methanol on the same time span for comparison. The insert, 
chromatogram (C), shows the baseline disturbance due to the methanol 
produced in chromatogram (B).
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Chromatography was then performed on a mixture of three model compounds, 
caffeine, paracetamol and antipyrine, on Zirconia-based and XTerra stationary phases, 
with pure water as the mobile phase, and column oven temperatures of 60°C and 
160°C respectively. Representative chromatograms are shown in Figures 4.3a and b 
for XTerra and Zirconica with the phases producing similar separation and peak 
shape.
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Figure 4.3. (A) 12C HPLC-ICP-MS chromatogram showing the separation of
paracetamol (1), caffeine (2) and antipyrine (3) on a Xterra column at 
160°C. (B, C) Chromatograms showing the detection of the same 
compounds, separated on a Zirconica column at 60°C, detected by ICP- 
MS and MS, respectively. (D, E, F) Mass spectra obtained for the 
three compounds.
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The response of the ICP-MS to 12C+ for these compounds was found to be linear over 
the range examined (16 to 320 pmol) with detection limits down to 1.28 pmol (0.64 
pmol of carbon) calculated for both columns and temperatures. Whilst not 
investigated exhaustively, reproducibility was examined by multiple injections of 
standards (six replicates) at a concentration of 16 pmol on column for the Zirconia 
column at 60 °C. The standard deviations obtained for this experiment were ca. 6.8, 
7.8 and 6.5 % for paracetamol, caffeine and antipyrine respectively.
Clearly, as detection in the ICP-MS is proportional to the amount of carbon in each 
compound, the potential exists for the quantitative analysis of compounds in a mixture 
as, if the atomic composition of the compound is known, an absolute value can be 
obtained for the response, which relates to the amount of carbon present in the 
molecule. Table 4.2 shows an example of this with the area response obtained 
proportional to the amount of carbon atoms present divided by relative molecular 
mass (RRM) in each compound. This information would allow the amount of 
compound to be quantified relative to an external standard. With unknowns the 
molecular masses of the individual components could be obtained by dividing the 
effluent from the column between the ICP-MS and a conventional MS, as described 
by O’Corcoron etal [62]. To illustrate this, an API-365 triple quadrupole mass 
spectrometer was connected into the system by splitting the eluent from the column to 
the ICP-MS as described in the experimental section. This system was used to obtain 
simultaneous HPLC-ICP-MS and MS data from the mixture of paracetamol, caffeine 
and phenacetin, separated on the Zirconia-HBD phase. Figure 4.3c shows the total 
ion chromatogram obtained from a scan over the range 100 to 400 m/z representing
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the three peaks of paracetamol, caffeine and antipyrine. The resulting mass spectra 
are shown in Figures 4.3 d, e and f giving the molecular masses of the components.
Table 4.2 Area response obtained proportional to the amount of carbon present in
each compound.
No. of Carbons Mass Carbon atoms
Compound present With formulae / MW Ratio Area Response
Paracetamol 8 152: C8H9N02 0.053 18278
Caffeine 8 194: C8H10N4O2 0.041 14885
Antipyrine 11 188: CnHi2N20 0.058 21109
The XTerra column, operated at 160°C, was used to determine the amount of caffeine 
in a coffee sample. The chromatogram shown in Figure 4.4 shows a large 
endogenous peak, with the caffeine peak detected on the tailing edge, at a retention 
time of 5.5 minutes. By comparison to an external standard an amount of ca. 2 pg of 
caffeine on column was calculated for the response (100 pg/g of instant coffee). For a 
quantitative method further work would clearly be required to separate the caffeine 
peak from the endogenous interferences.
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Figure 4.4. Instant coffee sample analysed on an XTerra column at 160°C and 1 
mL/min using HPLC-ICP-MS, ca. 2 jig on column of caffeine (100 
pg/g ‘instant coffee’). The insert shows the [M-H]+ ion for caffeine 
obtained by parallel MS.
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4.5.2: HPLC-ICP-MS With Isotopically Enriched Eluents
Although the aqueous mobile phases described above have many advantages for ICP- 
MS there are clear limitations on the types of compound that can be separated in this 
way. With this in mind alternative chromatographic separations were investigated 
using isotopically enriched methanol as the organic modifier for chromatography. 
Both [ C] and [ C]-enriched methanol can be obtained commercially and we
t o  i  jtherefore investigated the detection of [ C]-labelled analytes in a [ C]-solvent as 
well as [12C] detection of compounds in a [13C]-mobile phase. As the cost of such 
enriched solvents is not insignificant chromatography was performed on a narrow 
bore column in order to minimise solvent consumption. This had the added benefit 
that the low flow rates employed reduced the amount of methanol in the plasma, 
thereby aiding detection.
Highly isotopically enriched [12C]-methanol (99.95 atom %) was used as the organic 
modifier for the detection of [13C]-triple-labelled caffeine and [13C]-double-labelled
19phenacetin. The high degree of enrichment of the [ C]-labelled methanol used to 
make up the organic modifier meant that the interference on the m/z 13 channel was 
negligible. An example of this is shown in Figures 4.5a and b where the peaks for the 
[13C]-labelled caffeine (86 pmol of 13C on column) and phenacetin (79 pmol of 13C on 
column) are shown.
When gradient chromatography was investigated an increase in the background was 
noted as the proportion of organic modifier was increased, despite the high isotopic 
purity of the solvent. An example of the use of gradient HPLC-ICP-MS for the 
detection of [13C]-labelled phenacetin is shown in Figure 4.5c.
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4.95e5 Caffeine
1 2 3 4
Time (min)
4.69e5 Phenacetin
52 3 4 6 91 7 8
Time (min)
4.7e5' Phenacetin
2 3 4 5 6 81 7
Time (min)
Figure 4.5. HPLC-ICP-MS traces obtained for (A) a 13C+ caffeine peak 86 pmol 
for the three 13C- labels, (B) a 13C+ phenacetin peak 79 pmol for the 
two [13C]-labels. (C) Shows the chromatography of phenacetin using 
gradient elution with the enriched solvent. The rising baseline reflects 
the changing solvent composition. For experimental conditions see 
section 4.4.
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These preliminary experiments clearly demonstrate the potential for the detection of 
[13C]-enriched analytes in reversed-phase eluents. However, when [13C]-enriched 
methanol was used in an attempt to detect un-enriched 12C+ carbon similar success 
was not achieved. This was due to the lower degree of isotopic enrichment in the 
[13C]-methanol (99 atom %) compared to the [12C]-methanol. Thus, the residual 1 % 
of [12C]-methanol that remained in the [13C]-enriched methanol ensured that there was 
a significant 12C+signal that precluded detection of the analytes at these 
concentrations. No examples of chromatograms are available because no peaks were 
observed.
4.6: Conclusion
The results presented here demonstrate that HPLC-ICP-MS can be used for the 
detection of carbon under a limited set of analytical conditions, and under these 
conditions HPLC-ICP-MS can provide a “universal detector” for organic compounds. 
In practice, given both the expense and lack of high enough levels of isotopic 
enrichment, only those separations based on entirely aqueous eluents are likely to be 
economically viable. The combination of carbon detection via HPLC-ICP-MS- 
MSMS, for molecular mass determination and structure elucidation, may prove 
attractive for the quantification and identification of unknowns.
The data presented in this chapter was published in Rapid Communications in Mass 
Spectrometry 18, 2004,1487-1492. (Appendix A).
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Chapter 5
Halogen detection by HPLC-ICP-MS for metabolite profiling of Cl, Br and I 
containing compounds. 
5.1: Summary
In order to determine the pharmacological and toxicological properties of xenobiotics 
in biological systems it is often necessary to determine the disposition and metabolic 
fate of the compound in experimental animals and man. In the initial phases of 
determining the metabolism of new compounds the first step is to develop analytical 
methods that enable the detection and quantification of metabolites in biofluids and 
excreta, followed by identification of any unknowns. This process usually takes the 
form of placing a radiolabel in the structure of the compound and carrying out profile 
experiments looking at the label and quantifying the response. As previously 
described, platinum within a compound could be used as the label, which can be 
utilised to follow the metabolism of a compound [39]. However the numbers of 
compounds used in the pharmaceutical industry, which have a metallic element, are 
few and therefore the use of ICP-MS for metal detection is of limited use. Halogens, 
however, are more often found in compounds, and would make the use of ICP-MS on 
attractive technique. Studies were set up to look at Br, Cl and I and their use within 
metabolism work with HPLC- ICP-MS detection in parallel with a mass spectrometer 
to aid identification of metabolites.
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5.2: Introduction
The coupling of HPLC to ICP-MS has opened a new tool for metabolism studies. The 
ability to assign quantitative information to peaks found in the profile, without the 
need to produce a standard to quantify against or make a labelled compound for 
dosing, is extremely useful. Metallic elements such as platinum are relatively easy 
[39, 54], but application of the technique is then limited due to the small number of 
compounds containing such elements.
The evaluation of a halogen as the detection element was therefore considered 
because these elements are more prevalent in novel compounds. The main difficulty 
in using the halogens compared to metals is the lower sensitivity of detection with 
ICP-MS. The ionisation energy of iodine is 10.4 eV, resulting in an ionisation 
efficiency of between 14 and 33 %. For bromine and chlorine, ionisation efficiencies 
are only 18 and 5 % respectively, due to high first ionisation energies of 11.8 eV and 
13.0 eV. Fluorine was not considered because the ionisation potential of the element 
is 17.4 eV, is greater than that of the carrier gas argon (15.8 eV), therefore rendering 
fluorine ionisation virtually impossible. Instruments available at the present do not 
allow for detection in negative mode therefore F' cannot be examined.
Another complication that has to be taken in to account is that the halogens are 
affected by polyatomic interferences. Isobaric interferences are probably the largest 
class of interferences in ICP-MS and are caused by atomic or molecular ions that have
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the same mass to charge ratio as the analytes of interest. The polyatomic interference 
that cause problems for the halogens are shown in Table 5.1 [63]
Table 5.1 Possible spectral interferences for halogen elements
Halogen Isotope Polyatomic interferences
wBr 4UAriyK+ 3IPi<’0 3+ 35Ar4UArlH+
81Br 32s 16o 3'h + 40Ar40Ar1H+ 33s 16o 3+
35C1 ' W h 4 ^SH4
37C1 36Ar'H+ 36s 'h +
Isobaric interferences are not such a problem when considering iodine since the 
region of m/z 127 is clear of such problems, therefore allowing lower limits of 
detection for compounds containing this element.
Bromine and chlorine do suffer from isobaric problems, which affect the efficiency of 
the assay to detect the elements. These problems can be controlled by the use of the 
instrument collision cell, which allows gases into the hexapole region of the ICP-MS 
[24]. These gases, such as hydrogen and helium, react with the polyatomic 
interferants and stop them from reaching the detector of the ICP-MS, allowing 
detection of the halogens.
An additional manner of controlling interferences is to have knowledge of the type of 
polyatomic component causing the problem. Such areas as sample matrix, reagents
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used in preparation, plasma gases and entrained atmospheric gases are responsible for 
introducing some isobaric problems. Therefore if the mechanism of production of 
these components is known then the assay can be designed to preclude or at least 
reduce the possibility of their formation.
With this in mind an evaluation was undertaken of the usefulness of the halogens as 
elemental markers within the compound for balance and metabolism profiling studies.
5.3: Initial Evaluation of Bromine and Chlorine
Bromine and chlorine were considered initially because these elements are found 
more extensively in novel drug entities within the pharmaceutical industry. The 
compounds used are shown in Figure 5.1. They were chosen because they have 
similar structures and molecular weights, allowing for ease of comparison.
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Cl
ZD 1839 
Molecular weight 
483 amu
ZD6474 
Molecular weight 
479 amu
Figure 5.1 ZD1839 and ZD6126 development compounds from Astrazeneca used
for the evaluation of bromine and chlorine detection.
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5.4: Experimental
5.4.1: Standard Solution Preparation
The compounds were weighed and dissolved in methanol to a concentration of 1 
mg/mL. These two solutions were then further diluted to a concentration of 10 pg/mL 
in water.
5.4.2: Instrumentation
Flow injections of 20 pL were made using by a PE 200 series autosampler 
(PekinElmer Ltd, Beaconsfield, UK) in a flow of water (1 mL/min) generated from a 
Jasco PU-1580 HPLC pump (Jasco Ltd, Great Dunmow, Uk). A meinhard concentric 
nebuliser used with a double pass spray chamber, which passed into a Platform ICP- 
MS (GV Instruments, Wythenshawe, UK). MassLynx software (version 3.4) was 
used to collect data and quantify the results (GV Instruments, Wythenshawe, Uk).
5.5: Discussion
The difficulty in studying halogens by ICP-MS is that the sensitivity is low because 
the ionisation potentials of bromine and chlorine are close to that of argon, as 
discussed in section 5.2. When coupled with the problem of isobaric interferences the 
usefulness of the approach may be called into question. Figure 5.2 represents the 
response of the two test compounds for chlorine and bromine. The trace shows that 
the response for bromine is significantly better than for chlorine, which is expected
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since the ionisation energy for bromine is (11.8 eV) is lower than that for chlorine 
(13.0 eV), Figure 1.3 shows the percentage ionisation of elements in the plasma.
Sensitivity is also affected by the presence of isobaric polyatomic species and the 
collision cell was used to minimise the problem as described in section 5.2. However, 
the amount of the gas had to be monitored very closely, because an excess of gas 
added to the cell would not be a benefit. The gas may well react with the polyatomic 
interferences but it also inhibits the transition of the element of interest though to the 
multiplier for detection. A balance has to be found in the optimising step for all 
elements that require gas to aid detection.
Whilst the optimisation step was being carried out for chlorine, it was noted that the 
free radical of chlorine was able to react with hydrogen in the collision cell. This 
proved to be a beneficial since the chlorine collected two hydrogens, moving the 
detection masses from m/z 35, 37 to m/z 37, 39. This enabled the major isotope of 
chlorine (35) to be detected, but at m/z 37 where the interference was found to be less 
than at m/z 35. Table 5.2 shows the conditions used in the analysis of the halogens.
Table 5.2 Instrument operating conditions for chlorine and bromine analysis
Cool gas 16.00 L/min Plasma power 1400 W
Intermediate gas 0.80 L/min Acquisition mode SIR
Nebuliser gas 0.60 L/min Dwell time 0.5 s
Helium gas 2.0 mL/min Masses monitored 37, 79
Hydrogen gas 2.0 mL/min Total analysis time 4 min
102
Re
sp
on
se,
 c
ps
556e7-,
Bromine compound
Chlorine
compound
| t i i i | i i > i | - f - i  i t | i i i i i i i i i | i i i i | i i i i i i i t i  | i i i i | i i i i | i i i i | i ;  i t | 11 i i i | m  i f  | ~r
0.50 1.00 1.50 2.00 2.50 3.00 3.50
Time (min)
Figure 5.2 Flow injection ICP-MS responses for ZD 1835 and ZD6474, with
bromine monitored at m/z 79 and chlorine monitored at m/z 37 after 
reaction with hydrogen to allow the major isotope of chlorine to be 
monitored. Analysis carried out at a concentration of 10 pg/mL for 
both compounds. The signal to noise ratio for chlorine was 26 and for 
bromine was 686.
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5.6: Conclusion
From this initial work it was decided that bromine would be a better candidate for 
ICP-MS detection and is therefore considered in detail first, since the data indicated 
that more sensitivity and value could be gained from the work. An excretion balance 
study in the rat was used as an example application.
5.7: Bromine excretion balance studies 
5.8: Summary (4-Bromoaniline study)
In order to determine the disposition of dosed compounds, an “excretion balance” 
study is normally performed, whereby the amount of compound-related material is 
determined in the excreta. This provides quantitative information on the rate and 
routes of elimination of the drug or xenobiotic. For the metabolic profiling of novel 
drug candidates it is usually necessary for the drug to have a radiolabel placed in to its 
structure to enable accurate quantitative values for metabolite concentrations to be 
gained. The safety and toxicity issues associated with radiolabel production along 
with the expense means that if the same work could be done without a radiolabel then 
considerable benefit would ensue. The ICP-MS enables this process, in that instead 
of a [14C]-label for profiling, an element within the structure of the compound may be 
used, in this case bromine.
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5.9: Introduction (4-Bromoaniline study)
ICP-MS results in the complete atomisation of a biomolecule, and thus the detected 
signal is independent of the chemical properties of the parent molecule. For this 
reason, all of the element present in the sample should be detected and ICP-MS can be 
considered quantitative. 4-bromoaniline (Figure 5.3) was used as an evaluation 
compound to see if ICP-MS could offer an alternative for balance and metabolite 
profiling studies.
Br
n h2
Figure 5.3 Structure of 4-Bromoaniline
5.10: Experimental (4-Bromoaniline study)
5.10.1: Reagents (4-Bromoaniline study)
4-Bromoaniline, purity 98 %, was obtained from Sigma-Aldrich Co Ltd (Dorset, UK). 
Methanol used for the chromatographic separation was high purity HPLC grade and, 
along with ammonium formate (purity 99 %) obtained from Fisher Scientific UK Ltd.
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Water was obtained from an Elga water purification system (Elgastat Maxima, Elga, 
High Wycombe, UK).
5.10.2: Animal Dosing (4-Bromoaniline study)
Three male Wistar-derived rats (200-250 g) were fitted with biliary cannulae. Rats 
were permitted free access to food (R&M No. 1 Modified Irradiated Diet) and water 
throughout the study. The water was supplemented with glucose, NaCl and KC1 for 
24 hours prior to surgery until 48 hours after surgery, then with only NaCl and KC1 
until the end of the study. The rats were dosed with 4-bromoaniline, i.p., at 50 mg/kg 
in ethanol-water (50:50), at a concentration of 50 mg/mL. Urine was collected over 
solid CO2 into sterile containers 0-12,12-24 and 24-48 hr post dosing. Bile was 
collected for the periods 0-6, 6-12,12-24 and 24-48 hr post dosing. The samples were 
stored frozen at (-20°C) until analysis. At the end of the study, animals were killed by 
halothane inhalation, with death confirmed by cervical dislocation.
5.11: ICP-MS instrument settings (4-Bromoaniline study)
5.11.1: Instrumentation configuration (4-Bromoaniline study)
Ultra pure water was pumped though the system at 1 mL/min by a series 200 
PerkinElmer pump and the sample was introduced by a series 200 PerkinElmer 
autosampler, with an injection volume of 50 pL. The sample was passed though a 
concentric nebuliser to a double pass spray chamber before entering the ICP-MS (GV 
instrument, Platform). The run time for the excretion balance samples was 1.5
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minutes. The flow of the nebuliser gases and the operating and acquisition conditions 
of the ICP-MS are shown in Table 5.3. MassLynx software (version 3.4) was used for 
instrument control, data acquisition and handling.
Table 5.3 Instrument operating conditions for ICP-MS for excretion balance 
study
Cool gas 18.00 L/min Plasma power 1600 W
Intermediate gas 0.80 L/min Acquisition mode SIR
Nebuliser gas 0.60 L/min Dwell time 0.5 s
Helium gas 2.0 mL/min Masses monitored 79,81
Hydrogen gas 2.0 mL/min Total analysis time 1.5 min
Hexapole auxiliary gas 0 mL/min
5.11.2: Construction of Calibration Curves (4-Bromoaniline study)
Ten calibration standards were prepared of bromobenzene (Aldrich, purity ~ 99 %) in 
control (human) urine and in control (rat) bile. This compound was used because it 
was ready available and, as long as bromine is in the structure, any compound can be 
used for standard preparation. Concentrations ranged from 4 mg/mL of bromobenzene 
to 0.00004 mg/mL of bromobenzene (40 ng/mL) for both series of standards. This 
was carried out in duplicate for each standard and the average of the area under the 
peak (y axis) plotted against the bromine concentration (x axis) to give two straight- 
line graphs, one for bromine in urine, and one for bromine in bile (Figure 5.4 and 5.5).
107
5.11.3: Biofluid Analysis (4-Bromoaniline study)
Urine and bile samples from each timepoint from the one animal were centrifuged and 
either 25 pL or 50 pL injections made directly into the Platform ICP-MS, monitoring
7Q Q1both Brand Br isotopes. The response was measured over 1.5 minutes. This was 
carried out in duplicate for each sample, and the equation from the relevant straight- 
line graph applied to half of the average of these two values (to take into account 
monitoring of both bromine isotopes [ratio 50.69:49.31] in the biofluid analysis, and 
monitoring of only one when analysing the calibration standards). Hence the bromine 
concentration could be calculated for 1 mL of urine / bile, which when multiplied by 
the total volume of biofluid excreted during that timepoint, gave the overall bromine 
excretion.
5.11.4: HPLC-ICP-MS (4-BromoaniIine study)
The HPLC system comprised an Alliance 2695 separation module (Waters 
Corporation), coupled to a Platform ICP-MS (GV Instruments, Wythenshawe, UK
7 0  Q1Ltd.) tuned to monitor Br and Br. In order to avoid excessive carbon build-up on 
the cones of the instrument, the nebuliser gas was mixed with 5 % v/v oxygen using 
an onboard mass flow controller. Additionally, oxygen was used as the hexapole 
auxiliary gas. The flow of the nebuliser gases and the operating and acquisition 
conditions of the ICP-MS are shown in Table 5.4. The chromatographic separation 
was carried out using a Hichrom H5BDS Cig column (250 x 4.6 mm) (Waters 
Corporation) with 5 pm particles using a linear reversed-phase gradient method based
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on 0.01 M ammonium formate (solvent A) and methanol (solvent B) as follows; 0 to 
10 min 95 % A, 10 to 35 min 5 to 60 % B, 35 to 40 min 60 to 80 % B, then from 40 to 
50 min 80 to 5 % B. The flow rate was 1 mL/min, which was split to give 200 
pL/min entering the MS. 20 pL injections of urine or bile samples from one animal 
were made. The samples were initially run using a fast gradient method with a run 
time of 15 minutes to ensure the plasma would be stable at high methanol 
concentrations and additionally for comparative purposes. MassLynx software was 
used for instrument control, data acquisition and handling.
Table 5.4 Instrument operating conditions for HPLC-ICP-MS of Br containing 
drugs
Cool gas 13.0 L/min Plasma power 1450 W
Intermediate gas 0.7 L/min Acquisition mode SIR
Nebuliser gas 0.75 L/min Dwell time 0.2 s
Helium gas 2.0 mL/min Masses monitored 79,81
Hydrogen gas 2.0 mL/min Total analysis time 15.5 min
Hexapole auxiliary gas (O2) 0.2 mL/min
5.12: Results and Discussion (4-Bromoaniline study)
5.12.1: Excretion Balance
Figure 5.4 and 5.5 show the ICP-MS bromine response versus bromine concentration 
for the two series of standards in urine respectively. The calibrations were both linear
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9 9(for urine R = 0.998, for bile R = 0.996), demonstrating that no matrix suppression 
effects or background effects affected the calibrations. No extrapolations had to be 
carried out when analysing the biofluids since all bromine responses of the biofluid 
samples fell within the region of the calibrations standards analysed.
Tables 5.5 and 5.6 show that both the urine and the bile excretion data match the 
metabolite profiles when the areas of the different peaks are summed together.
Figures 5.5 and 5.6 show the profile over the time course for both bile and urine. 
These data show the usefulness of the technique in quantitative mapping of the 
excretion pathways of drugs containing bromine.
5.13: Conclusion (4-Bromoaniline study)
The bromine excretion balance study described was undertaken in part at GV 
Instruments and showed that the use of bromine as a marker in the study was possible. 
The process was therefore repeated for 2-, 3- and 4-bromobenzoic acids.
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Figure 5.4: Bromine ICP-MS response versus concentration of bromobenzene in
rat urine. For experimental conditions see section 5.10.
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Figure 5.5: Bromine ICP-MS response versus concentration of bromobenzene in
rat bile. For experimental conditions see section 5.10.
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Figure 5.6A: Bromine ICP-MS response from flow injected bile samples from rat 
dosed at 50 mg/kg with 4-bromoaniline. The area underneath each 
peak represents the total amount of bromine in the sample.
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Figure 5.6B: Bromine HPLC-ICP-MS chromatograms from rat bile samples, 
showing differences in the metabolite profile over time. For 
experimental conditions see section 5.10.
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Figure 5.7A: Bromine ICP-MS response from flow injected urine samples from rat 
dosed at 50 mg/kg with 4-bromoaniline. The area underneath each 
peak represents the total amount of bromine in the sample.
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Figure 5.7B: Bromine HPLC-ICP-MS chromatograms from rat urine samples, 
showing differences in the metabolite profile over time. For 
experimental conditions see section 5.10.
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Table 5.5: Bromine recovery from metabolite profiling of rat bile. Areas
calculated in cps. For experimental conditions see section 5.10.
Bile recoveries (cps)
Time (A) 0-6 hr (B) 6-12 hr (C) 12-24 hr (D) 24-48 hr
Profile
Total
percentage recocovery %
22617
231048
95.6
206198
222846
90.9
135221
132844
101.5
56539
55056
102.5
Table 5.6: Bromine recovery from metabolite profiling of rat urine. Areas
calculated in cps. For experimental conditions see section 5.10.
Jrine recoveries (cps)
Time (A) 0-12 hr (B) 12-24 hr (C) 24-48 hr
Profile
Total
percentage recocovery %
1996714
1861106
106.9
1292072
1193745
108.4
197534
185959
106.5
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5.14: Excretion balance study on 2-, 3-, and 4-bromobenzoic acids
Work carried out in cooperation with Berit Packert Jensen from University of 
Pharmaceutical Sciences Copenhagen.
5.15: Experimental (Bromobenzoic acids)
5.15.1: Reagents (Bromobenzoic acids)
2-, 3- and 4-bromobenzoic acids (98% purity) were purchased from Sigma-Aldrich 
Co Ltd (Dorset, UK) Figure 5.8. Ethanol, formic acid, sodium hydroxide and 
hydrochloric acid (37%) were of analytical grade and purchased from Fisher 
Scientific UK Ltd (Loughborough, UK). Methanol was of HPLC grade (Fisher 
Scientific UK Ltd, Loughborough, UK). Water was obtained from an Elga water 
purification system (Elgastat Maxima, Elga, High Wycombe, UK).
OOOH OOOH COOH
2-bromobenzoic acid 3-bromobenzoic acid 4-bromobenzoic acid
Figure 5.8 Structures of the bromobenzoic acids used for metabolism studies by 
ICP-MS.
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5.15.2: Animal dosing (Bromobenzoic acids)
Three male Wistar derived rats (230-260 g) were anaesthetised using halothane, bile 
duct-cannulated and acclimatised individually in glass metabolism cages 3 days prior 
to dosing. The animals were subjected to 12 h artificial light / dark cycles and were 
permitted free access to food and water throughout the study. Dosing solutions were 
made up by dissolving 2-, 3- and 4-bromobenzoic acid in ethanol-water (50:50), 
adjusting the pH to 6-8 using diluted NaOH, to reach a final concentration of 50 
mg/mL for 2- and 3-bromobenzoic acid and 40 mg/mL for 4-brombenzoic acid. The 
rats were dosed i.p. one compound per rat at 50 mg/kg. The remainder of the dosing 
solutions were stored at -20°C until analysis. Urine and bile were collected prior to 
dosing and for the periods 0-6, 6-12,12-24 and 24-48 h post dose and stored at -20°C 
until analysis. Cage wash was collected at 0-24 and 24-48 h post dose and stored at 
4°C until analysis.
5.15.3: Instrumental (Bromobenzoic acids)
Jasco PU-1580 HPLC pumps (Jasco Ltd, Great Dunmow, UK) and a CTC-HTC Pal 
autosampler (Presearch, Hitchin, UK) were used to introduce samples to a GVI 
Platform ICP-MS instrument (GV Instruments Ltd, Manchester, UK). The ICP-MS 
instrument was equipped with a concentric nebuliser and a cooled double pass spray 
chamber. Helium gas was added to the collision / reaction cell of the ICP-MS to 
reduce argon-based interferences in the mass 80 region (40Ar40Ar1H+, 40Ar38Ar1H+)
7 0  81[63] and both Br and Br could be measured. MassLynx software (GV Instruments 
Ltd) was used for instrument control, data acquisition and analysis. The operating 
conditions of the instrument are shown in Table 5.7.
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Table 5.7 Instrument operating conditions for ICP-MS for 4-brombenzoic acid 
metabolism study.
Parameter Excretion balance Metabolite profiling
Cooling gas flow 15.0 L/min 18.0 L/min
Plasma gas flow 0.8 L/min 0.8 L/min
Nebuliser gas flow (argon) 0.8 L/min 0.8 L/min
Helium gas flow 1.0 mL/min 1.0 mL/min
Plasma power 1450 W 1600 W
Dwell time 300 ms 300 ms
Mass monitored 79 79,81
Spray chamber temperature 8°C -7°C
For determining the total bromine content of urine and bile for the excretion balance 
study, no chromatography was performed and samples were introduced into the ICP- 
MS by flow injection into a carrier stream of water at a flow rate of 1.0 mL/min. For 
metabolite profiling, chromatographic separations were performed on a Polaris Cl 8- 
A, 3 j l i , 150 x 4.6 mm column with a matching guard column (Varian BV, 
Middelburg, the Netherlands) at a temperature of 40°C obtained with an Eppendorf 
TC-50 column heater (Presearch). The mobile phase consisted of 50 % methanol and 
0.1% formic acid in water. The flow rate of 1 mL/min was split using an accurate 
splitter (Presearch) allowing 250 pL/min into the ICP-MS and the remainder into a 
Jasco UV-1575 detector set at 254 nm.
For the multiple hyphenation experiments, where both ICP-MS and MS techniques 
were used, the eluent (1 mL/min) was split letting 250 pL/min into the ICP-MS and
the remainder into the UV detector and then into an MS (Applied Biosystems, 
Warrington, UK). A turbo ionspray inlet source was used in the positive mode and a 
Q1 full scan over the range m/z 100-600 was acquired. Analyst software was used for 
instrument control, data acquisition and analysis.
5.15.4: Sample analysis (Bromobenzoic acids)
For the excretion balance study, a stock solution of 150 mM 3-bromobenzoic acid was 
prepared in 0.2 M NaOH. This was further diluted in control urine to prepare 
standard solutions of 0.1, 0.5,1, 5,10, 25 and 50 mM. A similar procedure was used 
to prepare quality control samples at final concentrations of 0.1, 10 and 50 mM. 
Standard solutions in bile were prepared by diluting the stock solution in control bile 
to concentrations of 0.1, 0.25, 0.5 and 1 mM with quality control samples at 0.5 and 
1.25 mM. For analysis of cage wash and dosing solutions, aqueous standard solutions 
were prepared at concentrations of 0.05, 0.1, 5 and 10 mM and quality control 
samples of 0.1, 5 and 10 mM. The dosing solutions were diluted with water (1 in 49). 
The 0-6 hour urine samples and dosing solutions were analysed in triplicate, the 
remaining samples in singlicate. Samples were introduced by flow injection to the 
ICP-MS with an injection volume of 10 pL.
For metabolite profiling, 10 pL of neat urine and bile samples were injected on 
column. Selected urine and bile samples were further analysed by HPLC-MS. All 
samples were subjected to alkaline hydrolysis to obtain information on the identity of 
the metabolites and to estimate the distribution of metabolites. The alkaline 
hydrolysis was performed by incubating samples with 1 M NaOH (2 in 1) at 37°C for
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24 hours and then restoring the pH by adding an equivalent amount of 1 M HC1. 20 
pL aliquots of the hydrolysed samples were injected on column.
5.16: Results and discussion (Bromobenzoic acids)
5.16.1: Excretion balance study (Bromobenzoic acids)
Bile duct-cannulated animals were used to avoid the problems often associated with 
poor extraction recoveries from faeces. For sample analysis, a method based on total 
bromine content in the samples was developed and partially validated. Linear 
standard curves (r2 > 0.99) were obtained in urine, bile and water in the concentration 
range 0.05-50 mM bromine, which covered the concentration ranges found in the 
samples, with concentrations below 0.05 mM considered irrelevant. Based on the 
quality control samples, values for accuracy were found in the range 93-108% with 
relative standard deviations below 7% as seen in Table 5.8. Similar values were 
obtained regardless of the matrix used, indicating that the performance of the method 
was not matrix dependent. The ICP-MS method thus appeared to be well suited to 
determining bromine content in urine, bile and aqueous samples.
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Table 5.8 Accuracy and precision data for ICP-MS analysis of bromine at m/z 79
Matrix Bromine conc. (mM) n Accuracy (%). coefficient variation (%)
Urine 0.1 4 99.2 5.8
10 4 93.7 3.4
50 4 107.5 3.4
Bile 0.5 3 98.7 6.5
1.25 2 98.3 0.9
Water 0.1 3 94.1 5.2
5 2 93.0 4.7
10 3 96.1 5.6
Following administration of 2-, 3- and 4-bromobenzoic acids at 50 mg/kg i.p. to bile 
duct-cannulated rats, urine, bile and aqueous cage wash were collected. The 
measured bromine concentrations in the dosing solutions, cage wash, urine and bile 
samples are shown in Table 5.9. It was noticed that the predose urine contained 
substantial amounts (0.4-0.5 mM) of bromine. HPLC-ICP-MS showed that for the 
predose samples, bromine was only detected in the solvent front (tr =1.8 min) 
indicating inorganic bromine. This could be due to bromide originating from the 
halothane used to anaesthetise the rats 3 days prior to dosing, as bromide is a known 
halothane metabolite. No bromine patterns were found in the MS Q1 scan of the 
solvent front, but since the scan was performed over 100-600 amu in the positive 
mode, inorganic bromide at m/z 79 and 81 would not be detected. HPLC-ICP-MS 
analysis of all urine and bile samples revealed that the bromine peak in the solvent
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front decreased in area the later the sample was taken after anaesthesia of the rats. 
This supports the assumption that the peak is due to bromide being excreted as a 
halothane metabolite. No studies on the metabolism of bromobenzoic acids have 
been found in the literature, but, for bromobenzene, bromine is retained in the 
metabolites [64]. It was therefore assumed that the bromide peak found in the 
samples was not related to bromobenzoic acid metabolism. Based on the HPLC-ICP- 
MS chromatograms, the area percent bromide of each sample was found and used to 
correct the concentrations found in the excretion balance study with results shown in 
Table 5.9. It was noticed that practically no bromine was found in the cage wash, and 
the highest bromine concentrations were found in the 0-6 hour urine samples.
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Table 5.9 Bromine concentrations obtained in dosing solutions (n=3) and rat
urine samples (0-6 hour urine: n=3, otherwise n=l) after i.p. dosing of 
2-, 3- and 4-bromobenzoic acids (one compound per rat at 50 mg/kg). 
Concentrations corrected for inorganic bromide.
Bromine conc. (mM)
2-bromobenzoic acid 3-bromobenzoic acid 4-bromobenzoic acid
Sample Measured Corrected Measured Corrected Measured Corrected
Dosing solution 4.88 4.88 4.52 4.52 3.55 3.55
Urine predose 0.46 <0.1 0.48 <0.1 0.41 <0.1
Urine 0-6 h 24.2 23.9 9.91 9.71 8.19 8.03
Urine 6-12 h 4.10 4.05 0.88 0.69 0.70 0.54
Urine 12-24 h 0.62 0.46 0.42 0.24 0.62 0.53
Urine 24-48 h 0.61 <0.1 <0.1 <0.1 0.22 <0.1
Bile predose <0.1 <0.1 <0.1 <0.1 0.15 <0.1
Bile 0-6 h 0.29 0.18 0.45 0.28 0.78 0.70
Bile 6-48 h <0.1 <0.1 <0.1 <0.1 <0.1 <0.1
Cage wash <0.05 <0.05 <0.05 <0.05 <0.05 <0.05
Based on the corrected bromine concentrations and the volumes of the samples 
collected from the rats, the recovery of 2-, 3- and 4-bromobenzoic acid could be 
calculated (Table 5.10). As seen in the table, most of the dose given was recovered in 
the urine and bile, with recoveries of 82, 85 and 98% for 2-, 3- and 4-bromobenzoic 
acid, respectively. The excretion of all three bromobenzoic acids was rapid with
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approximately 70% of the dose recovered in the 0-6 hour urine. Only 2-7% of the 
dose was recovered in the bile.
Table 5.10 Percent recovery in urine, bile and cage wash of 2, 3- and 4-
bromobenzoic acids dosed i.p. to one rat per compound at 50 mg/kg
% dose recovered as total bromine 
Sample 2-bromobenzoic acid 3-bromobenzoic acid 4-bromobenzoic acid
Urine 0-6 h 66.7 70.5 79.7
Urine 6-12 h 8.6 5.4 4.1
Urine 12-24 h 2.7 5.8 5.3
Urine 24-48 h 1.4 0.0 1.8
Bile 0-6 h 2.3 2.9 7.1
Bile 6-48 h 0.0 0.0 0.0
Cage wash 0.0 0.0 0.0
Total 81.7 84.6 97.9
5.16.2: Metabolite profiling (Bromobenzoic acids)
As well as excretion balance data, additional information regarding the metabolic fate 
of test compounds is needed. The metabolism of 2-, 3- and 4-bromobenzoic acid was 
therefore investigated by profiling the urine and bile samples by HPLC-ICP-MS. 
Previous studies have demonstrated the use of reversed phase HPLC with ICP-MS as
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a bromine detector for xenobiotics and their metabolites [50, 54]. Methanol was 
chosen as organic modifier rather than acetonitrile because of its lower carbon loading 
and less change in electrical impedance of the plasma. The chromatographic method 
developed, based on 50 % methanol and 0.1 % formic acid, separated the metabolites 
from parent compound as well as from inorganic bromide. The metabolite profiles of 
the 0-6 h urine and 0-6 hour bile from 2-, 3- and 4-bromobenzoic acid dosing, based 
on bromine detection, are shown in Figure 5.9 and 5.10. The pre-dose samples 
showed no bromine peaks except in the solvent front.
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Figure 5.9 HPLC-ICP-MS bromine chromatograms of 0-6 hour urine profiles
after dosing with A) 2-bromobenzoic acid B) 3-bromobenzoic acid and 
C) 4-bromobenzoic acid. lOpL neat urine was injected on a Polaris 
C18-A, 150 x 4.6 mm column, 40°C, eluted isocratically with 50 % 
methanol and 0.1% formic acid and detected with 79/81Br-ICP-MS.
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Figure 5.10 HPLC-ICP-MS bromine chromatograms of 0-6 hour bile profiles after 
dosing with A) 2-bromobenzoic acid B) 3-bromobenzoic acid and C) 
4-bromobenzoic acid. lOpL neat bile was injected on a Polaris C l8-A, 
150 x 4.6 mm column, 40°C, eluted isocratically with 50 % methanol 
and 0.1% formic acid and detected with 79/81Br-ICP-MS.
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The profiles reveal that 2-, 3- and 4-bromobenzoic acids are extensively metabolised 
as little parent compound is excreted. There appears to be one major metabolite in the 
urine profiles, however, the metabolites are not well separated from each other. Since 
ICP-MS is an element-detection technique, these profiles do not yield any structural 
information for the metabolites, and so other measures are required to elucidate the 
identity of the metabolites and purity of the peaks. For this purpose, MS was 
connected in parallel (as described elsewhere [6-8]) to the HPLC-ICP-MS 
instruments, along with a UV detector. As an example of the type of data acquired, 
typical total ion current full scan MS, UV and bromine detected ICP-MS 
chromatograms are shown in Figure 5.12a-c, respectively for urine from a rat dosed 
with 4-bromobenzoic acid. Both the UV and the MS chromatograms show peaks 
from compound-related material as well as endogenous compounds further 
highlighting, if it were needed, the selectivity of the bromine-detected ICP-MS for 
quantitative metabolite profiling.
In the mass spectrum, the bromine related peaks are easily identified by the bromine 
pattern of the two isotopes. For the urinary profile of 4-bromobenzoic acid (Figure 
5.12), several bromine-containing ions were observed. A glycine conjugate is a likely 
metabolite for benzoic acids and this is supported by the observed m/z values of 
258/260 (and 280/282 for the sodium adducts). The m/z values of 399/401 suggest 
sodium adducts of ester glucuronide conjugates. The m/z 183/185 is a likely fragment 
of both metabolites due to in-source fragmentation as indicated in Figure 5.11. In the 
bile, similar m/z values were found and the pattern was similar for 2- and 3- 
bromobenzoic acids. These findings are consistent with the literature, in that glycine 
and glucuronide conjugates have been found as the major metabolites of substituted
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benzoic acids as well as unchanged parent [66]. Structures of the metabolites for 
benzoic acids are shown in Figure 5.11.
Potential
fragment
HOOC
HO
OH
HO OH
Br
Figure 5.11 Structures of the glucuronide and glycine metabolites of 4-
bromobenzoic acid with the potential site indicated for in source 
fragmentation occurring.
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Figure 5.12
183/1852.6eE
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0-6 hour urine profile following dosing of 4-bromobenzoic acid. 10 
pLof neat urine was injected on to a Polaris C l8-A, 150 x 4.6 mm 
column at 40°C, eluted isocratically with 50 % methanol and 0.1 % 
formic acid, detected by: A) Total ion current full scan MS m/z 100- 
600, B) UV 254 nm and C) 79mBr-ICP-MS. Insert in A shows mass 
spectrum recorded between 4 and 5 min.
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Due to the overlap of metabolite peaks and to further investigate the identity of the 
peaks, the urine and bile samples were treated with alkali to hydrolyse ester 
glucuronides (glycine and ether glucuronide conjugates are stable under these 
conditions). As seen in the urine HPLC-ICP-MS profiles in Figure 5.13, the majority 
of the metabolites in urine are resistant to alkali treatment indicating that glycine 
conjugates are primarily formed. In the bile, the metabolites observed accounted for a 
very small proportion of the dose, but out of these, some of the metabolites 
disappeared on alkaline hydrolysis with a related increase in peak area of the parent 
compound. The alkaline hydrolysis thus supported the MS data in that both glycine 
and glucuronide conjugates were present.
To estimate the percentage of glycine and ester glucuronide conjugates respectively, 
the relative areas of the peaks in the chromatograms with and without alkali treatment 
were calculated. The amount of metabolite remaining after alkali treatment was 
assumed to be due to a glycine conjugate, with the proportion of glycine assumed 
constant regardless of treatment. From the chromatograms of the untreated samples, 
the percentage of parent was found, as well as total metabolite percentage. Knowing 
the proportion of glycine, the remaining proportion of metabolites originating from 
glucuronides could then be estimated. Finally, these percentages were related to the 
total amount of bromine as found in the excretion balance study. By using this 
approach, the total degree of glycine and glucuronide conjugate formation of the 2-,
3- and 4- bromobenzoic acids could be estimated (Table 5.11). The results show that 
for 2-, 3- and 4-bromobenzoic acid, glycine conjugation was the major metabolic 
route, most markedly seen for 4- and 3-bromobenzoic acid. 2-bromobenzoic acid was
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metabolised to a lesser extent and a notable proportion of glucuronides was found as 
well.
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Figure 5.13 Profiles after alkaline hydrolysis of urine samples 0-6 hour from rat
dosed with A) 2-bromobenzoic acid B) 3-bromobenzoic acid and C) 4- 
bromobenzoic acid. 20 pi neat urine was treated with 1 M NaOH and 
injected on a Polaris C18-A, 150 x 4.6 mm column, 40°C, eluted 
isocratically with 50 % methanol and 0.1% formic acid and detected 
with 79/81Br-ICP-MS.
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Table 5.11 Percent formation of ester glucuronides and glycine conjugates in urine 
and bile after dosing of 2-, 3- and 4-bromobenzoic acid i.p. to rats at 50 
mg/kg.
% Formation based on bromine content
2-bromobenzoic acid 3-bromobenzoic acid 4-bromobenzoic acid
Urine Bile Total Urine Bile Total Urine Bile Total
Glycine conj. 48 0 48 76 1 77 84 3 87
Glucuronides 10 2 11 0 1 2 3 3 6
Parent 21 1 22 5 1 6 4 1 5
Total 79 2 82 82 3 85 91 7 98
5.17: Conclusion (Bromobenzoic acids)
This limited study of the application of ICP-MS to bromine-specific detection of the 
metabolites of 2-, 3- and 4-bromobenzoic acids in the urine and bile of rats clearly 
demonstrates the potential of using ICP-MS in metabolism studies, eliminating the 
need for radiolabelling. Quantitative excretion balances were performed as well as 
metabolite profiling using HPLC-ICP-MS. The study further shows the advantages of 
having MS detection in parallel with ICP-MS detection to gain structural information 
simultaneously.
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5.18: Iodine excretion study
Work carried out in cooperation with Berit Packert Jensen from University of 
Pharmaceutical Sciences Copenhagen.
5.19: Introduction (Iodobenzoic acids study)
Iodine, when present in a molecule, also provides an interesting opportunity for 
sensitive and specific detection with quantification, as demonstrated in X-ray contrast 
media [42], thyroid hormones [70], enzyme digests of bovine thyroid gland in urine 
[71] and serum [72]. A recent study has also demonstrated this approach to obtain 
metabolite profiles following exposure of earthworms to 2-fluoro-4-iodoaniline [8].
In this work, an excretion balance study and metabolite profiling was carried out in 
rats dosed with 2-, 3-, and 4-iodobenzoic acids.
5.20: Experimental (Iodobenzoic acids study)
5.20.1: Reagents (Iodobenzoic acids study)
2-, 3- and 4-iodobenzoic acids (98% purity) were purchased from Sigma-Aldrich Co 
Ltd (Dorset, UK). Ethanol, formic acid, sodium hydroxide and hydrochloric acid 
(37%) were of analytical grade and purchased from Fisher Scientific UK Ltd 
(Loughborough, UK). Acetonitrile was of HPLC grade (Fisher Scientific UK Ltd, 
Loughborough, UK). Water was obtained from an Elga water purification system 
(Elgastat Maxima, Elga, High Wycombe, UK).
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Figure 5.14 Structures of the compounds used for the iodine evaluation for ICP- 
MS.
5.20.2: Animal dosing (Iodobenzoic acids study)
Three male Wistar derived rats (250-300 g) were bile duct cannulated and 
acclimatised individually in glass metabolism cages 3 days prior to dosing. The 
animals were subjected to 12 h artificial light / dark cycles and were permitted free 
access to food and water throughout the study. Dosing solutions were made up by 
dissolving 2-, 3- and 4-iodobenzoic acid in 50 % ethanol, and adjusting pH to 6.5-8 
using diluted NaOH, to reach a final concentration of 50 mg/mL for 2- and 3- 
iodobenzoic acid and 40 mg/mL for 4-iodobenzoic acid. The rats were dosed i.p. with 
one compound per rat at 50 mg/kg. The remainder of the dosing solutions were stored 
at -20°C until analysis. Urine and bile were collected prior to dosing and for the 
periods 0-6, 6-12,12-24 and 24-48 hr post dose and stored at -20°C until analysis. 
Cage wash was collected at 0-24 and 24-48 hr post dose and stored at 4°C until 
analysis.
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5.20.3: Instrumental (Iodobenzoic acids study)
As described in section 5.15.3 with specific operating conditions described in Table 
5.12.
Table 5.12 Instrument operating conditions for ICP-MS for iodine excretion study
Parameter Excretion balance Metabolite profiling
Cooling gas flow 17.0 L/min 18.0 L/min
Plasma gas flow 0.8 L/min 0.8 L/min
Nebuliser gas flow (argon) 0.8 L/min 0.2 L/min
Nebuliser gas flow (argon/oxygen, 95/5% v/v) 0 L/min 0.5 L/min
Plasma power 1400 W 1650 W
Dwell time 300 ms 300 ms
Mass monitored 127 127
Spray chamber temperature 8°C -7°C
For the excretion balance study chromatography was not performed and samples were 
introduced directly into the ICP-MS by flow injection into a carrier stream of water at 
a flow rate of 0.6 mL/min. For metabolite profiling the chromatographic separations 
were performed on a Polaris C l8-A, 3 p, 150 x 4.6 mm column with a matching 
guard column (Varian BV, Middelburg, the Netherlands) at a temperature of 40°C 
obtained with an Eppendorf TC-50 column heater (Presearch). The mobile phase 
consisted of 30 % acetonitrile and 0.1 % formic acid in water for analysis of 3- and 4- 
iodobenzoic acid metabolites or 20 % acetonitrile and 0.1 % formic acid in water for 
analysis of 2-iodobenzoic acid metabolites. The flow rate of 1 mL/min was split
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using an accurate splitter (Presearch), allowing 50 pL/min into the ICP-MS and the 
remainder into a Jasco UV-1575 detector set at 254 nm. To avoid excess carbon 
build-up on the cones of the ICP-MS, the nebuliser gas was mixed with argon / 
oxygen (95/5 % v/v).
For the multiple hyphenation experiments, the eluent (1 mL/min) was split with 50 
pL/min directed into the ICP-MS and 250pL/min into the UV detector and then to an 
API-365 MS (Applied Biosystems, Warrington, UK). A turbo ionspray inlet source 
was used in the positive mode and full scan over the range m/z 100-500 was acquired. 
Analyst software was used for instrument control, data acquisition and analysis.
5.20.4: Analysis (Iodobenzoic acids study)
For the excretion balance study, a stock solution of 150 mM 2-iodobenzoic acid was 
prepared in 0.2 M NaOH. This was further diluted in control urine to prepare 
standard solutions of 0.1, 0.5,1, 5,10,15 and 20 mM I. A similar procedure was 
used to prepare quality control samples at final concentrations of 0.1, 5 and 20 mM I. 
Standard solutions in bile were prepared by diluting the stock solution in control bile 
to concentrations of 0.1, 0.5,1 and 5 mM I with quality control samples at 0.15 and 5 
mM I. For analysis of cage wash and dosing solutions, aqueous standard solutions 
were prepared at concentrations of 0.1, 5,10, 20 mM I and quality control samples of 
5 and 10 mM I. The dosing solutions were diluted with water (1 in 49) and analysed 
in triplicate. The urine, bile and cage wash samples were analysed in duplicate. 
Samples were introduced by flow injection to the ICP-MS with an injection volume of 
10 pL.
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For metabolite profiling, 20 pL of neat urine and bile samples were injected on 
column. Selected urine and bile samples were further analysed by MS and subjected 
to base hydrolysis to obtain information on the identity of the metabolites. Base 
hydrolysis was performed by incubating samples with 1 M NaOH (2 in 1) at 37°C for 
24 hours and then restoring the pH by adding an equivalent amount of 1 M HC1. 40 
pi of the hydrolysed samples were then injected on column.
5.21: Results and discussion (Iodobenzoic acids study)
5.21.1: Excretion balance study (Iodobenzoic acids study)
An experiment was set up similar to that described for the analysis of 2-, 3- and 4- 
bromobenzoic acid. Linear standard curves (r2 > 0.993) were obtained in urine, bile 
and water over the concentration range 0.1-20 mM iodine, which covered the 
concentration ranges found in the samples, with concentrations below O.lmM 
considered irrelevant. Based on the quality control samples, values for accuracy were 
found in the range 94-105% with relative standard deviations below 11% as seen in 
Table 5.13. Similar values were obtained regardless of the matrix used, indicating 
that the performance of the method was not matrix dependent. The ICP-MS method 
thus appeared to be well suited to determining iodine content in urine, bile and 
aqueous samples, in for example to obtain excretion balance data for iodobenzoic acid 
dosed to rats.
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Table 5.13 Accuracy and precision data for ICP-MS analysis of iodine at m/z 127 
in three different media to determine any differences from the matrix.
Matrix Iodine conc. (mM) n accuracy (%) coefficient of variation (%)
Urine 0.1 6 101.5 8.2
5 6 94.2 6.0
20 6 97.9 6.7
Bile 0.15 6 104.4 10.2
5 6 100.4 10.2
Water 5 3 98.5 9.9
10 3 100.2 3.7
Following administration of 2-, 3- and 4-iodobenzoic acids at 50 mg/kg i.p. to bile 
duct cannulated rats, urine, bile and aqueous cage wash were collected. The measured 
iodine concentrations in the dosing solutions, cage wash, urine and bile samples are 
shown in Table 5.14. These results show that practically no iodine was present in the 
predose samples or cage wash, and the highest iodine concentrations were found in 
the 0-12 hour post dose urine samples. As shown in Table 5.15, essentially a 
quantitative recovery of the test compounds was seen over the 24 hr time course of 
the study via urine and bile (102,101 and 93% for 2-, 3- and 4-iodobenzoic acids 
respectively). The excretion of all three iodobenzoic acids was rapid with 
approximately 90 % of the dose recovered in the 0-24 hour urine and the remainder 
excreted in the bile within 6 hours.
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These results clearly demonstrate that, as for the bromine compounds, there is 
potential for the ICP-MS to be used in quantitative excretion balance studies to be 
performed based on iodine-containing compounds without the need for radio­
labelling.
Table 5.14 Average iodine concentration obtained in dosing solutions (n=3) and 
samples (n=2) after i.p. dosing of 2-, 3- and 4-iodobenzoic acids to one 
rat per compound at 50 mg/kg) I conc.cO.lmM.
Iodine cone (mM)
Sample 2-iodobenzoic acid 3-iodobenzoic acid 4-iodobenzoic acid
Dosing solution 3.52 3.08 2.62
Urine predose - - -
Urine 0-6 h 12.3 9.36 10.1
Urine 6-12 h 3.84 4.18 18.1
Urine 12-24 h 0.33 0.19 0.53
Urine 24-48 h - - -
Bile predose - - -
Bile 0-6 h 0.52 0.43 0.96
Bile 6-48 h - - -
Cage wash - - -
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Table 5.15 Percent recovery based on iodine ICP-MS data in urine, bile and cage 
wash of 2, 3- and 4-iodobenzoic acids dosed i.p. to one rat per 
compound at 50 mg/kg. The data indicates that the urine is the main 
route of excretion.
% dose recovered
Sample 2-iodobenzoic acid 3-iodobenzoic acid 4-iodobenzoic acid
Urine 0-6 h 70.1 76.4 22.5
Urine 6-12 h 16.0 6.1 32.4
Urine 12-24 h 4.8 10.9 26.4
Urine 24-48 h 0.0 0.0 0.0
Bile 0-6 h 11.1 8.2 12.1
Bile 6-48 h 0.0 0.0 0.0
Cage wash 0.0 0.0 0.0
Total 102.0 101.6 93.4
5.21.2: Metabolite profiling and identification (Iodobenzoic acids study)
As before, additional information regarding the metabolic fate of test compounds was 
gained by HPLC-ICP-MS. For HPLC-ICP-MS, methanol is generally preferred as the 
organic modifier over acetonitrile (5.16.2). However, acceptable resolution of the 
iodobenzoic acid metabolites was not achieved within a reasonable analysis time 
using an isocratic methanol-based solvent system. Chromatographic methods based 
on 20-30 % acetonitrile and 0.1 % formic acid were however able to achieve the
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required separation. To minimise the organic loading to the plasma, the flow was 
split to direct only 50 pL/min to the ICP-MS. Oxygen was also added to the nebuliser 
gas to avoid excess carbon build-up on the torch and cones of the ICP-MS.
The metabolite profiles of the 0-6 hr urine and 0-6 hr bile samples obtained for 2-, 3- 
and 4-iodobenzoic acids, based on iodine detection, are shown in Figures 5.15 and 
5.16. The pre-dose samples showed only trivial amounts of iodine indicating that all 
the iodine-containing peaks were iodobenzoic acid-related compounds. These 
profiles reveal that 2-, 3- and 4-iodobenzoic acids were extensively metabolised with 
little unchanged parent compound excreted. For all three iodobenzoic acids, one or 
two major peaks dominated the urinary metabolite profile. For bile a more complex 
profile was generally obtained, with no particular metabolite predominating.
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Figure 5.15 HPLC-ICP-MS iodine chromatogram of 0-6 hour urine profiles from 
rats dosed with A) 2-iodobenzoic acid B) 3-iodobenzoic acid and C) 4- 
iodobenzoic acid. 20pl neat urine was injected on a Polaris C18-A, 150 
x 4.6 mm column, 40°C, eluted isocratically with 20 % (in A) or 30 % 
(in B and C) acetonitrile and 0.1 % formic acid. Detection with ICP- 
MS at m/z 127.
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Figure 5.16 HPLC-ICP-MS iodine chromatogram of 0-6 hour bile profiles from
rats dosed with A) 2-iodobenzoic acid B) 3-iodobenzoic acid and C) 4- 
iodobenzoic acid. 20pl neat bile was injected on a Polaris C18-A, 150 
x 4.6 mm column, 40°C, eluted isocratically with 20 % (in A) or 30 % 
(in B and C) acetonitrile and 0.1 % formic acid. Detection with ICP- 
MS at m/z 127.
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Coupling of a standard MS to the system was carried out to gain structural 
information. Typical total ion current full scan MS, UV and iodine detected ICP-MS 
chromatograms are shown in Figure 5.17a-c, respectively for 4-iodobenzoic acid.
Both the UV and the MS chromatograms show peaks from compound-related material 
as well as endogenous compounds comparison of the traces further highlights the 
selectivity of the iodine-detection ICP-MS trace for quantitative metabolite profiling.
To identify the individual metabolites, iodine-detected peaks in the ICP-MS 
chromatogram were used as guides to pinpoint relevant peaks in the total ion current 
mass chromatogram from which mass spectra were extracted. For the urine profile of 
4-iodobenzoic acid, shown in Figure 5.18, the major peak at 5.2 min had a m/z of 306 
suggesting a glycine conjugate. An ion with m/z of 447 was found in the other major 
peak (eluting at 4.4 min) suggesting the presence of an ester glucuronide (a typical 
metabolite for a small aromatic acid such as this), seen as sodium adduct. A minor 
component with m/z of 399 at 3.8 min was also observed, but the identification of this 
metabolite was not pursued further as it accounted for a very small proportion of the 
dose. For the bile profile of 4-iodobenzoic acid the same metabolites were observed 
but in addition several further peaks with a m/z of 447 were present suggesting the 
presence of ester glucuronides. These findings are consistent with the literature, in 
that both glycine and ester glucuronide conjugates are widely found as benzoic acid 
metabolites [73]. In the urine profiles from 2- and 3-iodobenzoic acid, similar m/z 
values (306, 447) were found. However, in the case of 2-iodobenzoic acid the glycine 
conjugate was observed to elute before the ester glucuronides, reversing the order 
seen for both the 3- and 4-iodobenzoic acid metabolites. In the bile, several peaks at 
m/z 447 for putative transacylated ester glucuronides were observed in the profiles of
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both 2- and 3-benzoic acids. However, the ion at m/z 306 for the glycine conjugate 
was only detected in the 3-iodobenzoic acid samples.
To further investigate the identity of the metabolites, the urine and bile samples were 
treated with alkali to hydrolyse ester glucuronides (glycine and ether glucuronide 
conjugates are stable under these conditions). As seen in the urine HPLC-ICP-MS 
profiles in Figure 5.19, the peaks postulated to be ester glucuronides all disappeared 
after alkaline hydrolysis with a related increase in peak area of the parent compound. 
In contrast, the glycine conjugates remained unaffected as did the minor unknown 
metabolite of 4-iodobenzoic acid. Similar effects were observed for the bile samples 
when alkaline hydrolysis was performed.
In summary 2-, 3- and 4-iodobenzoic acid were metabolised in the rat primarily to 
either glycine conjugates or ester glucuronides, but to varying degrees depending on 
the structure of the parent compound.
Quantification of the individual metabolites based on the HPLC-ICP-MS 
chromatogram was performed based on the peak areas of iodobenzoic acids standards, 
in a similar way to that performed for the excretion balance study. By using this 
approach, the total degree of glycine and ester glucuronide formation from the 2-, 3- 
and 4-iodobenzoic acids was determined (Table 5.16). The results show that 2- 
iodobenzic acid was mainly glucuronidated whereas 3-iodobenzoic acid primarily 
formed glycine conjugates. For 4-iodobenzoic acid, the balance between glycine 
conjugation and ester glucuronidation was similar but the former still accounted for
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the majority of the dose. The unknown metabolite of 4-iodobenzoic acid accounted 
for less than 1 % and is not presented in the table.
Table 5.16 Percent formation of ester glucuronides and glycine conjugates in urine 
and bile after dosing of 2-, 3- and 4-iodobenzoic acid i.p. to rats at 50 
mg/kg based on HPLC-ICP-MS iodine measurements.
2-iodobenzoic acid
Urine Bile Total
Dose Dose Dose
% % %
3-iodobenzoic acid
Urine Bile Total
Dose Dose Dose
% % %
4-iodobenzoic acid
Urine Bile Total
Dose Dose Dose
% % %
Glucuronide 
Glycine conj. 
Parent 
Total
60.3 10.7 71.0 5.4 4.6 10.0 18.6 9.7 28.3
19.5 0.0
11.0 0.4
19.5
11.4
87.1 3.6
0.8 0.0
90.7
0.8
58.1 0.7
3.7
90.8 11.1 101.9 93.3 8.2 101.5
58.8
5.5
80.4 12.2 92.6
5.22: Conclusion (Iodobenzoic acids study)
This limited study of the application of HPLC-ICP-MS to iodine-specific detection of 
the metabolites of 2-, 3- and 4-iodobenzoic acids in the urine and bile of rats clearly 
demonstrates that this element (iodine) can be used as an alternative to the use of 
radio-labelled compound allowing quantitative excretion balance studies can be 
performed as well as metabolite profiling.
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Figure 5.17 0-6 hour urine profile following dosing of rats with 4-iodobenzoic
acid. Reversed phase isocratic HPLC with 3 modes of detection: A) 
Total ion current full scan MS m/z 100-500, B) UV 254 nm and C) 
Iodine detection by ICP-MS at m/z 127. For experimental conditions 
see section 5.20.
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Figure 5.18 0-6 hour urine profile following dosing of rats with 4-iodobenzoic
acid. Reversed phase isocratic HPLC with A) Iodine detection by ICP- 
MS at m/z 127 and B) MS spectra obtained from metabolite peaks at 
same times in conventional MS recording. For experimental 
conditions see section 5.20.
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Figure 5.19 Profiles after basic hydrolysis of urine samples 0-6 hour from rats 
dosed with A) 2-iodobenzoic acid B) 3-iodobenzoic acid and C) 4- 
iodobenzoic acid. 20 pi neat urine was treated with 1 M NaOH and 
injected on a Polaris C l8-A, 150 x 4.6 mm column, 40°C eluted 
isocratically with 20 % (in A) or 30% (in B and C) and 0.1% formic 
acid. Detection with ICP-MS at m/z 127 (100% = 2.5 x 106 cps).
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5.23: Chlorine detection
The use of chlorine instead of Br or I was not possible. This is due to the amount of 
endogenous Cl found in biological matrices causing a high response in blank samples. 
Although chlorine may not be suitable for excretion studies it still has an important 
role in metabolite profiling [47].
The process is, however, more challenging than the two previous investigations with 
Br and I since the mass of Cl is in a region of isobaric interferences with polyatomic 
species such as 160 I80 1Hf, 34S1H+, 35C1+ for the 35Cl-isotope and 36Ar'H+, 36S'H+,
Cl+ for the 37Cl-isotope, causing background levels to be elevated [63]. The 
sensitivity of Cl-element is not particularly high as shown in the initial work 
described in section 5.3 due to the small difference in ionisation potential between Cl 
and Ar. Therefore the problems of sensitivity and isobaric interferences complicate 
the use of Cl for the metabolite.
Work carried out by Duckett with Micromass [66] showed that data could be obtained 
for a profiling experiment as seen in Figure 5.20. The chromatograms show 
metabolites of urine collected over sequential time intervals after dosing a rat with 3- 
chloro-4-fluoroaniline (50 mg/kg).
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Figure 5.20 (A) HPLC-ICP-MS chromatogram o f a metabolite profile using Cl-
detection, sample taken at 0-6h after dosing 3-chloro-4-fluoroaniline. 
(B) HPLC-ICP-MS chromatogram o f a sequential metabolite profile 
with the sample taken at 6-12h. The chromatograms show how the 
amount o f the metabolite decreases with time.
Chromatogram used with permission from GV instruments obtained 
from reference [66].
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This method used here was taken and transferred to the instrument in house with the 
same set-up, but the chromatograms could not be repeated and the background was 
too great to gain any results. The background isobaric inferences causing this 
problem can be controlled by the use of gasses in the collision cell. Hydrogen and 
helium are used with the Platform ICP-MS and react with the polyatomic atoms to 
remove them from the m/z value detected. When the same setting for the collision 
gases were used in house as at Micromass, the interferences appeared to get worse 
instead of better. The difference between the two set-ups was the source of hydrogen. 
The hydrogen was obtained from a generator in house while at Micromass high purity 
hydrogen was used from a cylinder. The generator, although advertised as giving the 
required level of purity, showed with standards not to give appropriate sensitivity 
changes, therefore indicating a problem. Due to regulations in the laboratory it was 
not possible to install a hydrogen cylinder to investigate the differences between the 
systems fully.
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5.24: Conclusion
The use of halogens for excretion studies has been shown possible with little or no 
sample preparation, minimum analysis time per sample, low detection limits and 
avoiding the use of radiolabels. When used for profiling experiments then the 
technique is very useful within a Drug Metabolism and Kinetics Department for 
quantification of potential metabolites without expensive labelling.
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Chapter 6
Halcogen detection by HPLC-ICP-MS for sulphur and phosphorus
containing compounds.
6.1: Summary
The sensitive detection of sulphur and phosphorus-containing compounds using 
HPLC-ICP-MS is difficult due to the high background caused by polyatomic isobaric 
interferences. One potential solution to the problem of polyatomic interferences of 
this sort for S and P is to react the latter with oxygen in the collision hexapole to 
separate them from the interferences (O2 on S and NOH on P). This has the effect of 
moving the detection mass from 31 and 32 to 47 and 48 m/z for P and S respectively. 
This region is clear from interferences thereby providing an increase in the sensitivity 
of detection for the analytes of approximately 50-100 fold. For omeprazole, a model 
S containing compound, a limit of detection (LOD) of 800 pg on column was 
achieved, an increase of ca. 100 fold in sensitivity. Similarly in the case of ZD6126, a 
phosphorus-containing pro-drug, an increase in sensitivity of 50 times was observed 
with an LOD of 1 ng on column. The technique of reacting sulphur with O2 was then 
applied to the metabolite profiling of omeprazole, a sulphur containing selective 
inhibitor of gastric acid secretion.
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6.2: Introduction
Inductively coupled plasma mass spectrometry (ICP-MS) has been used as an 
analytical technique since the 1980’s [2, 14], but the use of the instrument in 
combination with high performance liquid chromatography (HPLC) is more recent. 
Whilst mainly used for the analysis of metals [5, 39, 54] (e.g. Pt) HPLC-ICP-MS has 
also found some applications in drug and xenobiotic metabolism studies of halogen- 
containing compounds (Cl, Br and I) [40,41,47, 51], as well as initial studies on S 
and P-containing compounds [9,42]. However, in the case of S and P, detection 
sensitivity is compromised by the presence of a range of polyatomic interferences 
such as 14N180 + and 15N160 1Hfwhich lead to isobaric interference [25]. To improve 
the specificity of detection for S and P, and thereby enhance sensitivity, chemical 
reaction of S and P with O2 can be used to move them away from the region of 
interference [16]. The main difference between the analytes and the interferences is 
seen in the O-atom affinity. O-atom transfer from O2 to P+ and S+ is 
thermodynamically favourable while for NO+, NOH*, and 02+ it is endothermic and 
forbidden under thermal conditions. When oxygen is reacted with sulphur to produce 
a sulphoxide (SO+) the detection m/z value changes from 32 to 48. Similarly for P, 
the production of PO+results in an increase in m/z from 31 to 47. Table 6.1 shows the 
reaction enthalpy change and thermal reaction rate constant for oxygen with S, P and 
the interfering species.
The detection of some sulphur-containing metabolites can be important for 
understanding their toxicity. Certain toxic reactions arise as a result of the formation 
of reactive metabolites. These can be detected as they can react with the sulphur-
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containing tripeptide glutathione within the cell and can are then found in the excreta 
as sulphur-containing mercapturates [81].
Table 6.1 Reaction thermodynamics and kinetics of oxygen with sulphur,
phosphorus and relevant interfering ions.
Reaction
Reaction enthalpy 
change 
Kcal mol'1
Thermal reaction rate 
constant 
Kr, molecule'1 cm3s'1
P+ + o 2 —► PO+ + 0 -71.4 5 .3x1  O'10
S+ + 0 2 SO+ + 0 -6.2 1 .8x1 O'11
CO+ + Op p C 0 2+ + 0 -13.5 <2 x 10'14 (no reaction)
HCO+ + 0 2 COOH+ + 0 3.3 <2 x 10'14 (no reaction)
NO+ + 0 2 — ► N 0 2+ + 0 57.4 <1 x 10'11 (no reaction)
NOH+ + 0 2—► n o 2h+ + 0 19.3 no data
0 2 + 0 2 — ^  O3 + 0 102.1 no data
Table taken from ref [25]
In this section the utility of this approach for the quantitative analysis of sulphur 
compounds (omeprazole and sulphanilamide) and the phosphorus-containing 
compound ZD6126 (Figure 6.1) by HPLC-ICP-MS is described.
6.3: Experimental
6.3.1: Reagents
Chromatographic grade organic solvents were obtained from Riedel-de Haen (Sigma- 
Aldrich Ltd, UK) with formic acid purchased from Fisher (Fisher Scientific Ltd, UK),
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which were of analytical or HPLC grade. Sulphanilamide (purity 99 atom %) and 
omeprazole (purity 99 atom %) were purchased from Sigma (Sigma-Aldrich Ltd, UK) 
and the phosphorus-containing pro-drug was supplied by AstraZeneca 
Pharmaceuticals (Alderley Park, Macclesfield, UK).
6.3.2: Standard and Calibration Solution Preparation for Sulphur and 
Phosphorus.
A standard solution of sulphanilamide was prepared at a concentration of 10 pg/mL 
by dissolution in water aided by sonication for 10 min in an ultrasonic water bath 
(Ultrawave Ltd, Cardiff UK).
Omeprazole stock solution was prepared in mobile phase at a concentration of 1 
mg/mL in a 10 mL volumetric flask. The dissolution was aided by sonication for 10 
min in an ultrasonic water bath. The stock solution was then diluted with mobile 
phase to give final concentrations of 1000, 700, 500,400, 300,100, 50 20 and 10 
ng/mL.
ZD6126 stock solution was prepared by dissolving the compound in mobile phase to a 
concentration of 1 mg/mL, and sonication for 10 min to aid dissolution. Dilutions 
were prepared in mobile phase to give final concentrations of 1000, 700, 500, 400, 
300, 100, 50 and 10 ng/mL.
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Sulphanilamide (Mwt = 172)
Omeprazole
. 0 — P — O H  
O H
ZD6126 Phosphate pro-drug
Figure 6.1 Structures of the compounds used for sulphur and phosphorus HPLC- 
ICP-MS studies.
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6.3.3: Plasma Samples
200 pL samples of control plasma were spiked with either sulphanilamide or the 
phosphate pro-drug to a concentration of 100 ng/mL. These samples were then 
diluted with 100 pL of water, and 50 pL aliquots were injected on to the HPLC-ICP- 
MS system. Blanks were also prepared to check there were no interfering peaks 
present in the chromatograms.
6.4: Chromatography for Sulphur and Phosphorus Detection
An isocratic HPLC system was used for the analysis of sulphanilamide and the 
phosphate pro-drug with a Synergi Polar Rp column 150 x 4.6 mm (Phenomenex, 
Macclesfield, UK). The mobile phase consisted of acetoniltrile, water and formic 
acid (40:60 0.1 %), at a flow rate of 1 mL/min. An injection volume of 50 pL was 
used.
An isocratic HPLC system was used for the analysis of omeprazole with a C l8 Xterra 
150 x 2.1 mm, 3 pm column (Waters, Milford, USA). The mobile phase consisted of 
acetonitrile water (20:80) at a flow rate of 200 pL/min. The injection volume was 50 
pL.
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6.5: HPLC-ICP-MS
Initial work using this technique for sulphur-specific detection with sulphanilamide as 
the test analyte was carried out with an Elan DRCII ICP-MS at PerkinElmer 
Beaconsfield, equipped with a PE series 200 pump and a PE series 200 autosampler. 
The sample was introduced into the plasma via a concentric nebuliser. Interactive 
software was used for the instrument control and analysis (PerkinElmer, Beaconfield, 
UK). The flow of the nebuliser gases and the operating acquisition conditions of the 
ICP-MS are shown in Table 6.2.
Chromatography for the HPLC-ICP-MS of omeprazole and the phosphate-pro-drug 
was performed using a Jasco 1580 gradient HPLC system (Jasco Ltd, Great Dunmow, 
UK) with samples introduced via a PE 200 autosampler (PerkinElmer). The injector 
was flushed with mobile phase. ICP-MS was performed on a Platform ICP-MS (GV 
Instruments Ltd, Wythenshawe, UK) and the eluent was introduced to the ICP-MS via 
an Aridus nebuliser (Cetac Technologies, Omaha, Nebraska, USA). Masslynx 
software (GV Instruments, Wythenshawe, UK) was used for data analysis and 
instrument control. The flow of the nebuliser gases and the operating acquisition 
conditions of the ICP-MS are shown in Table 6.3.
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Table 6.2 Instrument operating conditions for the Elan DRC II with 
Sulphanilamide.
Nebulizer Gas Flow 0.77 L/min Analog Stage Voltage -2000
Auxiliary Gas Flow 0.8L/min ICPRF Power 1500 w
Plasma Gas Flow 20.00 L/min Ozgas 0.5 mT /min
Lois voltage 6.5 Mass monitored 31, 32,47, and 48
Table 6.3 Instrument operating conditions for the Platform ICP-MS with 
oeprazole and ZD6126.
Cooling gas 17.00 L/min Plasma Power 1700 w
Plasma gas 0.65 L/min Acquisition mode SIR
Nebuliser gas 0.6 L/min Dwell time 200 ms
Helium gas 0 mL/min Masses monitored 31,32, 34, 47 and 48
Hydrogen gas 0 mL/min Argon/Oxygen (95/5 %) 0.2 mL/min
Oxygen gas 0.8 mL/min Total analysis time 6 min
6.6: Results and Discussion
In order to perform “chemical resolution” a small amount of oxygen (Table 6.2 and 
6.3) was introduced into the dynamic reaction cell of the Elan DRC II or the hexapole 
collision cell of the GV Platform through which the analytes are passed after the 
inductively coupled plasma. Prior to their exit from the reaction area into the MS 
detector chemical reaction occurred to produce the oxidised species for detection.
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6.6.1: Sulphur Detection
Initial studies to investigate the potential of chemical resolution were carried out using 
sulphanilamide as a model compound on an Elan DRC II ICP-MS. The resulting 
increase in sensitivity obtained using such an approach is shown in Figure 6.2 A and 
B. Thus in Figure 6.2A, when the compound was monitored at m/z 32 only a 
relatively small signal was observed. In contrast, monitoring the signal for m/z 48 
after introduction of oxygen in to the dynamic reaction cell resulted in a dramatic 
increase in signal to noise as shown in Figure 6.2B. The calibration curve was found 
to be linear over a range of 0.2 ng to 19 ng (coefficient regression 0.9998). In Figure 
6.3 the chromatogram obtained following the injection of a spiked plasma sample 
(100 ng/mL, responding to 5 ng of analyte on-column) is shown.
Similar data were subsequently obtained for another sulphur-containing compound, 
omeprazole, on a Platform ICP-MS. Figure 6.4A-C shows the results obtained for 5 
fig on column of omeprazole with detection either of 32S, 34S or 32S160. Although 
only a minor isotope of sulphur (4.2 % abundance) the detection of 34S has been 
employed previously as a means of avoiding polyatomic interferences [67] and, as 
shown in Figure 6.4B there is a useful increase in sensitivity for this isotope compared 
to 32S. However, comparison with the trace shown in Figure 6.4C with oxygen 
infused in to the hexapole reaction cell, clearly indicates the superiority of the latter 
approach. The improvement in response was found to be an increase of ca. a 100 
times over the response found for 34S isotope and a 1000 times for the 32S isotope.
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HPLC-ICP-MS chromatogram A shows the response for 
sulphanilamide (100 pL injected of 10 pg/mL standard solution) 
monitored at m/z 32 (1 pg on column). HPLC-ICP-MS chromatogram 
B shows the improvement in response, of the same sample, after 
addition of oxygen to the collision cell to produce an SO+. ICP-MS 
data collected at m/z 48. For experimental conditions see section 6.3.
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Figure 6.3 HPLC-ICP-MS chromatogram of a diluted plasma sample spiked with 
sulphanilamide, detected at m/z 48 after sulphur was reacted with 
oxygen (4 ng on column). The compound could be detected in a 
plasma matrix using chromatography to separate the endogenous 
material from the peak of interest. For experimental conditions see 
section 6.3.
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Figure 6.4 HPLC-ICP-MS chromatograms for omeprazole at 5 pg on column: (A) 
S monitored at m/z 32, (B) S monitored at m/z 34 and (C) SO+ 
monitored at m/z 48. The figure demonstrates the reduction in the 
background when using SO+ for detection.
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The properties of the system with respect to sensitivity, accuracy, reproducibility and 
linear range were then investigated. Table 6.4 shows the accuracy and precision data 
collected using omeprazole with the chromatographic conditions described earlier, at 
three concentrations with six replicates at each concentration. This experiment was 
carried out with aqueous standards to show that the sulphur - oxygen reaction in the 
collision cell would not saturate rapidly and would maintain stability and sensitivity 
over a range of analyte concentrations. The system was linear over the range 800 pg 
to 400000 pg on column (regression coefficient 0.9998) with an accuracy at the 
lowest level (800 pg on column) of 98 % and coefficient of variation of 7.2 %. The 
data collected indicate that the use of oxygen in this manner was a reliable means of 
increasing sensitivity for S-containing compounds. Chromatographic traces obtained 
from the precision and accuracy experiment can be seen in Figure 6.5, where 
examples of the LOQ (800 pg compound on column) and a blank are represented. 
The amount of the sulphur detected corresponds to ca. 80 pg on column since there is 
only one S atom per molecule in the compound (Figure 6.1).
Table 6.4 Sulphur precision and accuracy data to determine the validity of using 
SO+
Quality control 
samples 
(pg on column)
Observed mean 
(pg on column) Accuracy (%)
Coefficient of variation (%) 
(n=6)
800 784 98 7.2
40000 35160 88 5.6
400000 438240 109 9.1
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Figure 6.5 HPLC-ICP-MS chromatograms from omeprazole evaluation monitored 
at m/z 48 to avoid polyatomic interferences: (A) Blank showing 
endogenous sulphur from the matrix and (B) lower limit of 
quantification for omeprazole (800 pg on column). For experimental 
conditions see section 6.3.
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6.7: Phosphorus-Detection
Evaluation of this methodology for the phosphate pro-drug ZD6126 was carried out 
on the Platform ICP-MS. Figure 6.6 shows that an increase in response of ca. 50 
times was obtained when PO+ instead of P+ detection was used. In Table 6.5 accuracy 
and precision data are shown, indicating an accuracy of 109 % at the LOD (1000 pg 
on column corresponding to 100 pg of P), with a coefficient of variation of 9.7 %.
The calibration was linear over the range tested (10 ng to 100 ng on column), with a 
coefficient of regression of 0.999. Although the linear range for this test was small, 
the characteristics of the ICP-MS should allow a much greater range to be used.
Table 6.5 Phosphorus precision and accuracy data.
Quality control 
samples 
(ng on column)
mean 
(ng on column) accuracy (%)
coefficient of variation (%) 
(n=4)
10 10.9 109 9.7
50 49.9 99.8 9.0
100 102.1 102.1 3.0
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HPLC-ICP-MS chromatograms for the phosphorous containing pro­
drug ZD6126 at 5 pg on column: (A) P monitored at m/z 31 and (B) P 
monitored at m/z 47. The figure shows the decrease in the background 
noise when the PO+ reaction is used for monitoring. For experimental 
conditions see section 6.3.
Similar improvements in sensitivity to those seen for S were also obtained with this 
approach using the Elan DRCII for the detection of P. When P is reacted with 
oxygen, moving the detection from 31 to 47, polyatomic interference such as 15N160 +, 
14N160 !H and 12C1H3160 + [25] are avoided. This is due to the reaction of P and O 
being exothermic and therefore going to completion, unlike the reaction of N and O, 
which is endothermic and therefore is unfavourable. The initial results for PO+ 
showed a calibration plot for the process to be linear over the range 100 ng to 1900 ng 
(regression coefficient of 0.999) for directly injected standards. A plasma sample 
analysed by HPLC-ICP-MS (Figure 6.7) to be showed the P-containing pro-drug (5 
ng on columns) resolved from endogenous phosphate.
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Figure 6.7 HPLC-ICP-MS chromatogram of a diluted plasma sample of ZD6126 
(100 ng on column) monitored at m/z 47. The trace shows an 
endogenous peak separated from the phosphourus pro-drug. For 
experimental conditions see section 6.3.
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6.8: Sulphur-specific detection of omeprazole metabolites in rat urine by 
ICP- MS
6.9: Introduction (Omeprazole metabolism study)
HPLC-ICP-MS with sulphur-specific detection was investigated as a method for 
obtaining metabolite profiles for the drug omeprazole administered as a 1:1 mixture of 
32S- and 34S-labelled material. Analysis based on the monitoring of the 
chromatographic eluent at either m/z 32 or 34 was not successful due to insufficient 
sensitivity caused by interferences from polyatomic ions as discussed earlier.
However, reaction of sulphur with oxygen in the hexapole collision cell, combined 
with monitoring at m/z 48 (for 32S) or m/z 50 (for 34S) provided a facile method for 
metabolite profiling. Detection of m/z 48 was superior in sensitivity to m/z 50.
6.10: Experimental (Omeprazole metabolism study)
6.10.1: Reagents
Omeprazole was purchased from Sigma (Sigma-Aldrich Co, St. Louis, MO, USA), 
[34S] omeprazole was synthesized at AstraZeneca R&D (Molndal, Sweden).
Methanol (HPLC-grade) and ammonium acetate were purchased from Fisher 
Scientific UK Ltd (Lougborough, UK). Water was obtained from an Elga water 
purification system (Elgastat Maxima, Elga, UK).
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6.10.2: Urine samples
Pooled urine samples (0-9 h post-dose), concentrated using Cig-solid phase extraction, 
were obtained from three male Sprague-Dawley rats dosed orally with 200 p mol/kg 
of a 1:1 mixture of [34S]-labelled and unlabelled omeprazole. The samples were 
produced by Lars Weidolf of AstraZencea and preparation and extraction is described 
in [68, 69]. 100 pL was injected on column.
6.10.2: Instrumental
Chromatography was performed using a Jasco gradient HPLC system (Jasco Ltd, 
Great Dunmow, UK) with samples introduced via a PE 200 autosampler (PerkinElmer 
Ltd, Beaconsfield, UK). A Ci8 Hichrom column, HI-RPB, 5pm, 150x4.6 mm was 
used at a temperature of 40°C. The flow rate of 1 mL/min was split with 250 pL/min 
introduced to the ICP-MS. 0.13 mm PEEK tubing was used throughout. A gradient 
was employed based on A) methanol / H2O (5/95), 2 mM ammonium acetate pH=7.0 
and B) methanol / H2O (95/5), 2 mM ammonium acetate pH=7.0 as follows: 0-5 min 
95 % A, 5-20 min 95-50 % A, maintained from 20 to 25 min, 25-30 min 50-95 % A, 
remaining at 95 % A until 35 min.
ICP-MS was performed on a GVI Platform ICP-MS (GV Instruments Ltd, 
Wythenshawe, UK) equipped with a concentric nebulizer coupled to a cooled (-7°C) 
double pass spray chamber. Masslynx software (GV Instruments Ltd, Wythenshawe, 
UK) was used for data analysis and instrument control. The operating conditions of 
the instrument are shown in Table 6.6.
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Table 6.6 Instrument operating conditions for ICP-MS for omeprazole metabolite 
profiling.
Parameter Without oxygen reaction With oxygen reaction
Cooling gas 17.0 L/min 15.0 L/min
Plasma gas 0.8 L/min 0.8 L/min
Nebuliser gas 0.8 L/min 0.8 L/min
Helium gas 9.8 mL/min 0 mL/min
Hydrogen gas 2.0 mL/min 0 mL/min
Oxygen gas 0 mL/min 0.60 mL/min
Plasma power 1700 W 1700 W
Acquisition mode SIR SIR
Dwell time 300 ms 300 ms
Masses monitored 32, 34 48, 50
6.11: Results and Discussion (Omeprazole metabolism study)
Previous studies have shown that, with suitably concentrated samples, sulphur- 
containing compounds can be monitored in chromatographic eluents without the need 
for special measures such as reaction with oxygen [57, 58]. For completeness 
therefore, the urine extract sample was initially analysed by ICP-MS for both 32S and 
34S without using the oxygen reaction to move from the region of polyatomic 
interferences. However, as Figure 6.8 shows, adequate sensitivity was not obtained
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for either isotope of sulphur. Thus, in the case of S, the high background due to 
polyatomic interferences meant that no S-containing peaks for the compound or its 
metabolites could be detected by monitoring at m/z 32. At m/z 34 it was possible to 
detect a few peaks but it is clear, even with the use of an isotopically labelled 
compound, that sensitive detection would not be obtained and that minor metabolites 
present in this sample would not be detected. The addition of oxygen to the hexapole 
collision cell and monitoring at m/z 48 and 50 was then attempted. As shown in 
Figure 6.9, the result was a dramatic increase in signal to noise ratio and many 
sulphur-containing peaks appeared.
Thus, in the case of 32S, where no peaks were detected with the conventional ICP-MS, 
more than 30 resolved sulphur - containing peaks were observed following addition of 
oxygen to the collision cell. In this study, omeprazole was dosed in a 1:1 ratio of 32S 
and 34S but, as seen in Figure 6.9, a higher sensitivity was obtained at m/z 48 (i.e. 
detection of 32S) compared to m/z 50 (34S). It is also noteworthy that, due to the lower 
sensitivity a generally higher background at 50 was observed. However, whilst these 
results show that there is no advantage in terms of sensitive detection to be obtained 
from isotopically labelling a compound with 34S for HPLC-ICP-MS, a comparison of 
the two profiles is instructive. The use of the labelled compound enables the 
omeprazole-related peaks are distinguished from endogenous sulphur-containing 
substances, as the former requires peaks to be present in both the 32S- and 34S- 
chromatograms. From the results obtained here, the bulk of the endogenous sulphur- 
containing material seems to elute early in the gradient.
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Figure 6.8 HPLC-ICP-MS chromatogram of omeprazole metabolites in rat urine 
extract detected at a) m/z 32 and b) m/z 34. The chromatograms show 
the poor response obtained without the enhancement shown with the 
addition of oxygen (Figure 6.9). 100 pL of sample was inject ed onto 
the column undiluted. For experimental conditions see section 6.10.
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Figure 6.9 HPLC-ICP-MS chromatogram of omeprazole metabolites in a rat urine 
extract detected at a) m/z 48 (32SO+) and b) m/z 50 (34SO+) run on the 
same HPLC conditions as in Figure 6.8. Comparison of the traces 
shows the difference between endogenous sulphur and sulphur related 
to a metabolite. For experimental conditions see section 6.10.
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ICP-MS provides no structural information so that the identity of the various peaks 
cannot be determined by this method. However, a peak corresponding to unchanged 
omeprazole was not detected (the drug would have eluted at 23.4 min in this system) 
clearly showing that the compound was extensively metabolised. Structural 
information was then obtained by simultaneously monitoring the chromatographic 
eluent by conventional mass spectrometry, as described for other elements in previous 
chapters.
6.12: Structural identification of omeprazole metabolites by HPLC-MS run in 
parallel with HPLC-ICP-MS. 
6.12.1: Introduction (Omeprazole structural study)
The samples used in the experiment to determine the metabolic profile of omeprazole 
were then re-analysed in a hyphenated system where the ICP-MS was linked in 
parallel with an MS (Applied Biosystems, Warrington UK) to gain simultaneous data 
for the profile and mass information for the sulphur-containing metabolites. One 
potential metabolite route for omeprazole is the glutathione pathway (scheme 6.1).
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Scheme 6.1 Previously identified metabolic pathway of omeprazole [68]
6.12.2: Experimental (Omeprazole structural study)
The same chromatographic conditions were used as in section 6.10.2 with a split to 
direct flow from the column to the ICP-MS (250 pL) and MS (750 pL). The mass 
spectrometer was set up in scan mode to capture data over the range 100 to 600 amu. 
The sample used in section 6.10.2 was injected (100 pL) on to the system.
6.13: Results and Discussion (Omeprazole structural study)
Parallel use of the ICP-MS with the MS was designed to maximise the amount of 
information gained from one sample committed to the analysis. The urine sample, 
from rats dosed with omeprazole as described in section 6.10.2, was profiled to gain 
quantitative data and related mass spectral data to enable tentative structural 
identification. From the ICP-MS trace of 32S160  an selection of peaks were chosen 
for quantification and these were compared to an external standard of omeprazole (10 
pg/mL concentration). The results are shown in Table 6.7, where the retention time 
of the peaks of interest are given as well as the amount of sulphur present in the 
metabolite. These were compared to the total ion current (TIC) scan from the MS, 
which is shown in Figure 6.10. The TIC chromatogram peaks were labelled to relate 
them back to the ICP-MS chromatogram and are summarised in Table 6.7. With this 
information the amount of sulphur in each peak could then be used to estimate the 
concentration of each potential metabolite. The omeprazole external standard has a 
molecular weight of 346, in which sulphur represents 10 percent of the structure by 
mass. The masses for the related peaks were obtained from the parallel MS system, 
then these were used with the amount of sulphur found in each peak to give a total 
metabolite concentration. The MS was also used to gain structural information, and 
the data compared with previous results from Lars Weidolf et al. [68, 69]. Parent 
omeprazole was not observed in the chromatogram since the animal does not excrete 
unchanged parent, however the peak would have eluted at 19.5 minutes according to 
the standard. Due to the isotope cluster in the spectrum it is possible to identify the 
metabolites in the trace relatively easily. The ions observed at m/z 346/348 have the 
same mass as the parent but elute later. These components have been reduced to
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sulphides after or prior to metabolic incorporation of an oxygen atom (Figure 6.19). 
Other metabolic transformations that involved oxidation are shown in Figures 6.16 
and 6.17, with the major metabolite 5-hydroxyomeprazole shown in Figure 6.18 
(concentration of 8.5 |ig/mL). Sulphated conjugates appeared in the region m/z 
396/398 to 442/444 including the compounds identified in Figures 6.11, 6.14 and 
6.15. The final set of compounds found in the samples analysed were in the m/z 
region 492/494 to 538/540, where glucuronides are found. These are shown in 
Figures 6.12 and 6.13. The data obtained from the system are summarised in Table 
6.7.
Table 6.7 Profile data obtained from ICP-MS trace of urine from omeprazole- 
dosed rats, monitored at 32S160+ against an external standard of 
omeprazole. The table shows the amount of sulphur present for each 
peak for the ICP-MS trace, which was related to the TIC of the MS 
trace and to allow the amount of each metabolite to be estimated.
Pro: He o f omeprazole urine sample
A B C D E F G H 1
Isotope masses 428/430 508/510 538/540 412/414 396/398 378/380 378/380 362/364 346/348
Structures
'tSOflQA
o Y •
" f e f Q A
Retention time (min) 
on ICPMS trace 9.3 9.9 12.1 12.8 16.1 17.2 19.2 20.1 22.8
amount o f sulphur present 
in metabolite (pg/mL) 0.24 1.04 0.2 0.57 0.61 0.22 0.22 8.5 0.32
Quantity o f metabolite 
present (pg/mL) 0.21 0.77 0.14 0.52 0.58 0.22 0.22 8.5 0.32
Full size diagrams of the structures are presented in Figures 6.11 though to 6.19.
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6.14: Conclusion (Omeprazole metabolism study)
The data shows that a parallel system consisting of HPLC-ICP-MS and MS works 
well to give a significant amount of information from a single injection. The 
integrated system provided quantitative and structural information for metabolite 
peaks. The work demonstrated what could be achieved for one injection of a sample, 
however if more structural data was required then the triple quadrupole MS could be 
used to provide positive identification of metabolites.
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Figure 6.10 HPLC-MS total ion current chromatogram obtained for the omeprazole 
rat urine sample dosed orally with omeprazole at 200 pmol/kg (data 
gained over the range 100 to 600 amu). The labelled peaks are 
potential metabolites and were looked at in detail in the ICP-MS trace 
as well as in ion spectra. For experimental conditions see section 6.10.
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Figure 6.11 A) MS TIC trace showing peak A. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak A (concentration calculated against 
an external standard: 0.21 pg/mL, 10.5 ng on column) C) MS spectrum 
of peak A as shown in both chromatograms showing a m/z of 428/430 
indicating 5-hydroy-5-desmethylomeprazole-5-sulphoconjugate [68, 
69]. For experimental conditions see section 6.10.
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Figure 6.12 A) MS TIC trace showing peak B. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak B (concentration calculated against 
an external standard: 0.77 pg/mL, 38.5 ng on column) C) MS spectrum 
of peak B as shown in both chromatograms showing a m/z of 508/510 
indicating 5-desmethylomeprazole glucuronic acid conjugate [68, 69]. 
For experimental conditions see section 6.10.
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Figure 6.13 A) MS TIC trace showing peak C. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak C (concentration calculated against 
an external standard: 0.14 pg/mL, 7 ng on column) C) MS spectrum of 
peak C as shown in both chromatograms showing a m/z of 538/540 
indicating 6-hydroxyomeprazole glucuronic acid conjugate [68, 69]. 
For experimental conditions see section 6.10.
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Figure 6.14 A) MS TIC trace showing peak D. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak D (concentration calculated against 
an external standard: 0.52 pg/mL, 26 ng on column) C) MS spectrum 
of peak D as shown in both chromatograms showing a m/z of 412/414 
indicating 5-desmethylomeprazole sulphconjugate [68, 69]. For 
experimental conditions see section 6.10.
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Figure 6.15 A) MS TIC trace showing peak E. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak E (concentration calculated against 
an external standard: 0.58 pg/mL, 29 ng on column) C) MS spectrum 
of peak D as shown in both chromatograms showing a m/z of 396/398 
indicating 5-desmethylomeprazole sulphide sulphconjugate [68, 69]. 
For experimental conditions see section 6.10.
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Figure 6.16 A) MS TIC trace showing peak F. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak F (concentration calculated against 
an external standard: 0.22 pg/mL, 11 ng on column) C) MS spectrum 
of peak F as shown in both chromatograms showing a m/z of 378/380 
indicating 5,6-dihydroxyomeprazole [68, 69]. For experimental 
conditions see section 6.10.
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Figure 6.17 A) MS TIC trace showing peak G. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak G (concentration calculated against 
an external standard: 0.22 |ig/mL, 11 ng on column) C) MS spectrum 
of peak G as shown in both chromatograms showing a m/z of 378/380 
indicating 5-hydroxysulphone [68, 69]. For experimental conditions 
see section 6.10.
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Figure 6.18 A) MS TIC trace showing peak H. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak H (concentration calculated against 
an external standard: 0.8.5 pg/mL, 42.5 ng on column) C) MS 
spectrum of peak H as shown in both chromatograms showing a m/z of 
362/364 indicating 5-hydroxyomeprazole [68, 69]. For experimental 
conditions see section 6.10.
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Figure 6.19 A) MS TIC trace showing peak I. B) ICP-MS trace gained from
monitoring at m/z 48 showing peak I (concentration calculated against 
an external standard: 0.32 pg/mL, 16 ng on column) C) MS spectrum 
of peak I as shown in both chromatograms showing a m/z of 346/348 
indicating 5-hydroxymeprazole sulphide [68, 69]. For experimental 
conditions see section 6.10.
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6.15: Conclusion
The use of ICP-MS with the addition of oxygen to the collision cell to increase the 
sensitivity of methods for compounds containing S and P elements has been 
demonstrated. An increase in response for S of 100 times for the SO+ compared to 
the 34S isotope, and 1000 times compared to 32S, was shown. Similar gains in 
sensitivity were achieved for P. This order of increase in sensitivity enabled the use 
of HPLC-ICP-MS for the analysis of compounds containing these elements at trace 
levels in complex matrices such as biological fluids.
The results presented in this chapter were published in, Chromatographia 59, 2004, 
165-170 and Rapid Communications in Mass Spectrometry 18,2004,, 181-183. 
[Appendix A].
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Chapter 7 
Conclusions and Future Work
7.1: Conclusions
ICP-MS has been shown to have a place within the quantitative and qualitative environment 
of a drug metabolism department. The complete atomisation of the biomolecule and the 
subsequent quantitative detection of a signal independent of chemical properties of the parent 
was the feature of interest in the technique. The elements contained in the sample are 
detected quantitatively, enabling the instrument sometimes to replace the use of [14C] radio­
labels in excretion balance studies and metabolite profile experiments.
Excretion balance studies using Br and I proved the concept that an element within the 
structure of the compound can be used to produce meaningful data. Once the excretion route 
was determined quantitative profiling could be used to determine the amounts of the 
individual metabolites present.
HPLC coupled to ICP-MS, separation of metabolite mixtures was possible and an element 
within the structure determined to give accurate quantification data for each metabolite as 
long as the element remained in the structure. Metabolite successfully were quantified against 
a non-related compound with the same element present, with due regard for the relative molar 
stereochemistry of the element within each compound. Profiling experiments were carried 
out with Br and I containing samples as well as for S and Pt containing compounds.
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ICP-MS, however is an element detector so no structural information is gained from it. With 
this in mind, MS detection was run in parallel with the ICP-MS to gain maximum information 
from each sample. This was taken even further for Pt anti cancer drug profiling (ZD0473) 
where a UV absorbance detector and a scintillation counter were also placed in line for each 
sample injected. The added benefit of such a system was that the [14C] radio-label was 
located in a different part of the molecule from the Pt and also more metabolites could be 
detected. Different metabolic pathways could be monitored with this extra information.
In most examples ICP-MS was run with MS only since the idea behind the system was to 
produce a technique that did not require [14C] radio-labels. Detection of [13C], either to 
produce a universal detector or to provide label-selective detection without radio isotopes, 
proved difficult because of the low ionisation efficiency for carbon, but proof of principle was 
established. Sulphur analysis was of particular interest since its presence in metabolites and 
drugs is not uncommon. The main problem found with this element was the sensitivity, 
because the interferences experienced with detection at m/z 32 showed the technique to be 
ineffectual. The problem was overcome by using a technique previously reported in 
environmental applications. By reacting oxygen with sulphur in the collision cell of the 
instrument to produce SO+, the detection mass was increased to m/z 48, which had the effect 
of increasing the sensitivity 100 fold. It was not possible to use sulphur in excretion balance 
studies due to the amount of endogenous sulphur present in samples, but it was of use in 
metabolite profiling where individual S-containing compounds derived from the parent drug 
could be quantified in DMPK.
Excretion balance and metabolite profile experiments involving halogen were also 
investigated. Excretion balance study for Cl is not practical, since Cl is present in the plasma
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making the background levels too great. Br also suffered from matrix Br and correction 
valves form the pre-dose samples were introduced to give an increased accuracy to the data. 
Iodine proved to be the most successful element in excretion balance experiment due to the 
lack of background interference from the matrix. Metabolite profiling in all cases was 
successful, using chromatography to separate the metabolite mixtures to quantifying 
metabolites against an none related standard.
Metabolism studies are only one area of interest; the quantification of drugs in kinetic studies 
is also of great importance. The sensitivity of ICP-MS to individual elements varies due to 
the ionisation energy of the element in relation to the ionisation energy of argon, the energy 
transfer gas. Pt was the only element, which showed sufficient sensitivity for kinetic studies 
to be carried out. For other elements the conventional method of HPLC-MSMS was superior. 
The Pt element used for the kinetic analysis of ZD0473 showed greater sensitivity compared 
with its HPLC-MSMS equivalent, 0.1 ng/mL compared to 5 ng/mL respectively. This 
increase in detection allowed the kinetic data to be followed to later time points.
Phosphorus was considered as possible element due to its importance within peptides as well 
as pro-drugs. The initial work using phosphorus used detection at m/z 31 which showed that 
detection limits were low. As for the sulphur, when phosphorus was reacted with oxygen an 
enhancement was seen which increased the sensitivity by a factor of 50. This work will by of 
great use in future projects into peptides and immunoassays.
Carbon was considered for a possible ICP-MS detection. The choice of carbon is a good 
choice since this element is present in all pharmaceutical drugs therefore goes to produce 
“universal detection system”. Ionising carbon is a challenge in itself but was managed to a
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degree and a proof of principle was achieved. If problems associated with mobile phase and 
poor sensitivity could be overcome the potential use for carbon detection within drug analysis 
is very high.
7.2: Future Work
7.2.1: Advancements in hardware
Throughout this project the equipment was being changed and enhanced to improve data and 
equipment reliability. An example of this was the addition of an automated RF box, so when 
the electrical impedance changes in the plasma occur due to introduction of organic modifier, 
the RF frequency can change to match the new conductivity. This stabilises the plasma and 
prevents it from extinguishing. Developments are continuing, and there are two main areas 
where work is still required.
Sensitivity is a major consideration for biological assays and for ICP-MS is governed by 
ionisation efficiency, background signal and nebulisation efficiency. The latter area is one 
where developments are occurring rapidly. Investments into new perfluoroalkoxy (PFA) 
nebulisers have produced more robust assays with slight increases in sensitivity with 
improvement in droplet size.
A particular interest would be the use of direct injection high efficiency nebulisation (DIHEN) 
[74]. This allows flow rates in the range of 1 to 100 pL /min to spray directly into the plasma. 
The advantage of this would be that the losses experienced in the spray chamber (which can 
be as high as 96 %) would be eliminated. An added advantage would be eradication of the
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peak broadening seen in assays using a spray chamber. Sharper peaks would give increased 
sensitivity and better resolution. There is however a down side in that the spraying of organic 
modifier directly into the plasma may cause too great a change in electrical impedance 
compromising the plasma flame. Narrow bore chromatography, which is becoming more 
widely used in industry, may work with this technique [75, 76].
Chromatographic separation is an integral part of metabolite profiling, whether with the ICP- 
MS or any other technique. Improving the efficiency of chromatographic separation is 
therefore an important task. Ultra high pressure liquid chromatography (UPLC) is one 
possibility for improved chromatographic separations. This process makes use of narrow bore 
columns with very fine packing, which require very high pressure and run at low flow rates. 
This allows more flexibility in mobile phase composition, producing shorter run times and 
high resolution. Examples of the potential benefit are shown in Figure 7.1, which shows the 
results for a separation with UV detection. When the same sample injected into the ICP-MS, 
peak broadening reduced the resolution, even though a reduction in run time was achieved. 
Improvement in reduction of dead volume in the ICP-MS coupling should allow the benefits 
of fast, high resolution UPLC to be seen with element-selective detection.
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Figure 7.1 Example of the flexibility provided by UPLC, with an omeprazole metabolite 
sample detected by UV absorbance at 254 nm. A) A gradient run over 17 
minutes which is faster than the original chromatography as shown in Figure 
6.9. B) The same gradient mixture but the rate speeded up by a factor of two; 
resolution was maintained. C) The same gradient mixture but with the rate 
increased by a factor of seven resolution was still maintained. The column 
used in the experiment was a waters C18 1.7um 2.1 x 100 mm with mobile 
phase conditions as described in section 6.10.
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7.2.2: Future applications
The use of ICP-MS in metabolite profiling is a continuing process, but needs improvement in 
the sensitivity and better separation techniques to maximise its usefulness. Technical 
developments may make the detection of halogens and halcogens easier. Improvement in 
phosphorus detection might be useful in the study of protein phosphorylation [77]. Reversible 
protein phosphorylation has been known for some time to control a wide range of biological 
functions and HPLC-ICP-MS for phosphorus may be of use in proteomics in parallel with MS 
to aid identification.
The element tagging work reported by Quinn etal and Baranov etal [78, 79] is of interest. This 
showed the advantages of tagging proteins with metals to improve the sensitivity of protein 
immunoassay. This work is particular interesting since it widens the application into an area 
where components not normally detectable can be detected due to the tag. Fluorescent tags 
and enzyme labels are widely used in immunoassay and nucleic acid research. Elemental tags 
will be smaller, which may benefit use in immunoassay in particular. The sensitivity of ICP- 
MS, and the number of metal’s available, may make multi-tagging attractive in the biological 
field. DNA sequence analysis currently uses four fluorescent dyes, with some difficulty in 
distinguishing between then, while in security applications tags of as many as 20 different 
metals have been used with ICP-MS detection.
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A Comparison of the Quantitative Methods for the Analysis of the Platinum-Containing Anticancer Drug {cis-[Amminedichloro(2-methylpyridine)]- platinum(ll)} (ZD0473) by HPLC Coupled to Either a Triple Quadrupole Mass Spectrom eter or an Inductively Coupled Plasma Mass Spectrom eter
Christopher J . Smith,* Ian D. W ilson, Fadi Abou-Shakra,T Richard Payne, Tony C. Party, 
P eta  Sinclair, and David W. Roberts
Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, 
Macclesfield, Cheshire SK10 4TG, U.K., and Micromass UK Ltd, Floats Rd, Wythenshawe, Manchester M23 9LZ, U.K.
The use of high performance liquid chromatography 
coupled with inductively coupled plasma mass spectrom­
etry (HPLC-ICPMS) as means for the quantitative deter­
mination of ZD0473, a platinum anticancer drug, and its 
related biologically active “aqua” compounds in biofluid 
samples is described. The performance of the resulting 
HPLC-ICPMS method was compared with that of a 
conventional HPLC-triple quadrupole mass spectrometer- 
based (HPLC-MS/MS) system for properties such as 
limit of detection, linearity, and reproducibility using 
spiked samples. The methods were then applied to the 
determination of plasma ultrafitrate concentrations of 
ZD0473 in dog plasma samples obtained following intra­
venous and oral administration at 0.5 and 6 mg/kg, 
respectively. These experiments showed that both meth­
ods were capable of providing accurate and precise results 
but that the HPLC-ICPMS method had advantages of 
extended linear range and superior sensitivity, providing 
a limit of quantification of 0.1 ng/mL for ZD0473, as 
compared to 5 ng/mL using the current HPLC-MS/MS 
method. In addition, by using a single combined HPLC- 
ICPMS/MS/MS system, it was possible to determine the 
relative MS/MS response of the aqua compounds for the 
first time.
ZD0473 {cis[amminedichloro(2-methylpyridine)] platinum (II)} 
is a new generation platinum compound designed to deliver an 
extended spectrum of antitumor activity and overcome platinum 
resistance.1-2 The structure of ZD0473 and the related biologically 
active “aqua” compounds are shown in Figure 1. Traditionally, 
the analysis of platinum drugs has relied upon atomic absorption 
spectrophotometry, ICPMS, or electrochemical detection.3-5 How­
* To whom correspondence should be addressed. E-mail: 
christopher.smith 1 @astrazeneca.com.
1 Micromass UK Ltd.
(1) Bonges, J.; Bell, J. U.; Richardson, D. E. J. Biochem. 1988, 34, 55-62.
(2) Brifere, K. M.; Shirazl, H. F.: Smith, I. C. P. Cancer Chemother. Pharmacol.
1996, 37, 518-524.
ZD0473 Aqua Species
Figure 1. The structure of ZD0473 and the associated aqua 
species.
ever, in the absence of a separation, these techniques do not 
provide an adequate process for a quantitative assay because of 
the failure to distinguish between the compound, the active aqua 
species, and inactive metabolites (including amino acid adducts)/ 
degradation products. If such information is required, a chro­
matographic separation coupled to fraction collection and subse­
quent off-line determination of the platinum content can be 
performed, but this is labor-intensive, time-consuming, and prone 
to error. Because of these practical difficulties, the initial method 
developed for the determination of ZD0473 in biological samples 
was based on the HPLC-M S/M S system developed by Oe et al.,6 
which enabled the compound to be quantified down to concentra­
tions of 10 ng/mL in biofluid samples, such as plasma ultrafiltrate 
and urine. However, the advent of robust HPLC-ICPMS systems 
offers great potential for the analysis of metal-containing com­
pounds in biological matrixes,7-10 as illustrated by a recent
(3) Aggorwal, K. S.; Gemma, N. W.; Kinter, M.: Nicloson, J.; Sipe, J. R.; Herold, 
D. A. Anal. Biochem. 1993 , 210, 113-118.
(4) Barefoot, R. R. J. Chromatogr., B  20 0 1 , 751, 205—211.
(5) Premstaller, A.; Ongania, K.; Huber, C. G. Rapid Commun. Mass Spectrum. 
2001: 15, 1045-1052.
(6) Oe, T.; Tian, Y.; O'Dwyer, P. J.; Roberts, D. W.; Malone, M. D.; Bailey, C. 
J. Blair, I. A. Anal. Chem. 2 0  02, 74, 591—599.
(7) Gilmour, M. J.; White, P.; McDougall, S.; Firth. W. J.; Woolfrey, S. G.: 
Graham, M. A.; Greenslade, D. J. Pharm. Biomed. Anal. 2 0 0 0 , 24, 1—10.
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example for a platinum-containing compound in human plasma.11 
We have, therefore, developed an HPLC-ICPMS-based method 
for the analysis of ZD0473 and related materials. This method 
has been compared to an in-house assay, based on the published 
HPLC-M S/M S procedure,6 via the analysis of both spiked 
samples and samples derived from a dog study following the 
intravenous and oral administration of ZD0473 at 0.5 m g/kg and 
6 m g/kg, respectively.
EXPERIMENTAL SECTION
Chem icals. Chromatographic solvents together with formic 
and hydrochloric acids were purchased from Fisher Scientific UK 
Ltd (Loughborough, U.K.) and were of analytical or HPLC grade. 
Ammonium acetate and sodium chloride were obtained from BDH 
Ltd (Poole, U.K.) and were of analytical grade. ZD0473 was 
formulated as a sterile solution in 0.9% sterile sodium chloride 
solution at a concentration of 0.5 mg/mL for intravenous admin­
istration, and at 50:50 w /w  with lactose at a concentration of 90 
mg for oral administration, which was obtained from the Media 
Preparation Laboratory at AstraZenenca Pharmaceuticals (Alderley 
Park, Macclesfield, U.K.). ZD0473 was supplied by AstraZeneca 
Pharmaceuticals (Alderley Park), and the deuterated internal 
standard, [2H7] ZD0473 (deuterated in the aromatic ring and 
methyl), was synthesized in the Isotope Chemistry Laboratory in 
the Department of Drug Metabolism and Pharmacokinetics at 
AstraZeneca Pharmaceuticals (Alderley Park).
Standard Solution Preparation. ZD0473 is light-sensitive, 
and care was taken when making up standard solutions for the 
two assays to avoid photodegradation. Typically, 5 mg of ZD0473 
was weighed out into an amber vial, and 10 mL of 0.15 M sodium 
chloride was then added to achieve a concentration of 0.5 m g/  
mL. The presence of chloride ions stabilizes ZD0473 by preventing 
the formation of the aqua species. Dissolution was obtained by 
stirring the sample for 2 h at room temperature. The spiking 
standards were prepared by making the appropriate dilutions with 
sodium chloride (0.15 M) to provide standards of concentrations 
500, 10, 1, 0.2 and 0.02 f ig /m L .  The initial solution was checked 
by UV spectroscopy at a concentration of 100 f ig /m L , and the 
data were compared to previously generated data at this concen­
tration to determine integrity of the preparation. The standard 
solution of the deuterated internal standard ([2H7]-ZD0473) 
employed in the HPLC-M S/M S assay was prepared in the same 
manner and diluted with sodium chloride to give a final concentra­
tion of 5 f ig /m L .
Intravenous and Oral Formulation of Z D 0473 and Sample 
Collection. ZD0473 was formulated in physiological saline at a 
concentration of 0.5 mg/mL. ZD0473 was dissolved in 0.9% w /v  
sodium chloride by stirring overnight and then filtering through 
a 0.2-/im filter into a sterile vial. The formulation was then dosed 
intravenously as a bolus over 1 min to a male beagle dog (12.8 
kg) at a dose level of 0.5 m g/kg. Blood samples (4 mL) were 
taken at 0.033,0.083, 0.167,0.25, 0.5, 0.75,1, 2, 3 ,6 , and 12 h post 
dose. The oral dose was formulated as a 50% w /w  mixture with 
lactose (90 mg) and dosed to a single male beagle dog (12.5 kg) 
at a level of 6 m g/kg. Blood samples were taken (4 mL) at 0.25, 
0.5, 0.75, 1, 2, 3, 6, and 12 h. On collection, blood samples were
(11) Galettis, P.; Carr, J.; Paxton, J. W.; McKeage, M. J. J. Anal. At. Spectrom. 
1999, 14, 953-956.
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placed in lithium heparin tubes and centrifuged at 3000 rpm for 
15 min to prepare plasma. Aliquots of these plasma samples were 
then taken (200 fiL ), placed into Amicon Centrifree Filter devices 
(30 000 molecular weight cutoff, Millipore Corporation, Bedford, 
MA), and centrifuged at 3000 rpm for 30 min at 4 °C to provide 
ultrafiltrates. The samples were then stored at - 7 0  °C in glass 
vials wrapped in aluminum foil to protect the samples from 
photodegradation until analysis (these conditions have been 
shown to provide stability for 5 months, unpublished observa­
tions).
Preparation of Standard Curve and Quality Control 
Sam ples. The standards and quality control (QC) samples were 
prepared by spiking control dog plasma ultrafiltrate with standard 
solutions to produce the required concentrations. The standard 
curve prepared for the H PLC-M S/M S assay contained samples 
spiked at 5, 10, 50, 200, 600, 1000, 2500, 5000, 7500, and 10 000 
ng/mL, respectively, whereas that for the HPLC-ICPMS method 
had additional standards at 0.1,0.5, and 1 ng/mL. The QC samples 
for the HPLC-M S/M S and HPLC-ICPMS assays were prepared 
at 5, 100, and 1000 ng/m L and 0.1, 0.5, 5, 1000, and 10000 n g /  
mL, respectively, and stored at - 7 0  °C in glass vials wrapped in 
aluminum foil until required.
Sam ple Preparation. Aliquots of the standards, QCs, and 
samples (0.1 mL in each case) were placed into glass tubes (12 
x 75 mm). To these, 25 fiL  of 0.15 M sodium chloride in 0.1 M 
hydrochloric acid was added, and the samples were then made 
up to 200 fiL  with 0.15 M sodium chloride. For the HLPC—M S/ 
MS method, 25 fiL  of the internal standard solution (5 fig /m L )  
was added before the sample was made up to 200 fiL . The 
mixtures were vortex-mixed for 20 s  and then transferred to HPLC 
vials ready for injection. The addition of hydrochloric acid was 
designed to ensure that the equilibrium favored ZD0473 rather 
than the aqua species in the presence of the ultrafiltrate. The 
samples were transferred to autosampler vials and then placed in 
the autosampler and kept in the dark prior to injection.
Chromatography. An isocratic reversed-phase HPLC method 
based on a mobile phase of methanol water (20:80 V/V) containing
0.1% formic acid and 0.15 mM ammonium acetate (pH 3) was used 
for both ICPMS and the M S/M S assays. The column used was a 
Phenomenex Synergi Polar RP 150 x 4.6 mm (Phenomenex, 
Macclesfield, U.K.) operated at ambient temperature with a flow 
rate of 1 mL/min, which gave a run time of 7 min. An injection 
volume of 50 fiL  was used in the assays.
H PLC -ICPM S. Chromatography for ICPMS was performed 
using a Jasco HPLC system (Jasco Ltd, Great Dunmow, U.K.) 
with samples introduced via a PE series 200 autosampler (Perkin- 
Elmer Ltd, Beaconsfield, U.K.). The injector was flushed using a 
methanol/water solution (1:1). ICPMS was performed on a 
Platform ICPMS, which uses a hexapole collision/reaction cell 
for simultaneous measurement of the platinum isotopes (Micro­
mass, Wythenshawe, U.K.). The eluent from the column was 
introduced to the ICPMS via either an ultrasonic nebulizer 
U-6000AT (Cetac Technologies, Omaha, NB) or a Meinhard 
concentric nebulizer coupled to a double pass spray chamber 
(Micromass, Wythenshawe, U.K.). MassLynx software was used 
for instrument control, data acquisition, and data handling. Table 
1 shows operating and acquisition conditions of the ICPMS, 
including the flow of the nebulizer gases for sample introduction
Table 1. Instrument Operating Conditions for the  
Platform ICPMS
cooling gas 
plasma gas 
nebulizer gas 
helium gas 
hydrogen gas
16.00 L/min plasma power
0.65 L/min 
0.75 L/min 
5 mL/min 
5 mL/min
total analysis time 7 min
1350 w
acquisition mode SIR
dwell time 200 ms
masses monitored 195
argon/oxygen (95/5%)0.2 mL/min
^  .a
C f ”CH, NH
✓Pt
CH3 NH
Figure 2. The multiple reaction monitoring transition for the HPLC- 
MS/MS system.
Table 2. Instrument Operating Conditions for API-3000 
MS/MS
ion transformation
component Qi Q3 dwell time (ms)
ZD0473 393.4 303.5 150
ZD0473D6 400.0 310.2 150
aqua species 358.0 303.5 150
as well as an argon oxygen mix (95:5 v/v), which is used to reduce 
carbon buildup from mobile phase combustion in the plasma.
H PL C -M S/M S. Chromatography for HPLC-M S/M S was 
performed using a PE series 200 pump (PerkinElmer Ltd, 
Beaconsfleld, U.K.) with samples introduced via a CTC HTC-PAL 
autosampler (Presearch, Hitchin, U.K.). The injector was flushed 
using a methanol/water solution (1:1). For quantification by M S/ 
MS, an API-3000 mass spectrometer (Applied Biosystems, War­
rington, U.K.) with a turbo ionspray inlet source was used for 
the multiple reaction monitoring of ZD0473 and its aqua species. 
Analyst software was used for the instrument control, data 
acquisition, and data handling. The operating conditions for the 
instrument are shown in Table 2.
H PL C -IC PM S/M S/M S. To evaluate the combination of 
HPLC-ICPMS/MS/MS, and enable the relative response for the 
aqua species by M S/M S to be determined, the chromatographic 
system used for HPLC-ICPMS described above was taken, and 
the effluent from the column was split using a splitter valve (Jasco 
Ltd, Great Dunmow, U.K.) positioned directly after the outlet of 
the column; this directed one-half of the flow (0.5 mL/min) to 
the HPLC-M S/M S and the remainder (0.5 mL/min) to the 
HPLC-ICPMS. PEEK tubing (0.005-in. bore) was used to connect 
the instruments, and the lengths were adjusted to give similar 
retention times for ZD0473 in both systems.
RESULTS AND DISCUSSION
Assay Development and Validation. Chromatography. ZD0473 
was found in biological fluids together with a mixture of the 
pharmacologically active aqua species (structures in Figure 1). 
Because the HPLC-ICPMS method is based on the detection of 
platinum, a chromatographic separation of ZD0473 from these 
aqua species was required to ensure specificity. Similarly, the use 
of M S/MS for quantification necessitated the separation of the 
two aqua components, because the same ion transformations are 
seen for both aqua species. The HPLC separation that was 
developed, based on reversed-phase chromatography with a 
methanol-ammonium acetate/formate (20:80) buffered eluent, 
provided this separation and was also compatible with both modes 
of MS detection.1213 The formic acid and ammonium acetate 
components of the mobile phase were there primarily for the
benefit of the HPLC-M S/M S system, with formic acid added to 
aid the ionization of the compounds in the turbo ionspray source, 
whereas the ammonium acetate was present in order to produce 
the ammonium adducts required for M S/M S detection (Figure 
2). For HPLC-ICPMS, methanol-water 20:80 alone would be 
suitable for chromatography, but a common mobile phase was 
used here to aid comparison of the two detection methods.
H P L C -IC P M S. Having obtained a suitable chromatographic 
separation, we then proceeded to develop and validate an HPLC- 
ICPMS-based assay for ZD0473. For this, the various argon gas 
flows were optimized to produce the best sensitivity for platinum 
in the ICPMS, and the hydrogen and helium collision cell gases 
were set to produce the lowest background,1415 as detailed in Table
1. For successful HPLC-ICPMS, efficient removal of the organic 
modifier prior to the introduction of the sample as an aerosol into 
the plasma is important. Various devices are available to achieve 
this,16 and in this study, two types of nebulizer were investigated, 
namely, an ultrasonic nebulizer and a concentric nebulizer with a 
double-pass spray chamber. The latter was water-cooled to - 4  
°C. The ultrasonic nebulizer is far more efficient than the 
concentric nebulizer in producing an ultrafine aerosol, which is 
desolvated prior to its introduction into the ICP flame. This 
increased efficiency leads to an increased sensitivity (5 pg on 
column limit of detection) and low backgrounds but at the expense 
of linear range as a result of losses of the analyte at high 
concentration in the desolvating step. However, in use, it has 
proven more time-consuming to set up and was found to be less 
reliable than the concentric nebulizer/double pass spray chamber 
combination. The latter provides an extended linear range (but 
with higher background levels) in comparison with the ultrasonic 
nebulizer and has also proved to be more robust. The higher 
backgrounds observed with the concentric nebulizer result from 
its poorer efficiency, as compared to the ultrasonic nebulizer, in 
removing the organic solvent from the mobile phase. However, 
this combination still offered a limit of quantification of 0.1 n g /  
mL (10 pg on column), with a signal-to-noise (S/N) of 10, 
combined with a linear range extending over eight orders of 
magnitude. Because of the extended linear range afforded by this 
method of sample introduction, further method development 
employed this nebulizer. If greater sensitivity was to be required 
and reduction in the calibration range was acceptable, the 
increased setup time for the ultrasonic nebulizer would then
(12) Axelsson, B.-O.; Jomten-Karlsson, M.; Michelsen, P.; Abou-Shakra, F. Rapid
Commun. Mass Spectrom. 2001; 15, 375-385.
(13) Sutton, K. L.; Caruso, J. A. J. Chromatogr., A 1999 , 856, 243—258.
(14) Ackley, K. L.; Sutton, K. L.; Caruso, J. C. J. Anal. At. Spectrom. 2 0 0 0 , 15
(9), 1069-1073.
(15) Koganogl, G. K.; Baranu, I. V.; Tanner, S. D.; Bohme, D. K. J. Anal. At.
Spectrom. 20  00, 15, 1207-1210.
(16) Feldmann, I. N.: Stuewer, J. D.; Jakubowski, N. Fresenlus'J. Anal. Chem.
1999, 365, 415-421.
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Figure 3. Examples of the calibration curves produced using two 
types of nebulizing sources: (a) ultrasonic nebulizer and (b) Meinhard 
double-pass spray chamber.
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Figure 4. Example chromatograms for HPLC-ICPMS: (A) blank, 
(B) limit of quantification 10 pg on column, and (C) 0.5-h sample.
become beneficial. Examples of the calibration curves for HPLC- 
ICPMS using both nebulizer systems are given in Figure 3, with 
representative chromatograms obtained using the concentric 
nebulizer illustrated in Figure 4. The equation of the calibration 
line for the concentric nebulizer is given by y  =  653.5* +  335.7, 
which was calculated by least-squares linear regression for a range 
of 0.1-10000 ng/mL.
On the basis of these conditions using the concentric nebulizer, 
the method was validated for spiked plasma samples over the 
range 0.1-10000 ng/mL. The results, shown in Table 3, clearly 
indicate that the method is suitable for use over the concentration 
range examined. The excellent accuracy and precision data 
obtained in the absence of an internal standard are noteworthy. 
No reduction in response throughout the course of the analysis 
was noted, as shown by QC sample sets at the start and finish of 
the individual runs. The limit of quantification of the method using 
these conditions was 0.1 ng/mL (10 pg on column) using
Table 3. A ccuracy and Precision  Data for 
HPLC-ICPMS*
quality control mean accuracy coefficient ofsamples (ng/mL) (%) variation (%)
LLQ6 (0.1 ng/mL) 0.101 101 19.9
LQCC (0.5 ng/mL) 0.47 95 9.3
MQCrf (5 ng/mL) 4.6 92 1.8
HQCe (1000 ng/mL) 913 91 2.5
UQC  ^(10000 ng/mL) 9949 99 3.2
a n  =  6. b Limit of quantification.c Lower quality control. d Mid quality control. e High quality control. r Upper quality control.
arguments based on either a S /N  of 10:1 or the precision being 
better than 20%. A limit of detection based on a criterion of the 
signal-to-noise ratio being 3:1 would allow the detection of ZD0473 
at 0.05 ng/mL.
H P L C -M S /M S . ZD0473 is not a particularly good candidate 
for HPLC-M S/M S because as a result of decomposition in the 
source, the compound could not be isolated in a Q1 scan. The 
method developed by Oe et al.6 overcame this problem by making 
use of the presence of ammonium acetate in the mobile phase to 
produce an ammonium adduct, which was then fragmented to 
form product ions, one of which was then used in the multiple- 
reaction-monitoring transition (Figure 2).
For tuning purposes on the API-3000 mass spectrometer to 
achieve the required sensitivity, the resolution setting in the Q1 
region was changed from unit resolution (peak width 0.7 ± 0 .1  
amu) to low resolution (peak width 0.8 ± 0 .1  amu). This process 
allowed more ions through to the Q3 region, thereby increasing 
sensitivity, albeit at the expense of reducing the selectivity of the 
assay. The linear range of the assay was, however, limited to 
5-1000 ng/mL, with the equation of the calibration line given by 
y — 0.00136*+ 0.00101 calculated by least-squares linear regres­
sion. Above this concentration, the assay showed signs of 
saturation, and the coefficients of variation were unacceptability 
large. Typical mass chromatograms are illustrated in Figure 5. 
These conditions were used to develop an HPLC-M S/M S  
method for ZD0473 over the range 5 -1000  ng/mL. The resulting 
data are summarized in Table 4. These results show the method 
to be suitable for the analysis of ZD0473, with a limit of 
quantification of 5 ng/mL (corresponding to an on-column loading 
of 125 pg). This limit of quantification was calculated on the basis 
of a signal-to-noise ratio of 10:1. Using a signal-to-noise ratio of 
3:1 would result in a limit of detection of ~ 2  ng/mL.
The method, as developed, has proved to be robust in practice 
and has been used to run numerous samples from animal studies.
As indicated above, the HPLC-ICPMS method was able to 
provide accurate and precise results in the absence of an internal 
standard. For comparison, we therefore evaluated the data from 
the HPLC-M S/M S method without taking the internal standard 
into account to see if a similar approach could be adopted. 
However, this analysis showed that there was a gradual decrease 
in the response of the M S/M S during the course of the run of 
150 samples, with a difference of ~24% for QC samples analyzed 
at the start compared to those at the end of the batch. A buildup 
of deposits on the source probably caused this effect, thus 
reducing the response of the HPLC-M S/M S. The use of a
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Figure 5. Example chromatograms obtained from the LC-MS/MS 
assay with MRM transition 393-303 amu: (A) blank, (B) 5 ng/mL 
standard of ZD0473, and (C) real sample taken at 0.5 h.
Table 4. A ccuracy and Precision Data for LC-MS/MS*
accuracyquality control samples
LLQ (5 ng/mL) 
MQC (100 ng/mL) 
HQC (1000 ng/mL)
a n  —  6.
mean(ng/mL)
5.2109
1076
104
109
107
coefficient of variation (%)
12.3
5.35.4
10000
1000
Concentration
(ng/mL)
100
121080 2 4 6
Time (hours)
Figure 6. Example of the intravenous profiles gained from a male 
dog at dose of 0.5 mg/kg: (A) relates to the trace obtained from the 
HPLC-MS/MS, and (B) relates to the trace obtained from the HPLC- 
ICPMS.
Table 5. Quality Control Data for Both HPLC-MS/MS 
and HPLC-ICPMS Obtained during th e  A nalysis of 
Plasm a Sam ples from a Single Dog D osed  
Intravenously a t 0 .5  mg/kg w ith ZD0473*
QC levels (ng/mL)
5 10 400 2500
4.5 9.0 419 2670
4.3 8.8 393 2490
4.4 8.9 406 2580
88 89 101 103
5.6 9.1 321 2700
5.6 9.3 320 25685.6 9.2 320 2634
112 92 80 105
HPLC-MS/MS QC set 1 
HPLC-MS/MS QC set 2 
meanaccuracy (%) 
HPLC-ICPMS QC set 3 
HPLC-ICPMS QC set 4 
mean
accuracy (%)
a N.B. The HPLC-MS/MS and HPLC-ICPMS were carried out on different days.
suitable internal standard is, therefore, mandatory for the assay 
of ZD0473 by HPLC-MS/M S.
Application to the Determ ination o f Z D 0 4 7 3  in Dog  
P lasm a. To enable a comparison of the two methods to be 
performed on study-derived rather than spiked samples, both the 
HPLC-M S/M S and the HPLC-ICPMS methods were used to 
analyze plasma ultrafiltrate obtained following iv administration 
of ZD0473 at 0.5 m g/kg to a single dog. The data obtained using 
both methods are graphically represented in Figure 6, with the 
corresponding QC data in Table 5. Peak observed plasma 
concentrations were a little over 2000 ng/mL, falling rapidly to 
~10 ng/m L by 3 h post dose. Using HPLC-ICPMS, the 
concentrations of ZD0473 in the 6- and 12-h post-dose samples 
could be determined (2.0 and 1.4 ng/mL, respectively). HPLC- 
M S/MS was, in contrast, unable to provide quantitative data for 
these samples. For those samples in which both methods were 
able to provide results, the correlation between the two sets of 
data was good, even though a small bias was observed. The 
HPLC-M S/M S method generally shows a 10-20% higher value 
as compared to the HPLC-ICPMS method. However, when the 
data was put through statistical analysis (see below), when QC
(validation study) and intravenous study sample data were 
included, the methods were shown to be equivalent.
The HPLC-ICPMS and HPLC-MS/MS-derived intravenous 
plasma profiles as illustrated in Figure 6 show the differences in 
the extent to which each technique can follow the plasma 
concentration of the drug leads to different plasma profiles being 
calculated. A two-compartment pharmacokinetic model consisting 
of a distribution phase and an elimination phase best fit the 
HPLC-MS/MS method, which followed the curve out to 3 h when 
modeled. The t\n  for the terminal phase was 0.46 h. When the 
HPLC-ICPMS data were modeled, the best fit was obtained using 
a three-compartment model. This consisted of a distribution phase 
followed by two apparent elimination phases. The first elimination 
phase gave a t\n  of 0.48 h, which is comparable with the data 
obtained from the H PLC-M S/M S system. The second apparent 
elimination phase gave a tm  of 13.3 h; however, more data points 
would be required to increase the degree of confidence in this 
value because it is based on data over a limited sampling period 
(12 h). The AUC value for the HPLC-ICPMS method was 
calculated to be 745 Ivng/mL, as compared with 820 hmg/mL  
for the HPLC-M S/M S method. The difference is primarily due 
to the slight bias observed in the methods with the HPLC-
Analytical Chemistry, Vol. 75, No. 6, March 15, 2003  1467
M S/MS system having higher results; the longer terminal-phase 
tm  value for the HPLC-ICPMS method has a much smaller 
impact.
Overall, the pharmacokinetic data obtained for the two systems 
were shown to be comparable, with additional information gained 
from the HPLC-ICPMS method as a result of the increased 
sensitivity of the instrument.
Statistical Com parison o f M ethods. To compare results 
statistically from two different instruments, it is necessary to look 
at random error and systematic error. The statistical method used 
to investigate these parameters was based on the methodology 
of Gilbert et al.,17 which requires at least 30 data points made up 
of QC and real samples. The data used for statistical comparison 
was, therefore, made up of the QC samples obtained from the 
validation experiments, together with the samples obtained from 
a single dog dosed intravenously. A total of 35 data pairs were 
included in this comparison.
Random error was compared by examining the differences 
between the two sets of results normalized to the reference 
concentration. The standard deviation was calculated, and then 
the range of the mean ± 2  x s.d. If this range includes the value 
of 0, then there is no significant random error between the two 
sets of results. The data from the two systems showed 4-2 s.d. of 
272 and - 2  s.d. —131, thereby showing that there was no random 
error associated with the data.
If the ratio between each pair of results is calculated, the 
standard deviation is then calculated from these ratios and then 
the range of the mean ± 2  x s.d. If this range includes the value 
of 1.0, then there is no significant systematic error between the 
two sets of results. The data from the two systems showed +  2 
s.d. of 1.4 and - 2  s.d. of 0.8. These data therefore confirm that 
the error is within acceptable limits.
Even with the apparent bias observed between the two 
analytical techniques when the single dose intravenous data were 
subjected to statistical analysis, the QC and real sample data sets 
were comparable within the limits of the test, indicating that the 
methods are equivalent.
Aqua Species Com parison o f H PLC -ICPM S and H P L C - 
M S/M S. Additional data were obtained from the HPLC-ICPMS 
method, which enabled the determination of the aqua species in 
addition to ZD0473. Thus, the response for platinum remains 
constant no matter which compound contains the element, and 
therefore, the concentrations of platinum-containing analytes such 
as the aqua species can be determined (Table 6), even in the 
absence of an authentic standard in plasma samples. These data 
show that, even though acid was added to the samples to force 
the equilibrium in favor of ZD0473, the aqua species were still 
present to some extent (e.g., see Figure 4C). In the case of M S/ 
MS, when the relative ionization efficiencies of the aqua species 
were not known, only qualitative data for these compounds could 
be obtained in the absence of response factor data. To determine 
the relative responses of for these aqua compounds, as compared 
to ZD0473, a hypemated HPLC-ICPM S/MS/M S system was 
constructed, and samples from an oral dog study were analyzed. 
From the chromatograms illustrated for the combined system  
(Figure 7), it can be seen that the integration of the two
(17) Gilbert, M. T.; Barinov-Colligon, I.; Mlksic, J. R. J. Pharm. Biomed. Anal.
1995, 13. 385-394.
Table 6. Data Obtained from HPLC-ICPMS and 
HPLC-MS/MS Run in Parallel after Ultrafiltrate Plasm a  
Sam ples Were C ollected  from a Single Male Dog Dosed  
Orally a t 6 mg/kg
sample(hour)
0.25
0.5
0.751
0.25
0.5
0.751
ZD0473(ng/mL)
200
326
230
196
224
352
253
210
aqua species at 2.3 min (ng/mL)
HPLC-ICPMS
14.1
25.9
17.9 
20.8
HPLC-MS/MSa
15.8
28.1 
19.7 
21.4
aqua species at 3.2 min (ng/mL)
9.4
21.8
12.0
14.2
10.6
22.8
15.7
14.8
a MS/MS data obtained by using response factors for the aqua species at Rt 2.3 min of 1.1 ±  0.1 and for the aqua species at Rt of 3.2 min 0.9 ±  0.2.
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Figure 7. Example chromatograms obtained from the HPLC- 
ICPMS and HPLC-MS/MS assay run in parallel on a sample taken 
at 0.5 h from a single dog dosed orally at 6 mg/kg: (A) HPLC-ICPMS 
trace and (B) HPLC-MS/MS traces showing the two aqua species 
and the parent component ZD0473 obtained for the sample.
spectrometers into a single system readily enables the determi­
nation of the MS/MS responses for the aqua species by compari­
son with the values obtained simultaneously by ICPMS. Thus, 
the relative responses for the aqua species, calculated by compar­
ing the ratio of the responses for the ICPMS based assay to the 
M S/M S assay, were 1.1 ±  0.1 for the aqua species at Rt 2.3 min 
and 0.9 ±  0.2 for the aqua species at Rt 3.2 min ( N =  4). In this 
instance, therefore, the relative M S/M S response for the aqua 
species was, in fact, essentially the same as that of ZD0473. The 
results for the aqua species present in the oral samples provided 
by both HPLC-ICPMS and HPLC-M S/M S (calculated using the 
above response factors) are given in Table 6.
As shown elsewhere, such combined system s also provide a 
powerful technique in metabolite identification studies9 in which
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the ICPMS data can be used to direct M S/M S analysis to 
compound-related materials.
CONCLUSION
Both HPLC-ICPMS and HPLC-M S/M S enabled the detec­
tion and quantification of ZD0473 in plasma samples and provided 
the basis for robust bioanalytical methods. However, the HPLC- 
ICPMS system was found to have greater sensitivity, with a limit 
of quantification for ZD0473 of 0.1 ng/mL (0.05ng/mL of plati­
num) , as compared to 5 ng/mL for the HPLC-M S/M S method. 
Because it is based on the quantification of platinum, the HPLC- 
ICPMS method also enables the facile quantification of the
platinum-containing aqua species, even in the absence of stan­
dards. HPLC-ICPMS provided an assay with a much greater 
linear range than HPLC-M S/M S, being linear over 8 orders of 
magnitude, as compared to just over 3 orders of magnitude for 
HPLC-MS/MS. These studies show that HPLC-ICPMS provides 
the basis for a routine method for the sensitive determination of 
ZD0473 and the related aqua species in biofluid samples.
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Analysis of a [14C]-Labelled Platinum Anticancer 
Compound in Dosing Formulations and Urine 
Using a Combination of HPLC-ICPMS and Flow 
Scintillation Counting
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The use of high perform ance liquid chrom atography with inductively co u p led  m ass spectro­
metry (HPLC-ICPMS) in com bination with on-line radioactivity determ ination is describ ed  for 
the an alysis of Z D 0473 , a  platinum  anticancer drug. The technique w a s used  to determ ine the 
purity of formulated m aterial in oral a n d  IV d osin g  solutions, an d  for the d etection  of Pt-con- 
taining m etabolites in urine following IV administration to the d o g . In add ition  to Pt, it w a s  
found p ossib le  to d etect 14C  directly by ICPMS w hen  a n a lysin g  solutions containing [14C]- 
D 0473 .
KeyWords
Column liquid chrom atography  
Inductively co u p led  p lasm a m ass spectrom etry  
Platinum anticancer drugs  
Z D 0 4 7 3
Summary
introduction
D 0 4 7 3  {cis-[am m inedichloro(2-m ethyl- 
yridine)] platinum (II)} is a new genera- 
on platinum  com pound designed to  deli- 
er an extended spectrum  o f  antitum our  
ctivity and overcom e platinum  (Pt) resis- 
ince [1]. The structure o f  Z D 0473 and re- 
ited com pounds, including the biologi- 
illy active “aqua” com pounds, is show n  
elow  (Figure 1). T raditionally the analy- 
s o f  Pt drugs has relied upon either 
om ic absorption spectrophotom etry,
esented at: 14th International Bioanalytical 
)rum: Sensitive Bioanalysis in Anti-cancer 
id other Drug Areas, Guildford, UK, Jul 3 -  
2001
riginal
IC PM S or electrochem ical detection [2]. 
H ow ever, in the absence o f  a separation  
m ethod these techniques do  not provide 
an adequate procedure as they fail to dis­
tinguish between active com pound and in­
active m etabolites. H istorically m etabo­
lite/im purity profiles have been obtained  
by fraction collection follow ing separa­
tion and then determ ining the Pt content 
o f  the individual fractions. This procedure 
is both slow  and tedious. H owever, the ad­
vent o f  H PL C -IC PM S [3 -5 ]  offers the 
potential to analyse such sam ples w ithout 
the need for fraction collection. Indeed, 
G alettis et al. [5] have used H PLC -ICPM S  
for the quantitative analysis o f  the plati­
num -containing drug JM 216 in hum an  
plasm a. W e have, therefore, attem pted to
Chrom atographia Supplem ent Vol. 55 ,2002
use this m ethodology (cf. p. S-9) to 
provide a rapid, efficient and sensitive  
m ethod o f  analysis for Pt in sam ples con ­
taining Z D 0473 and related materials. 
Here we describe the use o f  H PLC - 
IC PM S coupled w ith radio flow  scintilla­
tion counter and ultra v iolet detector to 
provide a m ethod o f  analysis for [,4C]-la- 
belled Z D 0473. T he tw o techniques were 
used in com bination to  determ ine if  the  
profile for [I4C]-labelled com pound  
m atched the profile obtained for the Pt in 
chrom atogram s obtained for dose form u­
lations and urine sam ples from  a m etabo­
lism study.
Experimental
Chemicals
Trifluoroacetic acid w as purchased from  
Fisher (Fisher Scientific U K  Ltd, L ough­
borough). Solvents for chrom atography  
were o f  H PL C  grade and were obtained  
from  Fisher Scientific. T he physiological 
saline used in the study for the d ilution o f  
sam ples and for the preparation o f  IV  for­
m ulations, together w ith.the H ydroxypro- 
pylm ethyl cellulose (H P M C ) used in the 
preparation o f  the oral dose  so lution , was 
obtained from  the M edia Preparation L a­
boratory at A straZ eneca Pharm aceuti­
cals. The scintillant used w as U ltim a-F lo  
M  from  Packard Ltd (Berkshire, U K ).
Z D 0473 was obtained from  A straZ e­
neca Pharm aceuticals (A lderley Park, 
M acclesfield, U K ) whilst [14C]-labelled  
Z D 0473 was synthesised in the Iso tope  
Chem istry Laboratory at A straZ eneca  
Pharm aceuticals at a specific activity o f
S-151
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Figure 1. The structure o f ZD0473 with the associated aqua species, and known impurities.
Table I. Chromatographic gradient conditions.
Time (min) Pump programming Mobile Phase A % Mobile Phase B %
0 -4 Isocratic 98 2
4-11 Linear gradient 98 to 80 2 to 20
11-14 Isocratic 80 20
14-20 Linear Gradient 80 to 98 20 to 2
Table II. Instrument operating conditions for the ICPMS.
Cooling gas 
Plasma gas 
Nebuliser gas 
Helium gas 
Hydrogen gas
16.00 L.min-1 
0.65 L.min-1 
0.75 L.min-1 
1 mL.min-1 
4.0mL.min-1
Plasma Power 
Acquisition mode 
Dwell time 
Masses monitored 
Total analysis time
1350 w 
SIR 
200 ms 
195,14 
20 min
55 pC i.m g 1. The 14C labelled isotope was 
laced in the arom atic ring o f  ZD 0473.
amples
)ro/ a n d  IV D o se  F orm ulations o fZ D 0 4 7 3
D 0 4 7 3  was form ulated in physiological 
aline or 0.5% H PM C  for IV and oral ad- 
linistration respectively at a concentra- 
on o f  0.5 m g m L -1 and a specific activity 
f  55p C i.m g- 1 . T o ensure that Z D 0473  
as com pletely dissolved the formula- 
ons were m ade up and stirred for 3 h 
rior to  analysis.
rine
rine was collected for the period 6 - 1 2  h 
B ow ing IV adm inistration to a male bea­
gle dog (age 11 months, weight 12.8 kg, 
0.5 m g.kg- 1,5 5  pCi.mg- 1) o f  [I4Q-ZD0473. 
A t the end o f  the sam ple period the weight 
was recorded and the urine split into two  
20 m L portions and stored at - 7 0  °C in a 
freezer. A n a liquot (25 pL) w as injected on  
to the system  after centrifuging in an Ep- 
pendorf 5417C centrifuge (Eppendorf, 
H am burg, D ) for 5 m inutes at 14000 rpm.
Chromatography
Reversed-phase H PLC was performed  
using a Jasco gradient H PL C  system  (Jas­
co Ltd, G reat D unm ow , U K ) with sam ­
ples introduced via a PE 200 autosam pler  
(PerkinElm er Ltd, B eaconsfield, U K ). 
Chrom atography was perform ed on  
Inertsil O D S-3 150 m m  x 4.6  m m  5 pm  
(H ichrom  Ltd, Reading, U K ) at a flow
rate o f  1.0 m L .m in- 1 . The solvent system  
used for these separations was a gradient 
form ed from  0.2% trifluoroacetic acid in 
water (solvent A ) and m ethanol (solvent 
B). The gradient conditions were as fo l­
lows. F or the period 0 - 4  m in isocratic 
elution was perform ed with 98% A: 2% B. 
Thereafter, a linear gradient was per­
form ed up to 20% B over 7 min. This was 
follow ed by an isocratic period at this so l­
vent com position  for 3 m in, at which  
point a further linear gradient was per­
form ed over 6 m in to  regain the starting 
conditions (Table I).
UVand [14C]-Detection
The eluent from  the colum n was directed  
via an accurate splitter (LC Packings, Pre­
search, H itchin, U K ) to  either a M icro­
m ass Platform  IC PM S (M icrom ass U K  
Ltd, W ythenshaw e, U K ) (2 5 0p L .m in - 1 ) 
or to a Jasco U V -1575 intelligent v is/U V  
detector (265 nm ) (Jasco Jasco Ltd, G reat 
D unm ow , U K ) and to  a F low  O ne radio 
scintillation analyser (Packard, Berkshire, 
U K ) (750 pL .m in- 1 ) connected in series. 
The F low  O ne detector was fitted w ith a 
low  volum e (50 pL) flow  cell in order to  
preserve the resolution between peaks. 
F or both  U V  and [14C]-detection M qs- 
slynx softw are (M icrom ass U K , W ythen­
shawe, U K ) was used for data analysis.
ICPMS
The Platform  IC PM S instrum ent em ­
ployed in these studies used a hexapole  
collision/reaction cell-based IC P m ass 
spectrom eter [6] for the sim ultaneous  
m easurem ent o f  the 14C and 195Pt ele­
m ents. T he eluent from  the colum n w as 
introduced to the IC PM S via a concentric  
nebuliser and a double pass spray cham ­
ber, which w as coo led  to  - 3  °C to  a llow  
an increase in the percentage o f  m ethanol 
to be used within the system . M asslynx  
softw are w as used for the instrum ent co n ­
trol, data acquisition and data handling. 
The flow  o f  the nebuliser gases and the o p ­
erating and acquisition conditions o f  the 
IC PM S are show n in Table II.
The isotope envelope for Pt contains  
m asses at 194, 195, 196 and 198 (at per­
centage abundances o f  32.9, 33.8, 25.3, 
8.0%). A lthough it is possib le to  run the 
instrum ent in such aw ay as to sum  these  
ions, which w ould theoretically give rise 
to an increased signal, in practice the in-
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crease in the background caused the pro­
cess not to be beneficial. Therefore the ion  
195 was m onitored because it is the m ost 
abundant isotope o f  Pt.
Results and Discussion
Assay Development
The chrom atographic system  designed for 
this assay had to achieve the objectives o f  
separation o f  the com ponents in Figure 1, 
whilst under the constraints o f  solvent 
com position  im posed by the IC PM S [7, 
8]. Thus, w ith the present set-up the per­
centage o f  organic m odifier needs to be 
kept below  approxim ately 40% or other­
wise the plasm a m ay be com prom ised  
and/or extinguished. T o overcom e this 
lim itation ion exchange buffers with a low  
percentage o f  m ethanol were used to o b ­
tain the required separation (data not 
shown). This approach provided an ade­
quate separation but was ultim ately un­
successful due to  the buffer creating 
blockages within the IC PM S system  and 
poor chrom atographic reproducibility be- 
ween runs. The buffers were therefore, re­
laced with a water-m ethanol gradient 
ystem , which had a final m ethanol com - 
osition  o f  30%. The instrum ent was able 
o run at this percentage o f  m ethanol due 
o the low  flow  rate (250p L .m in - 1 ) and  
he spray cham ber being cooled  to - 3  °C. 
he system  was further optim ised and the 
mal chrom atographic conditions were as 
escribed in Table I; a standard chrom a- 
ogram  is show n in Figure 2. The change  
f  H PLC system  resulted in im proved  
quipm ent reliability and m ore robust 
hrom atographic separation.
>ral and IV Dose Formulation urity Determination
he dose solutions prepared for the IV  
id  oral form ulations were analysed to  
e if  they were o f  the required purity be- 
>re dosing was carried out. Typical re- 
ilts for the U V , 195Pt, and [I4C]-profiles 
;nerated for the oral and IV formula- 
Dns are show n in Figures 3 and 4 respec- 
/ely. T he dose purity can be calculated  
' sum m ing the Z D 0473 peak area with  
ose for the aqua species to  give the total 
rcentage o f  active drug (Z D 0473/ 
30473  total area o f  other analysed  
aks *100). In this instance this was 
und to be 91% for the oral dose solution
10O-i
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Figure 2. A typical example of the methanol-water gradient chromatography developed for the se­
paration o f the aqua species and impurity components: A: TCAP B: Aqua species 1 C: 2-Picoline 
D: ZD0473 E: Aqua species 2 F: TCPP. a) uv strace, b) 195Pt trace.
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Figure 3. Typical a) platinum, b) radio and c) UV traces obtained for the oral dose solution. Key as 
for Figure 2.
and 93% for the IV dose by IC PM S. These  
results show  that for the dose solutions 
there is a good  degree o f  correspondence 
between the chrom atogram s obtained for 
the 3 m odes o f  detection.
The m ethod dem onstrated that the ra­
tio o f  aqua species was different for each  
sam ple analysed. The reason for the in­
creased levels and different ratio o f  aqua  
species in the oral sam ple was due to the 
form ulation having a higher water com ­
ponent and therefore driving the equili­
brium in the direction o f  the aqua species.
Analysis of Urine Samples 
Obtained from IV Dosing
The chrom atographic system  developed  
for the analysis o f  the form ulation  sam ­
ples was also applied to urines obtained  
from  a radiolabelled excretion balance  
study carried out in the dog, fo llow in g  in­
travenous adm inistration o f  [14C ]-Z D  
0473. The U V , 14C and 195Pt traces o b ­
tained for a single dog ( 6 - 1 2  h post dose) 
are show n in Figure 5. F rom  the 195Pt 
trace, unchanged Z D 0473 accounted for  
6.95% o f  the total based on the retention
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Figure 4. Typical a) platinum, b) radio and c) UV traces obtained for the IV dose solution. Key as 
for Figure 2.
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"igure 5. A typical set of traces for A) platinum, B) radio and C) UV obtained for a dog urine sam­
ple.
ime. The remainder consisted o f  8 Pt- 
:ontaining peaks, eluting between 2 and 
4 m inutes. N o n e  o f  these peaks corre- 
ponded to  any o f  the degradation pro- 
lucts represented in Figure 1. Com pari- 
on o f  the 195Pt trace with the radioactiv- 
ty profile revealed several noticeable dif- 
srences. In particular a large radiola- 
>elled peak was observed at 13.10 min, 
/hich was not present in the 195Pt trace, 
his discrepancy in the profiles obtained
for the 195Pt and 14C traces indicates that 
at som e stage in the m etabolism  o f  the 
com pound by the dog, the 2-picoline m oi­
ety, which contains the radiolabel, has 
been detached from  the platinum . The use 
o f  both detectors, therefore, provides va­
luable and more robust m etabolic infor­
m ation that w ould not have been obtained  
had only one been used. The identity o f  all 
o f  these m etabolites is currently being 
pursued. D ue to the presence o f  endogen­
ous material interfering in the U V  trace, 
no useful inform ation could be gained.
Detection of 14C by ICPMS
W hilst IC PM S has been used predom i­
nantly to determ ine m etal species such as 
e. g. Pt, Se, Cd and A s, it is also capable o f  
analysing sam ples for m any other ele­
ments. W e have recently dem onstrated  
applications o f  H PL C -IC PM S for the de­
tection o f  Br, Cl and S-containing xeno- 
biotics or their m etabolites [ 9 -  l l ] . 1’ In 
addition to the detection o f  l95Pt in the 
present study, we also undertook an inves­
tigation o f  the potential o f  H PL C -IC PM S  
to detect the l4C isotope present in [14C]- 
ZD 0473. D etection  o f  ,4C + is subject to 
two m ajor difficulties nam ely; 1) high  
background at m ass 14 from  the presence 
o f  14N + ions, and 2) relatively low  sensitiv­
ity due to  the high ion isation  energy o f  
carbon.
The atom ic m ass o f  I4N  is 14.00307 
am u whereas the atom ic m ass o f  l4C is 
14.00324 am u. Therefore, the resolution  
required to  separate these tw o ions by 
m ass spectrom etry is m /Am  =  82371. 
Com m ercially available h igh-resolution  
IC P-M S system s do not offer m uch higher 
resolution than m /Am  =  10000. A s such, it 
is im possible to  separate 14N + from  ^ C + 
by high resolution IC P-M S. H ow ever, the 
IC P-M S instrum ent used in this study, al­
beit being a quadrupole-based system  
with a nom inal resolution o f  m /Am  =  400, 
is equipped w ith a hexapole collision /reac­
tion cell. It was therefore decided to  inves­
tigate the potential o f  using this cell to  
chem ically separate the 14C + and 14N + 
ions. Literature data o f  ion/m olecule reac­
tions clearly show  that C + ions do  not re­
act w ith H 2 whilst the reaction o f  N + and  
H 2 (N + +  H 2 - » N H + + H ) is very efficient 
[12]. In agreem ent w ith these data, we o b ­
served that the addition o f  4  m l/m in o f  H 2 
in the cell resulted in a virtually com plete  
conversion o f  the N + ions into N H + w ith­
out significantly affecting the sensitivity  
for 14C +.
O wing to the high first ion isation  en ­
ergy o f  C (11.3 eV) the pop u lation  o f  C + 
ions form ed in the ICP is relatively low  
(c.a. 5%). Therefore, the sensitivity o f  
IC P-M S for 14C + is about 20 tim es low er  
than it is for elem ents w ith low  ion isation
^See also the opening article in this supple­
ment (F. Abou-Shakra et al., p. S-9).
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energies (where the ionisation efficiency is 
nearly 100%). H owever, it is possible to 
optim ise for m axim um  sensitivity for  
l4C +, by adjusting the plasm a operating  
conditions and the ion extraction condi­
tions.
A s a result o f  tuning the instrum ent 
and using H 2 in the collision cell, it was 
possible to detect 14C + in the sam ples un­
der investigation. The chrom atogram  
show n in Figure 6 was obtained for radi­
olabelled Z D 0473 in the IV form ulation. 
This quantity o f  material represented 
25,600 dpm  injected on-colum n. It is ap ­
parent from  this chrom atogram  that m in­
or peaks were not observed and that in its 
current state o f  developm ent IC PM S de­
tection could not be used alone for the de­
term ination o f  both  195Pt and I4C +. 
Nevertheless the detection o f  the radiola­
bel associated with the m ain peak o f  
TD0473 is prom ising, and strategies
ZD0473
aim ed at im proving the sensitivity o f  the 
technique are currently being investi­
gated.
Conclusion
H PL C -IC PM S provided a sensitive and  
specific m ethod for the detection o f  the 
anticancer drug Z D 0473 and its Pt-con- 
taining im purities and m etabolites in for­
m ulations and urine. The use o f  IC PM S  
and a radio detector in parallel enabled  
the sim ultaneous detection o f  radioactiv­
ity and Pt, providing a m ore com plete and 
robust profile o f  com ponents in sam ples 
than w ould have been possible using each  
technique on its own. This com bination  
show ed clear benefits when com ponents 
were produced which contained only Pt or 
14C.
W e also dem onstrated that it was p os­
sible to detect l4C +using IC PM S. T o our  
know ledge this is the first report to show  
such analytical capability o f  the techni­
que. The full potential o f  the H PL C - 
IC PM S for this type o f  work is still being  
assessed, and new m odes o f  operation  
such as the use o f  the technique for l4C + 
detection for qualitative and quantitative  
analysis will be investigated further.
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0.5 mgmL-1 standard containing 25,6000 dpm.
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High-performance liquid chromatography (HPLC) combined with inductively coupled plasma 
mass spectrometry (ICPMS) has been studied as a means for the detection of carbon to provide a 
'universal' method for detecting organic compounds in chromatographic eluents. Carbon is parti­
cularly difficult to ionise and the amount of carbon present in normal chromatographic systems 
leads to high backgrounds, making detection a challenge. Novel separation approaches were there­
fore employed, using either entirely aqueous eluents (at temperatures of 60 and 160°C, dependent 
on the column used) to eliminate the organic modifier completely, or isotopically enriched solvents. 
For the aqueous eluents, detection limits for sulphanilamide were found to be 2.26 fig, correspond­
ing to 1.13 fimol (0.47 fimol of carbon), injected on a conventional 4.6 mm i.d. column. The use of a 
narrow bore column with highly isotopically enriched 12C-methanol (99.95 atom%) as organic 
modifier for the mobile phase enabled the detection of 86 fimol for 13C-triple-labelled caffeine 
and 79 fimol for 13C-double-labelled phenacetin. The sensitive detection of 12C-compounds with 
13C-enriched methanol as organic modifier proved impractical due to a lower level of isotopic 
enrichment (99 atom%) of this solvent, with the residual 12C-methanol resulting in significant inter­
ference. Copyright © 2004 John Wiley & Sons, Ltd.
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The hyphenation o f ind uctively  coupled plasm a m ass spec­
trometry (ICPMS) w ith  liquid  chrom atography has resulted  
in renew ed interest in  elem ent specific detection in  high-per­
form ance liquid  chrom atography (HPLC) w ith in  the phar­
m aceutical industry. In addition  to the detection o f m etals 
such as platinum ,1'2 the technique has been  found to be suita­
ble for the detection o f elem ents such  as brom ine,3,4 chlorine,5 
iodine,6,7 phosphorus8'9 and su lphur10-12 for both quantita­
tive and qualitative analysis.
A s part of our investigations on the u se  o f H PLC /ICPM S  
for drug analysis w e  investigated  the ability of H PLC /ICPM S  
to detect a [14C]-labelled anti-cancer com pound in a 
form ulation,13 based on the presence of the 14C-isotope. The 
specific detection o f the 14C -isotope by  ICPMS w as possible  
because of the lo w  natural abundance o f this isotope. This 
m eant that interference from  endogenou s carbon, for 
exam ple from the HPLC m obile phase, w as negligible.
Correspondence to: C. Smith, Department of Drug Metabolism  
and Pharmacokinetics, AstraZeneca, Mereside, Alderley Park, 
Macclesfield SK10 4TG, UK.
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D esp ite the fact that the reso lv ing  p ow er o f quadrupole  
ICPMS instrum ents is insufficient to separate the m asses of 
the elem ent 14N + (14.0031) and  the 14C+ (14.001) isotope, the  
addition  o f H 2 to the collision  cell to rem ove 14N + a llow ed  
14C+ to be detected w ith  g o o d  specificity. These results led  us  
to consider the possib le  u se  o f ICPMS to provide a 'universal' 
m ethod for the detection of organic com poun ds based on the  
detection  o f the m ore abundant isotopes o f carbon (as has 
been  investigated  to som e extent in  H P L C /A E S14). Such a 
technique w o u ld  potentially  be usefu l in  that it w o u ld  enable  
the am ounts o f ind iv idu al com ponents in  a m ixture (e.g. from  
com binatorial syn thesis) to be determ ined in the absence of 
authentic standards or k n ow led ge  o f e.g. m olar U V  extinction  
coefficients, etc. Such inform ation is currently sou ght u sin g  
e.g. chem ilum inescent nitrogen detectors (CLND) for N - and  
S-containing com poun ds, or evaporative ligh t scattering  
detectors (ELSD),15 but sim ilar results sh ou ld  be obtained  
u sin g  H PLC /IC PM S w ith  carbon detection. Such inform a­
tion m ight be especia lly  valuab le w h en  com bined w ith  
som e m eans, such  as m ass spectrom etry, o f determ ining the  
m olecular m ass of analytes to enable m olar responses to be  
calculated. The problem  w ith  the detection o f 12C and 13C is
Copyright ©  2004 John Wiley & Sons, Ltd.
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that they are present in the organic m odifiers used  for 
conventional chrom atography. This leads to h igh back­
ground interferences, so  that sensitive  detection is not 
possible. H ow ever, analysis o f  the m ore com m on isotopes 
of carbon m ight be possib le if such interferences could be  
rem oved from the system . O ne possib le answ er (explored  
here) is the u se  of entirely aqueous eluents, including  
superheated w ater,16 w here the m obile phase consists 
entirely o f water, w ith  separation controlled by changing  
the colum n tem perature. Indeed, in m any w ays, water  
provides the perfect chrom atographic eluent to u se  w ith  
ICPMS since there are no organic com ponents present to 
quench the plasm a. H ydrogen  and helium  are norm ally  
em ployed  in  the collision  cell for the reduction o f isobaric 
interferences.17 In this instance the gases w ere used  to 
im prove transfer o f the elem ents through the hexapole. A n  
alternative w ay  o f reducing background interferences to 
m anageable levels, a lso  investigated  here, is the u se  of 12C- or 
13C-enriched so lvents for the detection o f 13C-enriched and  
norm al 12C-containing com pounds, respectively.
EXPERIMENTAL 
Chemicals
Sulphanilam ide, caffeine, antipyrine, and paracetam ol (acet­
am inophen) used  in  this stu d y  w ere obtained from  Sigm a- 
A ldrich (Poole, UK) at a purity of 99%. The 13C-enriched caf­
feine (13C-triple-labelled, 99 atom%), phenacetin (R e ­
double-labelled, 99 atom%) and the 12C-enriched m ethanol 
(99.95 atom%) w ere also supp lied  by  Sigm a-Aldrich. The 
13C-enriched m ethanol (99 atom%) w a s obtained from  
Cam bridge Isotope Laboratories (A ndover, M A, USA).
Standard solution preparation
Caffeine, antipyrine and paracetam ol stock solutions w ere  
prepared in water at a concentration o f 5 m g /m L  in 10 mL  
volum etric flasks w ith  gentle heating to aid d issolution. 
Further d ilutions w ere prepared in w ater to the concentra­
tions o f 1 and 0.1 m g /m L . 13C-enriched caffeine and phenace­
tin w ere d isso lved  in  12C-enriched m eth an o l/w ater  (1:1) 
m ixture to a concentration o f 1 m g /m L .
Preparation of standard curve and quality control 
samples
A  standard curve w a s constructed for caffeine w ith  quality  
control data also obtained at each calibration point by  inject­
ing the sam ple six  tim es. The caffeine standard curve w as  
prepared at concentrations o f 10, 5, 2, 1, 0.75, 0.5, 0.25, 0.1 
and 0.05 m g /m L . A  sim ilar experim ent w as carried out for 
the 13C-labelled caffeine w ith  concentrations o f 1, 0.5, 0.3, 
0.15 and 0.075 m g /m L  used  to construct the standard curve.
HPLC/ICPMS and HPLC/ICPMS/MS
The H PLC /ICPM S system  w a s set up in three different con­
figurations as described below .
Chrom atography for ICPMS w ith  entirely aqueous solvent 
system s w a s perform ed u sin g  a Jasco PU-1580 HPLC pum p  
(Jasco Ltd, Great D u nm ow , UK) w ith  sam ples introduced via  
a PE 200 series autosam pler (Perkin Elmer Ltd., Beaconsfield, 
UK). C olum n heating w a s carried out u sin g  an Eppendorf
Copyright ©  2004 John Wiley & Sons, Ltd.
T ab le  1. Instrum ent operating conditions for ICPMS
Cooling gas 16.00 L/min Plasma power 1350 W
Plasma gas 0.65 L/min Acquisition mode SIR
Nebuliser gas 0.75 L/min Dwell time 200 ms
Helium gas 1 mL/min Masses monitored 12,13 Da
Hydrogen gas 4.0 mL/min Total analysis time 7 min
TC-50 colum n heater (Presearch, H itchin, UK). ICPMS w as  
perform ed on  a Platform  ICP m ass spectrom eter, w h ich  used  
a hexapole co llision /reaction  cell for sim ultaneous m easure­
m ent o f the carbon isotopes (GV Instrum ents, M anchester, 
UK). M assLynx softw are w as u sed  for instrum ent control, 
data acquisition and data handling. H o w  rates o f the 
nebuliser gases and operating conditions o f the ICPMS 
system  are sh o w n  in  Table 1.
For som e experim ents, see  be low , an API-365 m ass 
spectrom eter (A pplied  B iosystem s, W arrington UK) w as con­
nected in parallel v ia  an in-line splitter w ith  a turbo ionspray  
inlet source used  in  scan m ode over the range m /z  100-400. 
A nalyst softw are w as used  for the instrum ent control, data 
acquisition and data handling. The system  w a s connected to 
the H PLC /IC PM S system  via PEEK tubing (0.13 m m ) w ith  
the flow  controlled b y  an accurate sp litter (Presearch).
Aqueous separations at 60°C
The separation of caffeine, antipyrine and paracetam ol w ith  
an aqueous m obile phase at 60°C w a s perform ed on  a D iscov­
ery Zirconia-PDB 150 x  4.6 m m , 5 pm  colum n (Supelco, 
Bellefonte PA, USA) at a flow  rate of lm L /m in .  The flow  
w as sp lit u sin g  an accurate splitter w ith  700 pL to an API- 
365 m ass spectrom eter and 300 pL to the ICP m ass spectro­
m eter u sin g  a concentric double  pass spray cham ber (GV 
Instrum ents), for sam p le introduction. The flo w  into the  
API-365 w as adjusted to a llow  200 pL to enter the turbo ion­
spray source. The injection v o lu m e u sed  in  the experim ents 
w as 20 pL.
Aqueous separations at 160°C
The separation o f caffeine, paracetam ol and phenacetin w as  
also perform ed u sin g  superheated w ater at 160°C as the 
m obile phase on  an XTerra C8 150 x 4.6 m m  5 pm  colum n  
(W aters, W atford, UK) at a flow  rate o f 1 m L /m in  w ith  an  
IS6000 ultrasonic nebuliser (Cetec T echnologies, O m aha, 
N E, USA) for sam p le introduction into the ICP m ass spectro­
m eter. The injector w a s flushed  w ith  100 pL of w ater betw een  
sam ples w ith  an injection vo lu m e o f 20 pL.
Application to caffeine determination in coffee
Coffee (20 m g, Carte N oire), purchased from  a local super­
market, w as d isso lved  in w ater (1 mL, w ith  gentle  heating  
to aid dissolution). A n  aliquot (100 pL) o f this sam p le w as  
analysed by H P L C /IC P M S/M S usin g  an XTerra colum n  
operated at 160°C and a flow  rate o f 1 m L /m in  as described  
above.
Separations with isotopically enriched solvents
For both the 12C- or 13C -isotop ically  enriched m obile phases a 
m icrobore chrom atographic system  w a s used . Jasco PU-1580  
pu m ps w ere used  for so lvent delivery  at a flow  rate of
0.1 m L /m in . Separations w ere perform ed on  a Polaris 
50 x 1 m m  i.d ., 3 p colum n (Varian, Lake Forest, U SA ) w ith
Rapid Commun. Mass Spectrom. 2004; 18: 1487-1492
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injection vo lum es of 10 pL from  a PE 200 series autosam pler. 
M obile phases w ere m ade up  o f the enriched 12C- or 13C- 
m ethanol w ith  w ater (proportion o f enriched so lvent to water  
w as 20:80, v /v ) .
G radient elu tion  w a s also  em ployed  for the chrom atogra­
ph y  of phenacetin (usin g  95% m eth an o l/w ater  to 50% 
m eth an o l/w ater  (v /v )  linearly over 10 min).
RESULTS AND DISCUSSION 
HPLC/ICPMS with entirely aqueous mobile 
phases
Initial experim ents w ith  su lphan ilam ide, u sin g  superheated  
w ater chrom atography at 160°C on the XTerra phase, con­
firm ed the principle and indicated that a detection lim it of 
ca. 2.26 gg, or 1.13 pm ol, o f m aterial could  be achieved  
(470 nm ol o f carbon). U nder these conditions su lphanilam ide  
eluted rapidly from  the colum n, w ith  a retention tim e o f just 
over 2 m in, as sh ow n  in  Fig. 1(A). In add ition  these early  
investigations h igh lighted  the critical im portance o f elim inat­
ing  organic so lvents from  the system . Thus, in  one experi­
m ent, the com pound w a s taken up  in  m eth an o l/w ater  
(5:95% v / v )  and then d ilu ted  w ith  w ater (1:10) for injection  
onto the system . A s sh o w n  in Fig. 1 (B), w h ilst the peak corre­
sp ond in g  to the analyte is still clearly v isib le, it is superim ­
posed on a m uch larger, and very broad, peak d u e to the 
residual m ethanol present in the injection solvent. It is note­
w orthy that the m ethanol peak required ca. 40 m in  o f elu tion  
before it returned to baseline again (Fig. 1(C)). Thus the 
required solvent for both sam ple d issolution  and chrom ato­
graphy is clearly water, though this does place constraints on
the type o f com poun ds for w h ich  this strategy w ou ld  be 
suitable.
W e also noted that w h en  the PEEK tubing w a s used  at these  
high operating tem peratures it sh o w ed  signs o f degradation, 
w h ich  caused an elevated  background level. Stainless steel 
tubing w as therefore substitu ted  to m in im ise this problem .
Chrom atography, based on  prev iou sly  d evelop ed  separa­
tions,18 w a s then perform ed on  a m ixture o f three m odel 
com pounds, com prising caffeine, paracetam ol and antipyr­
ine on  Zirconia-based and XTerra stationary phases, w ith  
pure w ater as the m obile phase, and colum n ov en  tem pera­
tures o f 60 and 160°C, respectively. R epresentative chrom a­
togram s are sh o w n  in  Figs. 2(A) and 2(B) for XTerra and  
Zirconica w ith  the phases producing sim ilar separation and  
peak shape.
The response o f the ICPMS system  to 12C for caffeine w as  
found to be linear over the range exam ined (25 -5 0 0  gg  on- 
colum n, corresponding to 1 6 -3 2 0  gm ol) w ith  the equation of 
the calibration line g iven  b y  y  =  774x -f 568 and correlation  
coefficient r =  0.999. The detection  lim its w ere d o w n  to 2.5 gg  
(1.28 gm ol) (0.64 gm ol o f carbon) back-calculated from  the 
standard calibration curve for both  colum ns and tem pera­
tures. W hilst not investigated exhaustively , reproducibility  
w a s exam ined by  m ultip le injections o f standards (six  
replicates) at a concentration o f 25 g g  on-colum n (e.g. 16 gm ol 
of caffeine) for the Zirconia colum n at 60°C. The standard  
deviations obtained for this experim ent w ere ca. 6 .8 ,7 .8  and  
6.5% for paracetam ol, caffeine and antipyrine, respectively.
Clearly, as detection in  the ICPMS system  is proportional to  
the am ount o f carbon in  each com pound, the potential exists  
for the quantitative analysis o f com poun ds in a m ixture as, if
100
%
Tinr(rrin)
0 2 3
Time, min
F igure 1. (A) Chrom atography of 2.26 gg of sulphanilam ide (1.13 gmol, 470 nmol of 
carbon) on an XTerra column a t 160°C and 1 mL/min. (B) The sam e analysis for a  
sulphanilam ide sam ple m ade up in 0.5% methanol on the sam e time span  for com parison. 
The insert, chrom atogram  (C), show s the baseline disturbance due to the  methanol 
produced in chrom atogram  (B).
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F igure 2. (A) Chrom atogram  show ing the separa tion of parace tam ol (1), caffeine (2) and 
antipyrine (3) on an XTerra column a t 160°C. (B, C) Chromatograms showing the detection o f  the 
same compounds, separated on a Zirconica column at 60°C, detected by ICPM S and MS, 
respectively. (D , E, F) M ass spectra obtained for the three compounds.
the atom ic com position  o f the com pound is know n, an  
absolute value can be obtained for the response, w h ich  relates 
to the am ount o f carbon present in  the m olecule. Table 2 
sh o w s an exam ple o f this w ith  the area response obtained  
proportional to the am ount o f carbon present in each  
com pound. This inform ation a llow ed  the am ount of com ­
pound to be quantified relative to an external standard. 
W here unknow ns w ere present the m olecular m asses o f the
T ab le  2. Area respon se  obtained proportional to the amount 
of carbon presen t in each  compound
Compound
No. of 
carbons 
present
MW with 
formulae
Carbon 
atoms/ 
MW ratio
Area
response
Paracetamol 8 151 C8H9N 02 0.053 18278
Caffeine 8 194 C8H:oN40 2 0.041 14885
Antipyrine 11 188 C„H,2N20 0.058 21109
Copyright ©  2004 John Wiley & Sons, Ltd.
ind iv idu al com ponents cou ld  be obtained b y  d iv id in g  the 
effluent from  the colum n betw een  the ICP and a conventional 
m ass spectrom eter. This approach has been  dem onstrated  
elsew here.19 To illustrate this, an API-365 triple quadrupole  
m ass spectrom eter w a s connected into the system  b y  sp litting  
the e luent from  the colum n to the ICP m ass spectrom eter as 
described in  the Experim ental section . This set up  w a s u sed  to 
obtain sim ultaneous H PL C /IC PM S and M S data from  the  
m ixture of paracetam ol, caffeine and phenacetin , separated  
on the Zirconia-H BD phase. Figure 2(C) sh o w s the total 
ion  chrom atogram  obtained from  a scan over the range m /z  
140-210 , representing the three peaks of paracetam ol, 
caffeine and antipyrine. The resulting m ass spectra are 
sh o w n  in Figs. 2(D), 2(E) and 2(F), g iv in g  the [M + H ]+ ions  
(and thus the m olecular w eights) o f the com ponents.
The XTerra colum n, operated at 160°C, w a s u sed  to  
determ ine the am ount o f caffeine in a coffee sam ple. The  
chrom atogram  presented in  Fig. 3 sh o w s a large endogenou s
Rapid Commun. Mass Spectrom. 2004; 18:1487-1492
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F igure 3. Coffee sam ple run on an  XTerra column a t 160°C 
and 1 mL/min, ca. 2 p g  on-column of caffeine (100pg/g 
‘Instant C offee’). The insert show s the [M-f H]+ ion obtained 
for caffeine ob tained by parallel MS.
peak, w ith  the caffeine peak detected on the tailing edge, at a 
retention tim e of 5.5 min. This w a s confirm ed by  parallel 
w ork w ith  an API-365 m ass spectrom eter obtaining a scan  
over the range m/z 1 4 0 -170  sh o w in g  the ion  for the 
protonated caffeine m olecule. By com parison w ith  an  
external standard, an am ount of ca. 2 p g  of caffeine on- 
colum n w as calculated for the response (100 p g /g  o f 'Instant 
Coffee'). For a quantitative m ethod further w ork w ou ld  
clearly be required to separate the caffeine peak from the 
endogenou s interferences.
HPLC/ICPMS with isotopically enriched eluents
A lthough the aqueous m obile phases described above have  
m any advantages for ICPMS there are clear lim itations as to 
the types o f com pound that can be separated in this w ay. 
W ith this in m ind alternative chrom atographic separations 
w ere investigated u sin g  isotopically  enriched m ethanol as 
the organic m odifier for chrom atography. The enriched 12C- 
and 13C-m ethanol can be obtained com m ercially and w e  
therefore investigated  the detection  o f 13C-labelled analytes 
in a 12C -solvent as w e ll as 12C detection  o f com pounds in a 
13C m obile phase. A s the cost o f su ch  enriched solvents is 
not insignificant, chrom atography w a s perform ed on a nar­
row  bore colum n in order to m in im ise so lvent consum ption. 
This had the add ed  benefit that the lo w  flow  rates em ployed  
reduced the am ount o f m ethanol in the plasm a flam e thereby  
aid ing detection.
H igh ly  isotopically  enriched 12C-m ethanol (99.95 atom%) 
w a s used  as the organic m odifier for the detection of 13C- 
triple-labelled caffeine and 13C -double-labelled phenacetin. 
The high degree o f enrichm ent of the 12C-labelled m ethanol 
used  to m ake up  the organic m odifier m eant that the 
interference on the m/z 13 channel w as negligible. A n  
exam ple of this is sh ow n  in Figs. 4(A) and 4(B), w here the 
peaks for 5 pg on-colum n o f each of the 13C-labelled caffeine 
(86 pm ol o f 13C) and phenacetin (79 pm ol o f 13C) are show n.
W hen gradient chrom atography w a s investigated an 
increase in the background w as noted as the proportion of
Copyright ©  2004 John Wiley & Sons, Ltd.
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F igure  4. C hrom atogram s show ing (A) a  13C caffeine peak 
a t concen tration of 86pm ol for the three 13C labels; (B) a  13C 
phenacetin peak a t a  concen tration of 79 pmol for the two 13C 
labels; and (C) the chrom atography of phenacetin using 
gradient elution.
organic m odifier w as increased, desp ite  the h igh  degree of 
isotopic purity o f the solvent. A n  exam ple o f the u se  of 
gradient H PLC /IC PM S for the detection  o f 13C-labelled  
phenacetin is sh o w n  in Fig. 4(C).
These prelim inary experim ents clearly dem onstrate the  
potential for the detection o f 13C-enriched analytes in  
reversed-phase eluents. H ow ever, w h en  13C-enriched  
m ethanol w as used  in  an attem pt to detect un-enriched 12C- 
carbon com pounds, sim ilar success w as not achieved. This 
w a s d u e to the low er degree o f isotopic enrichm ent in  the 13C- 
m ethanol (99 atom%) than in  the 12C-m ethanol. Thus, the  
residual 1% of 12C -m ethanol that rem ained in  the 13C- 
enriched m ethanol ensured that there w a s a significant 12C- 
signal that precluded  detection  o f the analytes at these  
concentrations.
CONCLUSIONS
The results presented here dem onstrate that H PLC /IC PM S  
can be used  for the detection  o f carbon under a lim ited  set 
of analytical conditions, and under these  conditions H P L C / 
ICPMS can provide a 'universal' detector for organic com ­
pounds. In practice, g iven  both the expense  and  lack of 
high enou gh  leve ls of isotopic enrichm ent, on ly  those separa­
tions based on  entirely aqueous e luents are likely  to be eco­
nom ically  viable. Carbon detection  via H PL C /IC P M S/M S, 
for m olecular m ass determ ination and structure elucidation,
Rapid Commun. Mass Spectrom. 2004; 18: 1487-1492
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m ay prove attractive for the quantification and identification  
of unknow ns.
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Abstract
The sensitive detection of sulphur and phosphorous-containing compounds using HPLC-ICPMS is 
difficult due to the high background caused by polyatomic interferences. One potential solution to 
the problem of polyatomic interferences for S and P is to react the latter with oxygen in the collision 
hexapole to separate them from interferences eg; (O2 on S and NOH on P). This has the effect of 
moving the detection mass from 31 and 32 to 47 and 48 m /z for P and S respectively. This region 
is clear from interferences thereby providing an increase in the sensitivity of detection for the 
analytes of approximately50-100 fold. For omeprazole, a model S containing compound, a limit 
of detection (LOD) of 800 pg on column was achieved, an increase of ca. 100 fold in sensitivity. 
Similarly in the case of ZD6126 a phosphorous-containing pro-drug, an increase in sensitivity of 
50 times was observed with an LOD of 1 ng on column.
Keywords
Column liquid chromatography 
Inductively coupled plasma mass spectrometry 
Phosphorous-containing pro-drugs 
Sulphur-containing drugs
Introduction
Inductively coupled plasma mass spec­
trometry (ICPMS) as an analytical tech­
nique has been around since the 1980’s 
[1-2], however, the use o f  the instrument 
in combination with high performance 
liquid chromatography (HPLC) is more 
recent.
Presented at: 15th International Bioanalytical 
Forum. The Changing Role of Bioanalysis 
Discovery to Market, Guildford, UK, July 
1-4, 2003
Whilst mainly used for the analysis 
of metals [3-5] (e.g. Pt) HPLC-ICPMS 
has also found some applications in 
drug and xenobiotic metabolism for 
halogen-containing compounds (Cl, Br 
and I) [6-9], as well as some limited 
investigations for S and P-containing 
compounds [10, 11]. However, in the 
case o f S and P, sensitive detection is 
compromised by the presence o f a range 
o f polyatomic interferences such as 
l4N ,80 + and 15N ,60 ' H + which, lead to 
elemental overlap [12]. A  specific process 
to improve the specificity o f detection
for S and P, and thereby enhance sen­
sitivity, is to make use o f  chemical res­
olution with the reaction o f  S and P 
with 0 2 to move them from the region 
o f  polyatomic interference [13]. The 
main difference between the analytes 
and the interferences is seen in the O- 
atom affinity. O-atom transfer from 0 2 
to P + and S + is thermodynamically al­
lowed while for N O + , N O H + , and 0 2+ 
it is endothermic and forbidden under 
thermal conditions. When oxygen is re­
acted with an S element to produce a 
sulphoxide (SO +) the detection mass 
changes from 32 to 48 m /z .  Similarly for 
P, the production o f  P O + results in an 
increase in mass from 31 to 47 m /z. 
Table 1 shows the reaction enthalpy 
change and thermal reaction rate con­
stant for S and P with O with the cor­
responding interference ion processes 
[12]-
In this paper we have evaluated the 
utility o f  this approach for the quantita­
tive analysis o f  sulphur compounds 
(omeprazole and sulphanilamide) and 
phosphorous-containing compound 
(ZD6126).
Experimental
Chemicals
Chromatographic organic solvents were 
obtained from Riedel-de Haen (Sigma- 
Aldrich Ltd, UK ) with formic acid pur­
chased from Fisher (Fisher Scientific 
Ltd, UK ), which were o f  analytical or
Original Chromatographia Supplement Vol. 59, 2004
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Table 1. Reaction of oxygen with sulphur and phosphate elements and relevant interfering ions
Reaction Reaction enthalpy 
change Kcal moP1
Thermal reaction rate constant 
Kr, molecule-1 cm V 1
P+ + 0 2 -  PO+ + 0 -71.4 5.3 x 10-10
S+ + 0 2 -► SO+ + O -6.2 1.8 x 10-u
CO+ + o 2 -  c o 2+ + O -13.5 <2 x 10-14 (no reaction)
HCO+ + 0 2 -  COOH+ + O 3.3 <2 x 10-14 (no reaction)
NO+ + 0 2 -» N 02+ + O 57.4 < 1 x 10-n (no reaction)
NOH+ + 0 2 — N 02H+ + O 19.3 no data
o 2+ + o 2 -  o 3+ +0 102.1 no data
Table taken from ref [12]
Sulphanilamide (M w t= 1 7 2 )
Omeprazole (M wt = 440)
H,CO
H,CO
H3CO
O— P— OHIOH
> = °
Phosphate pro-drug (M wt = 453)
Fig. 1. Structures of the compounds used in the evaluation
Table 2. Instrument operating conditions for the Elan DRC II
Nebulizer Gas Flow 0.77 L min-1 Analog Stage Voltage -2000
Auxiliary Gas Flow 0.8 L min-1 ICP RF Power 1500 w
Plasma Gas Flow 20.00 L min-1 0 2 gas 0.5 mL min-1
Lens voltage 6.5 Mass monitored 31, 32, 47, and 48
HPLC grade. Sulphanilamide and 
omeprazole were purchased from Sigma 
(Sigma-Aldrich Ltd, UK ) and the phos­
phorous-containing pro-drug, ZD6126,
was supplied by AstraZeneca Pharma­
ceuticals (Alderley Park, Macclesfield, 
UK). Structures for test compounds are 
shown in Fig. 1.
S tandard and Calibration 
Solution Preparation for 
Sulphur and Phosphorous
A  standard solution o f sulphanilamide 
was prepared at a concentration o f  
10 pg mL-1 by dissolution in water aided 
by sonication for 10 min in an ultrasonic 
water bath (Ultrawave Ltd, Cardiff UK).
Omeprazole stock solution was pre­
pared in mobile phase at a concentration 
o f  1 mg mL-1 in a 10 mL volumetric 
flask. The dissolution was aided by soni­
cation for 10 min in an ultrasonic water 
bath. The stock solution was then serially 
diluted with mobile phase to give final 
concentrations o f  1000, 700, 500, 400, 
300, 100, 50 20 and 10 ng mL-1.
ZD6126 stock solution was prepared 
by dissolving the compound in mobile 
phase at a concentration o f 1 mg mL-1, 
and sonication for 10 min to aid disso­
lution. Serial dilutions were prepared by 
diluting the stock solution in to mobile 
phase to give final concentrations o f  
1000, 700, 500, 400, 300, 100, 50 and 
10 ng mL-1.
P lasma Samples
200 pL samples o f  control plasma were 
spiked with either sulphanilamide or the 
phosphate pro-drug at a concentration o f  
100 ng mL-1. These samples were then 
diluted with 100 pL o f  water and 50 pL 
aliquots were injected on to the HPLC- 
ICPMS system.
Chrom atography
Sulphur an d  Phosphorous Detection
An isocratic HPLC system was used for 
the analysis o f  sulphanilamide and the 
phosphate pro-drug with a Synergi 
Polar Rp column, 150 x  4.6 mm, from 
Phenomenex (Macclesfield, UK ). The 
mobile phase consisted o f  acetoniltrile, 
water and formic acid (40:60 0.1), which 
was delivered at a flow rate o f  
1 mL.min-1 . An injection volume o f  
50 pL was used.
An isocratic HPLC system was also 
used for the analysis o f  omeprazole with 
a C l8 Xterra 1 5 0 x 2 .1  mm, column 
(Waters, Milford, USA). The mobile 
phase consisted o f  actonitrile: water
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Quality control
samples
(pg on column)
mean
(pg on column)
accuracy
(%)
coefficient of variation 
(%)(« = 6)
800 784 98 7.2
40000 35160 88 5.6
400000 438240 109 9.1
Table 3. Instrument operating conditions for the Platform ICPMS
Cooling gas 17.00 L min-1 Plasma Power 1700 w
Plasma gas 0.65 L min-1 Acquisition mode SIR
Nebuliser gas 0.6 L min-1 Dwell time 200 ms
Helium gas 0 mL min-1 Masses monitored 31, 32, 34, 47 and 48
Hydrogen gas 0 mL min-1 Argon/Oxygen 0.2 mL min-1
(95/5 %)
Oxygen gas 0.8 mL min-1 Total analysis time 6 min
1 xe7
a,o
<|  « * .'<U£
2 xe'
4 xe
C/3do
S o£  2 xec
5 xe‘
1.0 2.0 3.0 4.0 5.0Time (min)
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J L .
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Time (min)
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Fig. 2. Trace A shows the response of a sulphanilamide (1 pg on column) and trace B shows the 
improvement of the same sample after the addition of oxygen
(20:80) and was delivered at a flow rate o f  
200 uL.min-1 . The injection volume was 
50 pL.
HPLC-ICPMS
Initial work using this technique for sul­
phur-specific detection using sulphanila­
mide as the test analyte was carried out 
on an Elan DR C II ICPMS (Perkin 
Elmer, Beaconsfield, UK ) equipped with 
a PE series 200 pump and a PE series 200 
autosampler. The sample was introduced 
into the plasma via a concentric nebulis­
er. Interactive software was used for the 
instrument control and analysis (Perkin- 
Elmer, Beaconfield, UK ). The flow o f  the 
nebuliser gases and the operating acqui­
sition conditions o f  the ICPMS are 
shown in Table 2.
Chromatography for the HPLC-IC­
PMS o f  omeprazole and the phosphate- 
pro-drug was performed using a Jasco 
HPLC system (Jasco Ltd, Great Dun- 
mow, UK ) with samples introduced via a 
PE 200 autosampler (PerkinElmer). The 
injector was flushed with mobile phase. 
ICPMS was also performed on a GVI 
Platform ICPMS (GV Instruments Ltd, 
Wythenshawe, UK ) and the eluent was 
introduced to the ICPMS via an Aridus 
nebuliser (Cetac Technologies, Omaha, 
Nebraska, USA). Masslynx software (GV  
Instruments, Wythenshawe, UK ) was 
used for data analysis and instrument 
control. The flow o f the nebuliser gases 
and the operating acquisition conditions 
o f the ICPMS are shown in Table 3.
Results and Discussion
In order to perform “chemical resolu­
tion” a small amount o f  oxygen 
(Tables 2, 3) was introduced into the 
dymanic reaction cell o f the Elan DR C II 
or the hexapole collision cell o f  the GVI 
platform through which the analytes are 
passed after the inductively coupled 
plasma. Prior to their exit from the 
reaction area into the MS detector 
chemical reaction occurs to produce the 
oxidised species for detection.
Sulphur-Detection
Initial studies to investigate the potential 
o f chemical resolution were first per-
Table 4. Sulphur precision and accuracy data
formed for S using sulphanilamide as a 
model compound on an Elan DR C II 
ICPMS. The resulting increase in sensi­
tivity obtained using such an approach is 
shown in Fig. 2 A  and B. Thus in Fig. 2A  
when the compound was monitored at
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Fig. 4. Example chromatograms for omeprazole at 5 pg on column: (A) S monitored at 32 m/z, (B) 
S monitored at 34 m/z and (C) SO+ monitored at 48 m/z
32 m /z , only a relatively small signal was 
observed. In contrast, monitoring the 
signal for 48 m /z  after introduction of 
oxygen in to the dynamic reaction cell 
resulted in a dramatic increase in signal to 
noise as shown in Fig. 2B. The process 
was found to be linear over a range o f 
0.2 ng to 19 ng (coefficient regression
0.9998). In Fig. 3 the chromatogram ob­
tained following the injection o f  spiked 
plasma sample (100 ng mL-1 corres­
ponding to 5 ng o f  analyte on-column) is 
shown.
Similar data were subsequently ob­
tained for another sulphur-containing 
compound, omeprazole, on a Platform 
ICPMS. Given the promising nature o f  
this result we then progressed to a more 
in-depth evaluation o f  the potential o f  
this methodology. Thus in Fig. 4A -C  the 
results obtained for 5 pg on column o f 
omeprazole are shown with detection 
either o f  32S, 34S or 32S160 .  Although a 
minor isotope o f  sulphur the detection o f 
34S has been employed previously as a 
means o f  avoiding polyatomic interfer­
ences [14] and, as shown in Figure 4B 
there is a useful increase in sensitivity, for 
this isotope compared to 32S. However, 
comparison with the result shown in 
Figure 4C for the response obtained 
when oxygen is infused in the hexapole 
reaction cell clearly indicates the superi­
ority o f the latter approach. The 
improvement in response was found to be 
ca. a 100 times over the response found 
for 34S isotope and a 1000 times for the 
32S isotope.
We therefore proceeded to investigate 
the properties o f  the system with respect 
to sensitivity, accuracy, reproducibility 
and linear range. Table 4 shows the 
accuracy and precision data collected 
using omeprazole and the chromato­
graphic conditions described earlier at 
three concentrations with six replicates at 
each concentration. This experiment was 
carried out on aqueous standards to show  
that the S oxygen reaction in the collision 
cell could meet the requirements o f an 
analytical method. The system was linear 
over the range 800 pg to 400000 pg on 
column (coefficient regression 0.9998) 
with an accuracy at the lowest level 
(800 pg on column) o f  98 % and coeffi­
cient o f  variation o f  7.2%. The data col­
lected indicates that the use o f  oxygen in 
this manner was a reliable means o f  
increasing sensitivity for S-containing 
compounds. Chromatographic traces 
obtained from the precision and accuracy
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Fig. 6. Example chromatograms for ZD6126 at 5 pg on column: (A) P monitored at 31 m /z and 
(B) P monitored at 47 m /z
experiment can be seen in Fig. 5 where 
examples o f  the limit o f  quantification 
(LOQ) (800 pg on column) and a blank 
are represented. The amount o f  the S 
element detected corresponds to 80 pg on 
column since there is only one S present 
in the compound (Fig. 1).
Phosphorous-Detection
Evaluation o f this methodology for the 
phosphate pro-drug ZD6126 was carried 
out on the Platform ICPMS. The gains 
in (Fig. 6) reveal an increase in response 
of ca. 50 times. In Table 5 accuracy and 
precision for this analyte are shown. The 
data indicates an accuracy o f 109 % at 
the lowest point o f  detection (1000 pg on 
column corresponding to 100 pg o f P), 
with a coefficient o f  variation o f  9.7. The 
run was linear over the range 10 ng to 
100 ng on column, with a coefficient o f 
regression 0.999. The tested linear range 
was small in this evaluation however, 
the characteristics o f  the ICPMS 
would allow for a much large range to 
be used.
Similar improvements in sensitivity to 
those seen for S were also evaluated with 
this approach using the Elan DRC II for 
the detection o f  P. When P is reacted with 
oxygen, moving the detection mass from 
31 to 47 m /z , polyatomic interference 
such as 15N 160  + , 14N I60 'H  and
,2C iH3160 + [12] are avoided. This is due 
to the laws o f thermodynamics which 
allow the reaction o f P and O as an 
exothermic reaction, however the reac­
tion o f  N  and O is an endothermic reac­
tion and therefore not seen. The initial 
results for the PO + showed the process to 
be linear over the range 100 ng to 
1900 ng on column with (regression 
coefficient o f  0.999) for directly injected 
standards. A  plasma sample was analysed 
by HPLC-ICPMS (Fig. 7) and this shows 
the P-containing pro-drug (5 ng on col­
umn) resolved from endogenous phos­
phate.
Conclusion
The use o f  the ICPMS with the addition 
o f  oxygen to the collision cell to increase 
the sensitivity o f methods for com­
pounds containing S and P elements has 
been demonstrated. An increase in re­
sponse for S o f  100 times for the SO + 
compared to the 34S isotope, and 1000
times compared to 32S, was shown. 
Similar gains in sensitivity were achieved 
for P. This type o f  increase in sensitivity 
should enable the use o f HPLC-ICPMS
for the analysis o f  compounds contain­
ing these elements at trace levels in 
complex matrices such as biological flu­
ids.
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Table 5. Phosphorous precision and accuracy data References
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(ng on column)
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(%)
coefficient of variation 
(%)(« = 4)
10 10.9 109 9.750 49.9 99.8 9.0
100 102.1 102.1 3.0
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Fig. 7. An example of a diluted plasma sample of ZD6126 (100 ng on column)
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Sensitive sulphur-specific detection of omeprazole 
metabolites in rat urine by high-performance liquid 
chromatography/inductively coupled plasma mass 
spectrometry
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The use of high-performance liquid chromatography/inductively coupled plasma mass spectrome­
try (HPLC/ICPMS) with sulphur-specific detection was investigated as a method for obtaining 
metabolite profiles for the drug omeprazole administered as a 1:1 mixture of 32S- and 34S-labelled 
material. Analysis based on the monitoring of the chromatographic eluent at either m/z 32 or 34 was 
not successful due to insufficient sensitivity caused by interferences from polyatomic ions. How­
ever, reaction of sulphur with oxygen in the hexapole collision cell, combined with monitoring at 
m/z 48 (for 32S) or m/z 50 (for 34S), provided a facile method for metabolite profiling. Detection of ml 
z 48 was superior in sensitivity to detection of m/z 50. Copyright © 2003 John Wiley & Sons, Ltd.
RCM
In the pharm aceutical industry, the detection, profiling and  
identification of m etabolites o f drugs are essential com po­
nents of drug d iscovery and developm ent. C onventional 
m ethods use  HPLC coupled  to m ass spectrom etry for detec­
tion and identification and this approach works w ell for both  
early stage discovery and later develop m en t studies. H o w ­
ever, in the absence of authentic standards, the production  
of accurate, quantitative, m etabolite profiles usually  requires 
the tim e-consum ing and expensive synthesis o f isotopically  
labelled com pounds and then HPLC w ith  radiochem ical 
detection. The ability to short circuit this process and obtain  
the required m etabolite profiles based on  som e feature of the  
m olecule under stu dy  cou ld  therefore provide a significant 
sav ing  in tim e and resources, w ith  environm ental benefits 
resulting from  the avoidance o f radioactivity. To this end, 
w e have extensively  investigated the u se  o f 19F N M R  (e.g. 
see  Ref. 1) and have m ore recently begun to investigate  
approaches based on elem ent-specific detection using  
HPLC/ICPM S. For d rug substances containing heteroatom s 
such  as su lphur, elem ent-specific detection can be obtained  
usin g  H PLC /ICPM S w ithout the need  for labelling.
H ow ever, su lphur detection  by  ICPMS is com prom ised by  
a range o f interfering polyatom ic ions, lead ing to h igh  
backgrounds and poor sensitivity. This is especially  the case  
for the major isotope 32S (95.0% abundance), w h ich  suffers 
from  interference by  16O j , and to a m inor extent for 34S (4.2% 
abundance), from, e.g., and 160 180 + 2 Detection
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of 34S u sin g  H PLC /IC PM S on  a quadrupole-based instru­
m ent has been  app lied3 and sulphur-containing m etabolites 
of brom oaniline and diclofenac have been  detected by  
m onitoring 32S.4,5 Increased sensitiv ity  can be obtained by  
usin g  a sector field instrum ent to resolve su lphur from  the  
interferences and the effectiveness o f  this approach has been  
dem onstrated on stu d ies o f the im purities o f the sulphur- 
containing drug cim etid ine.6 H ow ever, su ch  instrum ents are 
expensive  and less w id e ly  available than the quadrupole- 
based ICPMS system s. For these spectrom eters, another  
approach to im prove the sensitiv ity  o f su lphur is to m ake use  
of chem ical resolution  by  reacting su lphur w ith  oxygen  in a 
co llision /reaction  cell and thereby m ove to a region w ith  less  
interference.7 The reaction o f O 2 w ith  S+ to form  su lphoxide  
(SO+) is therm odynam ically  a llow ed , w h ich  is not the case  
for the interfering polyatom ic ions, and hence sensitiv ity  is  
increased.7 By u sin g  an oxygen  reaction in a hexapole  
collision  cell and m easuring SO+ at m /z  48, Sm ith el al.8 
obtained an increase in response of ca. 100 tim es over the  
response found for and a 1000 tim es for 32S. The m ethod  
w a s u sed  for the quantitative analysis o f om eprazole and w as  
found to be linear over the range 0 .8 -4 0 0  n g  om eprazole on- 
colum n w ith  good  precision and accuracy.
This w ork describes the u se  o f su lphur-specific  detection to  
stu dy  the m etabolite profile o f  [32S ] / [ 34S]om eprazole in  rat 
urine fo llow in g  oral adm inistration.
EXPERIMENTAL 
Chemicals
O m eprazole w a s purchased from  Sigm a-A ldrich Co. (St. 
Louis, M O, U SA ) and [34S]om eprazole w a s syn thesised  at 
AstraZeneca R&D (M olndal, Sw eden) u s in g  C3^ . 9 The
Copyright ©  2003 John Wiley & Sons, Ltd.
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F igu re 1. S tructure of om eprazole (MW 345).
structure of om eprazole is sh o w n  in  Fig. 1. M ethanol (HPLC- 
grade) and am m onium  acetate w ere purchased from  Fisher  
Scientific UK  Ltd (L oughborough, UK). W ater w a s obtained  
from an Elga w ater purification system  (Elgastat M axim a, 
Elga, H igh  W ycom be, UK).
Urine samples
Pooled urine sam ples (0 -9  h post-dose), concentrated using  
Ci 8 so lid-phase extraction, w ere obtained from  three m ale  
Sprague-D aw ley rats dosed  orally w ith  2 0 0 g m o l/k g  o f a 
1:1 m ixture of [34S]-labelled and unlabelled  om eprazole as 
described in W eidolf et a l / °  100 pL w ere injected on colum n.
Instrumental
Chrom atography w as perform ed u sin g  a Jasco gradient 
HPLC system  (Jasco Ltd, Great D u nm ow , UK) w ith  sam ples  
introduced via a PE 200 autosam pler (Perkin-Elmer Ltd, Bea- 
consfield, UK). A  C i8 H ichrom  colum n (HI-RPB; 5 pm, 
150 x 4.6 m m ) w as used  at a tem perature o f 40°C. The flow  
rate o f 1 m L /m in  w as sp lit w ith  250 p L /m in  introduced to 
the ICPMS system . 0.13 m m  i.d. PEEK tubing w as used  
throughout. A  gradient w as em ployed  based on (A) m etha- 
n o l /H 20  (5:95), 2m M  am m onium  acetate, pH  7.0, and (B) 
m eth a n o l/H 20  (95:5), 2 m M  am m onium  acetate, pH  7.0, as 
follow s: 0 - 5  m in 95% A , 5 -2 0  m in 95-50%  A , m aintained  
from  20 to 25 m in, 2 5 -3 0  m in  50-95%  A , rem aining at 95% 
A  until 35 m in.
ICPMS w as perform ed on  a GVI Platform  instrum ent 
(GV Instrum ents Ltd., M anchester, UK) equipped w ith  a 
M einhard concentric nebuliser coupled  to a cooled (—7°C) 
double pass spray chamber. M asslynx softw are (GV Instru­
m ents Ltd.) w as used  for data analysis and instrum ent 
control. The operating conditions o f the instrum ent are 
sh ow n  in Table 1.
T ab le  1. Instrumental operating conditions for ICPMS
Parameter
Without oxygen 
reaction
With oxygen 
reaction
Cooling gas 17.0 L/min 15.0 L/min
Plasma gas 0.8 L/min 0.8 L/min
Nebuliser gas 0.8 L/min 0.8 L/min
Helium gas 9.8 mL/min 0 mL/min
Hydrogen gas 2.0 mL/min 0 mL/min
Oxygen gas 0 mL/min 0.60 mL/min
Plasma power 1700 W 1700 W
Acquisition mode SIR SIR
Dwell time 300 ms 300 ms
Masses monitored 32,34 48, 50
Copyright © 2003 John Wiley & Sons, Ltd.
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Figure 2. HPLC/ICPMS chrom a togram s of om eprazole 
m etabolites in a  rat urine extract de tec ted a t (a) m / z  32  and 
(b) m / z  34.
RESULTS AND DISCUSSION
Previous stu d ies have sh o w n  that, w ith  su itab ly concentrated  
sam ples, su lphur-containing com poun ds can be m onitored  
in chrom atographic eluents w ithou t the need  for special m ea­
sures su ch  as reaction w ith  oxygen .4,5 For com pleteness  
therefore, the urine extract sam ple w a s initially analysed by  
ICPMS for both  32S and 34S w ithou t u sin g  the oxygen  reaction  
to m ove from  the region o f polyatom ic interferences. H o w ­
ever, as Fig. 2 sh ow s, adequate sensitiv ity  w a s not obtained  
for either isotope o f su lphur. Thus, in the case o f 32S, the 
high background d u e to polyatom ic interferences m eant 
that no S-containing peaks for the com poun d or its m etabo­
lites could  be detected by  m onitoring at m /z  32. A t m /z  34 it 
w as possib le to detect a few  peaks but it is clear, even  w ith  
the u se  of an isotop ically  labelled com poun d, that sensitive  
detection w o u ld  not be obtained and that m inor m etabolites 
present in this sam ple w o u ld  not be detected. The add ition  of 
oxygen  to the hexapole collision  cell w ith  m onitoring at m /z  
48 and 50 w a s then attem pted. A s sh o w n  in  Fig. 3, the result 
w as a dram atic increase in  signal-to-noise (S /N )  ratio, and  
m any S-containing peaks appeared.
Thus, in the case o f 32S, w h ere  no  peaks w ere detected by  
conventional ICPMS, m ore than 30 resolved  S-containing  
peaks w ere observed fo llow in g  add ition  o f oxygen  to  the  
collision  cell. In this stu dy , om eprazole w a s d o sed  in  a 1:1 
ratio o f 32S and 34S but, as seen  in  Fig. 3, a higher sensitiv ity  
w as obtained at m /z  48 (i.e. detection  of 32S) than at m /z  50 (^S) 
w ith  respect to the S / N  ratios obtained. It is also  notew orthy  
that, d u e to the generally  higher background at m /z  50, the  
increase in  background as an effect o f the m ethanol gradient 
becom es m ore apparent at m /z  50. H ow ever , w h ilst these  
results sh o w  that there is no  advantage in  term s o f sensitiv ity  
to be obtained from  isotopically  labelling a com poun d  w ith  
34S for H PLC /ICPM S, a com parison o f the tw o  profiles is 
instructive. This exam ination o f the tw o  profiles sh o w s that 
the u se  of the labelled com poun d  readily enables the 
om eprazole-related peaks to be d istin gu ished  from  en d o­
genous S-containing substances, as the form er requires peaks
Rapid Commun. Mass Spectrom. 2004; 18: 181-183
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F igure 3. HPLC/ICPMS chrom atogram s of om eprazole 
m etabolites in a  rat urine extract de tec ted at (a) m/z 48 
(32SO +) and (b) m/z 50 (34SO +).
to be present in both the 32S- and 34S-chrom atogram s. From  
the results obtained here, the bu lk  of the endogenous S- 
containing material w o u ld  seem  to elute early in the gradient. 
W hilst sensitivity per se w a s not stud ied  in this prelim inary  
work, previous stu d ies8 have sh ow n  that the detection of 
800 pg  on-colum n of unlabelled om eprazole is possib le by  
this approach (approxim ately 80 p g  S). This represented an  
increase in sensitiv ity  o f 100-fold com pared w ith  the 
detection lim its attainable w ithout addition  o f oxygen  to 
the hexapole collision  cell.
ICPMS provides no structural inform ation so  the identity  
of the various peaks cannot be determ ined by  this m ethod.
Sulphur-specific detection by HPCL/ICPMS 183
H ow ever, a peak corresponding to unchanged om eprazole  
w a s not detected (the drug w o u ld  have elu ted  at 23.4 m in in  
this system ) clearly sh o w in g  that the com pound w as  
exten sively  m etabolised . Should  structural inform ation be 
required, this can be obtained b y  sim ultaneously  m onitoring  
the chrom atographic e luent b y  conventional MS.
CONCLUSIONS
The poor sensitiv ity  of ICPMS for 32S and ^ S  m eant that m eta­
bolite profiling for om eprazole in  rat urine cou ld  not be per­
form ed. H ow ever, m ov in g  to a region w ith  less polyatom ic  
interference by  reaction w ith  oxygen  provided a readily  
im plem ented m eans o f increasing the sensitiv ity  o f conven­
tional quadrupole-based instrum ents for sulphur-containing  
com poun ds enabling good-quality  m etabolite profiles to be 
obtained.
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